SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions May archived by USPTO category 05/12

20120134917 - Dermatological composition: Dermatological methods of cosmetic, therapeutic, prophylactic, and/or diagnostic treatment by topically applying compositions comprising a multiplicity of particles, at least one of the particles comprising porous and/or polycrystalline silicon. Included are methods and compositions for sun protection applications. The use of porous silicon, polycrystalline silicon, and porous silicon oxide mirrors... Agent: Psimedica Limited

20120134918 - Gum arabic coated 198gold radioactive nanoparticles for cancer therapy: The invention provides a cancer therapeutic and imaging agent comprising a solution containing Gum Arabic coated 198Au nanoparticles. The Gum Arabic coated 198Au nanoparticles have been demonstrated experimentally shown to have a surprising efficacy for a single dose direct injection, reducing tumors in analog mice by 82% over a short... Agent: The Curators Of The University Of Missouri

20120134919 - Ion substituted calcium phosphate particles: A method for formation of spherical particles of ion substituted calcium phosphate. The method is based on precipitation of particles from a buffered solution under static, stirring or hydrothermal conditions. Also, the use of the formed materials and the particles in itself.... Agent: Biomatcell Ab

20120134920 - Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules: The present application discloses compositions and methods of synthesis and use of 18F or 19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex... Agent: Immunomedics, Inc.

20120134921 - Solid compositions comprising 5-aminolevulinic acid: This invention relates to solid compositions and solid pharmaceutical products for use in methods of photodynamic diagnosis of cancer, pre-cancerous and non-cancerous conditions in the lower part of the gastrointestinal system. The solid pharmaceutical compositions and pharmaceutical products comprise an active ingredient which is 5-aminolevulinic acid (5-ALA) or a precursor... Agent: Photocure Asa

20120134922 - Peptides whose uptake in cells is controllable: Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A—X—B—C)n—M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein... Agent: The Regents Of The University Of California

20120134923 - Radioiodination method: The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are novel radioiodinated BTMs prepared using the method, as well as radiopharmaceutical compositions comprising such radioiodinated BTMs. The invention also provides radioiodinated intermediates useful in the method, as well as in... Agent:

20120134925 - Application and uses of prg4 and therapeutic modulation thereof: The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a... Agent:

20120134927 - Beta cell marker antibody: The present invention relates to an antibody directed to a beta cell marker protein, in particular to an antibody directed to the protein TMEM27.... Agent: Hoffmann-la Roche, Inc.

20120134926 - Charge-dynamic polymers and delivery of anionic compounds: The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the... Agent: Wisconsin Alumni Research Foundation

20120134924 - Micro-vesicles providing contrast to target tissue electrical property gradients: Micro-vesicles that become acoustically sensitive in the presence of a Radio Frequency (RF) Electromagnetic (EM) field are presented. The micro-vesicles can comprise a main body having one or more affinity ligands configured to preferentially bind to a target tissue. Once bound, the micro-vesicles and the target tissue can be bathed... Agent: Magnetus, LLC

20120134928 - Modulation of terminase activity at telomeres and dna double-strand breaks: The present invention is directed to compositions and methods concerning terminase proteins. In particular, the present invention is directed to terminase proteins and their function in processing telomeres and double-strand breaks.... Agent: The Salk Institute For Biological Studies

20120134929 - Treatment of macrophage-related disorders: The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in... Agent:

20120134932 - Manganese-oxo clusters as contrast agents for magnetic resonance imaging: Nanoparticles for use as magnetic resonance imaging contrast agents are described. The nanoparticles are made up of a polymeric support and a manganese-oxo or manganses-iron-oxo cluster having magnetic properties suitable of a contrast agent. The manganese-oxo clusters may be Mn-12 clusters, which have known characteristics of a single molecule magnet.... Agent: Georgetown University

20120134931 - Peptides whose uptake in cells is controllable: Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A-X-B-C)-M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein... Agent: Regents Of The University Of California

20120134933 - Use of high-doses of monomeric contrast medium containing iodine in x-ray diagnostics, in particular in interventional x-ray diagnostics and in radiation therapy assisted by contrast media containing iodine: The invention relates to a diagnostic or therapeutic composition comprising a monomeric X-ray contrast medium containing iodine, in particular iopromide, for use in an X-ray assisted diagnosis or therapy and for the use of high doses of an X-ray contrast medium given to a patient, in particular patients with restricted... Agent: Bayer Pharma Aktiengesellschaft

20120134930 - Pyrazine derivatives for bioconjugation: Provided are compounds and compositions of general Formula IX: E1-L-Ar-X-PA, that may be utilized in bioconjugation procedures, where Ar is a chromophore and PA is a functional group capable of being attached to any bioactive molecule of interest. The present invention provides Formulas I-III that are capable of being attached... Agent: Mallinckrodt LLC

20120134934 - Glycine derivatives and medicinal compositions thereof: Alkaloid aminoester derivatives according to formula (I) and (VI) act as muscarinic receptor antagonists.... Agent: Chiesi Farmaceutici S.p.a.

20120134935 - Use of mometasone furoate for treating airway passage and lung disease: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.... Agent: Schering Corporation

20120134936 - Tooth whitener: A tooth whitener is provided, including a water-in-oil (W/O) emulsion phase including: a discontinuous phase comprising a peroxide, a hydrophilic solvent, and a polyol, and a continuous phase comprising a glycerol monooleate, a polymer and a polyol, wherein the tooth whitener is flowable upon being applied to teeth and is... Agent: Lg Household & Health Care Ltd.

20120134942 - Hybrid copolymer compositions for personal care applications: A personal care composition includes a hybrid copolymer including at least one ethylenically unsaturated monomer and a naturally derived hydroxyl containing chain transfer agent as an end group, a hybrid synthetic copolymer including one or more synthetic polymers derived from the at least one ethylenically unsaturated monomer with at least... Agent: Akzo Nobel N.v.

20120134938 - Melanin promoting topical composition: The invention provides sunless tanning compositions for application to skin comprising an effective amount of at least one dopamine precursor, an effective amount of curcumin and a dermatologically acceptable carrier. Methods for preparation of said compositions are disclosed. When applied to the skin, the compositions may be used darken skin.... Agent:

20120134941 - Method for smoothing out the skin by filling in recessed portions: The invention relates to a method for smoothing out the skin by filling in recessed portions of the skin, said method comprising filling the recessed portions by means of a filling-in product which has an elastic modulus of greater than 20 000 Pascals at 25° C. for a stress frequency... Agent: L'oreal

20120134940 - Nanodispersions: e

20120134937 - Personal care compositions having reduced eye irritation: The present invention is directed to a stable, minimal energy required self-assembling lamellar and spherulitic composition comprising: mixture water, fatty alcohol, fatty acid, salt of fatty acid, polyglyceryl fatty acid ester and oils. The present invention relates to composition that can benefit eye mildness, even distribution of sunscreen physical filters... Agent:

20120134939 - Water-in-oil emulsion sunscreen cosmetic composition: To provide a low-viscosity water-in-oil emulsion sunscreen cosmetic composition which is extremely excellent in UV protective enhancing effect (as the protective boosting effect of the UV absorption capability thereof) over a broad UV radiation region and has superior feeling in use (smooth feeling, dry feeling, and non-sticky feeling, etc.). A... Agent: Shiseido Company, Ltd.

20120134943 - Topical compositions comprising an alkoxylated diphenylacrylate compound and an aryl carboxylic ester: A topical composition containing an alkoxylated diphenylacrylate compound and an aryl carboxylic ester is provided. Preferably, the topical composition is a sunscreen composition containing α-ethylhexyl α-cyano-β-(4-methoxyphenyl)-β-phenylacrylate and 2-phenylethyl benzoate, and optionally further containing 4,4′-t-butyl methoxydibenzoylmethane, which is characterized by improved photo-protection of the skin and is effective in preventing/reducing photo-damage... Agent:

20120134945 - A3 adenosine receptor ligands for modulation of pigmentation: The present invention relates to compositions and methods for modulating melanin production, secretion and/or accumulation in human skin cells. In particular, the present invention relates to the use of A3 adenosine receptor antagonists in compositions and methods for the treatment and amelioration of hyper-pigmentation conditions and for the lightening of... Agent: Oradin Pharmaceutical Ltd.

20120134946 - Composition having antioxidant and whitening effects containing a concentrate of korean rice wine: Disclosed is a composition containing a concentrate of Korean rice wine as an active ingredient. The composition exhibits antioxidant and whitening effects, and thus can be variously used in the fields of cosmetics, functional food or medicine.... Agent: Amorepacific Corporation

20120134944 - Whitening agent and skin external preparation: s

20120134948 - Antimicrobial ether guanidines:

20120134947 - Antiperspirant compositions and products having cooling sensation effects and methods for making the same: A personal care product comprises an antiperspirant product that is housed within a container. The antiperspirant product includes a first portion comprising a dispersed cooling sensation agent. A second portion has a composition different from the first portion and comprises a solubilizer.... Agent: The Dial Corporation

20120134949 - Polymeric collagen biomaterials: This invention relates to the production of biomaterials from polymeric collagen (PC) and its seeding with cells and other components of biomaterials. Polymeric collagen is isolated from tissue, suspended in an acidic solution, and then neutralised at low temperature. The neutralised suspension is then seeded with biomaterial components, such as... Agent: Ucl Business PLC

20120134950 - Adhesion-promoting thin film and moisture resistant skin barrier compositions: Adhesion-promoting, thin film, moisture resistant skin barrier formulations are composed of a fugitive solvent mixture consisting of t-butanol and an alkane fraction composed of at least one alkane, where the t-butanol is in the range of 40-70% by weight of the solvent mixture, and a film-forming solute dissolved in the... Agent:

20120134951 - Topical gels and methods of using the same: Provided according to some embodiments of the invention are topical gels that may release nitric oxide. Also provided are methods of using such topical gels in the treatment of wounds and other skin ailments. The topical gels comprise diazeniutndiolate-functionalized polysiloxane macromolecules.... Agent:

20120134952 - Antiviral method: This invention provides a method of inactivating non-enveloped virus particles. The method includes the step of contacting the virus with a virucidally-enhanced alcoholic composition that includes an alcohol, and an enhancer selected from the group consisting of cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof.... Agent:

20120134953 - Anti-microbial composition: Anti-microbial compositions including an anti-microbial polymer containing silicon-containing quaternary ammonium groups, polyvinyl alcohol (PVA), at least one short chain alcohol, optional fragrance, and water are provided. The anti-microbial compositions may be used to disinfect both porous and non-porous surfaces. Exemplary compositions may include 0.1-10 wt % of the anti-microbial polymer... Agent: Minntech Corporation

20120134954 - Defensin-antigen fusion proteins: The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides... Agent: The Gov. Of The U.s.a. As Represented By The Secretary Of The Dept. Of Health & Human Services

20120134956 - Colloidal metal compositions and methods: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for... Agent: Cytimmune Sciences, Inc.

20120134958 - Hydroxyethyl starch-containing polypeptide compositions: The invention provides compositions containing hydroxyethyl starch and polypeptides, including therapeutic polypeptides such as interleukin-11, that provide for enhanced stability of the polypeptide following storage at room temperature or elevated temperatures.... Agent: Wyeth

20120134957 - Latent phase viral interleukin-10-(vii-10) and uses thereof: The present invention relates to a purified nucleic acid sequence encoding a homologue of human interleukin 10 (IL-10), wherein said IL-10 homologue is expressed during the latent phase of infection by a virus of the herpesvirideae group. The present invention also relates to uses of this polypeptide, in particular for... Agent: The University Of Syndey

20120134955 - Pyrimidopyrimidoindazole derivative: The invention is to provide a novel anticancer agent or sensitizer for cancer chemotherapy or radiotherapy. A compound of a general formula (I): wherein A means an aryl group or a heteroaryl group, or a group of a formula (a):; R1 means a —(C═O)aOb(C1-C6)alkyl group, a —(C═O)aOb(C2-C6)alkenyl group, a —(C═O)aOb(C3-C6)cycloalkyl... Agent:

20120134959 - Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses: The invention relates to pyrimidine compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.... Agent: Wyeth LLC

20120134960 - Glycosylated human alpha interferon muteins, method for obtaining them and use: A recombinant human interferon-alpha mutein that contains at least one glycosylation site at a position of its amino acid sequence that is a part of an alpha helix-type secondary structure, a gene encoding the mutein, a method for producing the gene, a method for obtaining an eukaryotic cell producing the... Agent: Protech Pharma, S.a.

20120134961 - Interferon-alpha (ifn-alpha) fused protein having ifn-alpha and cytoplasmic transduction peptide (ctp): Disclosed is an interferon-α (IFN-α) fused protein having IFN-α fused to a cytoplasmic transduction peptide (CTP). The disclosure relates to a fused protein wherein a CTP, which binds well to cell-membrane barriers and enables translocation into the liver, is genetically fused to a human IFN-α, thereby enhancing the conjugation capacity... Agent: Jw Pharmaceutical Corporation

20120134971 - Engineered biological pacemakers: Biological pacemakers engineered to intrinsically generate rhythmic excitations are disclosed. In addition, methods of producing the biological pacemakers are disclosed. Methods of treating or preventing arrhythmia and heart disease associated with a defective pacemakers are also disclosed.... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services

20120134972 - Novel polypeptides having endolysin activity and uses thereof: The present invention provides isolated polypeptides comprising a fragment of the amino acid sequence of SEQ ID NO:1, or a variant, derivative or fusion thereof, which is capable of binding specifically to and lysing cells of Clostridium difficile, wherein the polypeptide exhibits greater lytic activity on cells of Clostridium difficile... Agent: Plant Bioscience Limited

20120134970 - Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same: The present invention relates to compositions and methods for creation of vector nucleic acid sequences (e.g., retroviral nucleic acid sequences) that comprise two or more exogenous nucleic acid sequences that encode highly homologous (e.g., identical) polypeptide sequences, yet wherein at least one of the exogenous nucleic acid sequences has been... Agent:

20120134963 - Compositions and methods for enhancing virus efficacy: Provided are viral sensitizing compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the cytotoxicity of virus to cells. Other uses, compositions and methods of using same are also provided.... Agent: Ottawa Hospital Research Institute

20120134962 - Methods and compositions for tissue regeneration: Disclosed is a method of treating a wound comprising applying a composition to a wound site on a patient in need of wound treatment, wherein the composition comprises mitotically inactive allogeneic cells that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF,... Agent: Dfb Technology Holdings, LLC

20120134973 - Novel use of probiotics: The present invention relates to use of a probiotic to normalize abnormal inflammation markers. The present invention also relates to use of a probiotic for preventing and/or treating low-grade inflammation. Further, the present invention relates to use of a probiotic for preventing and/or treating disorders and/or diseases relating to low-grade... Agent: Valio Ltd.

20120134964 - Human matrix metalloproteinase-8 gene delivery enhances the oncolytic activity of a replicating adenovirus: The present invention discloses a method of treating cancer in a subject. This involves co-administering a replicating virus and a matrix metalloproteinase to the subject under conditions effective to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic... Agent: New York University

20120134968 - Composition for manufacturing a scaffold for tissue engineering, and a method of making it: The invention relates to a composition comprising a mixture of at least one degradable hydrogel and at least one kind of degradable and surface cross-linked particle. The at least one kind of degradable and surface cross-linked particle comprises a material which degrades faster than the degradable hydrogel. The composition can... Agent: Nanyang Technological University

20120134966 - Embryonic stem cell specific micrornas promote induced pluripotency: The methods of the present application describe that introduction of physiologically relevant miRNAs can enhance or modulate somatic cell reprogramming, generating induced pluripotent stem cells (iPS cells). These miRNAs did not further enhance reprogramming in the presence of cMyc. Furthermore, unlike previously described methods of generating iPS cells, such as... Agent: The Regents Of The University Of California

20120134965 - Method for differentiation of stem cells into vascular cells and the induction of angiogenesis using the same: The present invention relates to a method for differentiating stem cells into vascular cells by culturing them in the form of a three-dimensional cell cluster and the use of the three-dimensional cell cluster for angiogenesis. Specifically, the present invention teaches a method for differentiating stem cells into vascular cells comprising... Agent:

20120134969 - Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells: With an aim to provide a novel factor inducing proliferation of neural stem cells and differentiation of these cells into nerve cells, a pharmaceutical composition comprising 1) CRBN, 2) a nucleic acid encoding CRBN, or 3) a stem cell or a neural progenitor cell in which CRBN is expressed, a... Agent:

20120134967 - Scaffolds for cell transplantation: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release... Agent:

20120134974 - Methods for removing plasma: A method for preparing a blood component composition for reducing risk of transfusion related injury includes passing a blood component composition through a tangential flow filter unit comprising one or more filter membranes. A diafiltration solution is added to the blood component composition during the filtration process. Non-cellular plasma components,... Agent: Biovec Transfusion, LLC

20120134975 - Biological targeting compositions and methods of using the same: Modified red blood cells are described. In an embodiment, the modified red blood cell includes a target-binding agent. Targeted delivery of imaging agents, drugs, and peptide and protein pharmaceuticals using modified red blood cells are described. Processes for preparing the modified red blood cells, pharmaceutical and diagnostic compositions containing the... Agent: Searete LLC, A Limited Liability Corporation Of The State Of Delaware

20120134976 - Oral formulations for counteracting effects of aging: An oral formulation as described herein can comprise pomegranate extract, panax ginseng extract, and c. sinensis, where each is present in an amount effective to counteract and/or prevent effects of aging in a subject when administered to the subject. The effects of aging can include age-related changes in gene expression.... Agent:

20120134978 - Cross-linking of superoxide dismutase monomers: A stabilized superoxide dismutase (SOD1) analogue, wherein the side chains of two amino acids on two different SOD1 monomers are connected is provided. A method of producing a stabilized superoxide disumutase (SOD1) analogue comprises reacting a first SOD1 monomer, a second SOD1 monomer, and a cross-linker.... Agent: Brandeis University

20120134977 - Prodrugs containing albumin binding probe: The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses... Agent: Yeda Research And Development Co. Ltd.

20120134979 - Methods and compositions for the treatment of sickle cell disease: Presented are mechanism based compositions and methods for treatment of SCD and SCD associated symptoms and disorders, particularly increased RBC sickling, HbS polymerization, hemolysis, tissue congestion and disruption and organ damage or failure in a mammal. The disclosed methods feature the identification of the heretofore unknown role of adenosine levels... Agent:

20120134980 - Fragmented polymeric compositions and methods for their use: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels... Agent: Baxter International Inc.

20120134981 - Genes linking several complications of type-2 diabetes (t2d): The invention provides means and methods to predict, in subjects affected by type II diabetes (T2D), the probability of developing complications which include, but are not limited to, micro/macrovascular disorder, hypertension, neuropathy, atrial fibrillation, nephropathy and other major adverse cardiovascular events (MACE) that are associated with the disease, by detecting... Agent: Prognomix, Inc.

20120134983 - Method for identifying interventions that control the translational activity of ribosomal proteins in different mrna expression: The present invention relates to systems and methods for screening compounds and/or mutant ribosomal proteins in a eukaryotic cell that increase or decrease the translation of a target gene and thereby ameliorate or revert a defective and/or undesired translation of a target gene. Disclosed are compounds and proteins as identified... Agent:

20120134984 - Molecules with extended half-lives and uses thereof: The invention is directed to a molecule comprising an albumin binding domain (ABD) and an FcRn binding moiety, wherein said molecule has enhanced pharmacologic properties in vivo.... Agent:

20120134982 - Polypeptides, antibody variable domains & antagonists: The present invention relates to polypeptides e.g. protease resistant polypeptides, immunoglobulin (antibody) single variable domains e.g. which are protease resistant and also to vascular endothelial growth factor (VEGF) antagonists comprising these. The invention further relates to uses, formulations, and compositions comprising such polypeptides e.g. for delivery to the eye.... Agent:

20120134985 - Methods for modulating metabolic and circadian rhythms: The role of AMPK in arcadian rhythms and methods of screening for agents that modulate such rhythms are disclosed. Compositions that are useful for modulating such rhythms and uses thereof are also disclosed.... Agent: The Salk Institute For Biological Studies

20120134989 - Antibody formulations: Formulations of VLA-4 binding antibody are described.... Agent: Biogen Idec Ma Inc.

20120134990 - Combination therapy with type i and type ii anti-cd20 antibodies: The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a... Agent: Roche Glycart

20120134987 - Kinase inhibitors and methods of their use: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and... Agent:

20120134986 - Methods of prognosis for non-hodgkin lymphoma: Measurement of a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9), which determination may be referred to herein as a two gene score (TGS), powerfully predicts overall survival in patients with NHL, particularly overall survival in the context of anthracycline-based chemotherapy... Agent:

20120134988 - Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods: The invention provides methods of altering properties of Fc-containing molecule, comprising altering the sialylation of the oligosaccharides in the Fc region. Proteins having Fc regions having altered sialylation patterns are also provided.... Agent: The Rockefeller University

20120134991 - Compositions and methods for modulating d1-d2 dopamine receptor interaction and function: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor... Agent: Centre For Addiction And Mental Health

20120134993 - Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination: Disclosed are bispecific binding proteins comprising a antibody/soluble receptor bispecific binding protein that reduces the biological activity of both VEGF-A and FGF. The FGF binding moieties are generally soluble FGFR3 or FGFR2. An Fc polypeptide is fused to the C-terminus of the FGF binding moiety and VEGF-A binding moiety are... Agent: Zymogenetics, Inc.

20120134992 - Mesothelin antibody protein fusions and methods of use: The invention relates to fusion proteins comprising a stress protein fused with an engineered antibody or fragment that binds to mesothelin, or a stress protein fused with a biotin-binding protein in combination with a biotinylated engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins... Agent: Boston Biocom LLC

20120134994 - Monoclonal antibodies to fibroblast growth factor receptor 2: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.... Agent: Galaxy Biotech, LLC

20120134996 - Anti-met monoclonal antibody, fragments and vectors thereof , for the treatment of tumors and corresponding products: Use of a monoclonal antibody directed against the extracellular domain of hepatocyte growth factor is disclosed for the preparation of a medicament for the treatment of tumors and/or metastases and of a diagnostic tool for detecting neoplastic cells as well as vectors comprising at least a portion of the nucleotide... Agent: Metheresis Translational Research Sa,

20120134995 - Method for predicting the therapeutic responseiveness of a patient to a medical treatment with an egfr inhibitor: The invention provides a method of predicting the response of a patient affected with cancer to a treatment with an EGFR inhibitor, wherein the said method comprises detecting the level of expression of the phosphoprotein pP70S6k in sample from said subject. The invention also provides methods of treatment of cancer... Agent:

20120135000 - Methods and compositions for treating ocular disorders: The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis... Agent: Yale University

20120134997 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung... Agent: Compugen Ltd.

20120134999 - Porin b (porb) as a therapeutic target for prevention and treatment of infection by chlamydia: The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which... Agent:

20120134998 - Secreted ap2 and methods of inhibiting same: A method of reducing a symptom of a clinical disorder characterized by aberrantly elevated circulating aP2 is carried out by administering to a subject an inhibitor of secreted aP2, secretion of aP2, or a serum aP2 blocking agent. For example, glucose intolerance is reduced following administration of such an inhibitor... Agent: President And Fellows Of Harvard College

20120135001 - Combination of anti-ctla4 antibody with dasatinib for the treatment of proliferative diseases: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.... Agent: Bristol-myers Squibb Company

20120135002 - Compounds and methods for the treatment of cancer: The present invention relates to a pharmaceutical composition comprising: a) at least one iron uptake inhibitor, and b) at least one vitamin D and/or at least one analog thereof and/or at least one vitamin D receptor modulator, and optionally a pharmaceutically acceptable carrier.... Agent:

20120135003 - Anti-ilt7 antibody: An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of... Agent: Sbi Biotech, Ltd.

20120135005 - Anti-tnf-a antibodies and their uses: The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-α”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-α.... Agent:

20120135004 - Antibodies to matrix metalloproteinase 9: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light... Agent: Gilead Biologics, Inc.

20120135006 - Ultra high affinity neutralizing antibodies: Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such... Agent: Medimmune, LLC

20120135007 - Anti-lps enriched immunoglobulin preparations for the treatment and/or prophylaxis of a pathologic disorder: The invention relates to the use of preparations enriched with anti LPS antibodies, such as those derived from mammalian colostrum or avian eggs, and optionally further antibodies against disease-associated antigens, colostrums, milk or milk product component/s and any adjuvants for treating, delaying or preventing the progression of a pathologic disorder... Agent:

20120135009 - Cleaved and phosphorylated crmp2 as blood marker of inflammatory diseases of the central nervous system: The present invention relates to a method for in vitro prognosis, diagnosis and/or monitoring of an inflammatory disease of the central nervous system in a subject, said method comprising detecting, in a sample of cells of the immune system from the subject, the presence of a Collapsin Response Mediator Protein... Agent:

20120135008 - Methods and compositions for targeting polyubiquitin: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.... Agent: Genentech, Inc.

20120135010 - High affinity human antibodies to human il-4 receptor: An isolated human antibody or antigen binding fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with an affinity constant (KD) of less than 200 pM, as measured by surface plasmon resonance, is provided.... Agent: Regeneron Pharmaceuticals, Inc.

20120135011 - Method for in vivo expansion of t regulatory cells: Compositions specific for TNF-receptor superfamily member 25 (TNFRSF25, DR3) modulate the immune response by regulating T regulatory cells.... Agent: University Of Miami

20120135012 - Trans-membrane-antibody induced inhibition of apoptosis: Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis... Agent: Innexus Biotechnology Inc.

20120135013 - Cd45 and methods and compounds related thereto: Disclosed herein are compounds, compositions and methods for preventing, reducing or inhibiting an amount of protein tyrosine phosphatase receptor type C (CD45) expressed or activity of CD45 in a cell or a subject. Also disclosed are methods for preventing, inhibiting or treating an infection in a cell or a subject... Agent:

20120135016 - Induction of neurogenesis and stem cell therapy in combination with copolymer 1: A method for inducing and enhancing neurogenesis and/or oligodendrogenesis from endogenous as well as from exogenously administered stem cells comprises administering to an individual in need thereof an agent selected from the group consisting of Copolymer 1, a Copolymer 1-related polypeptide, a Copolymer 1-related peptide, and activated T cells which... Agent:

20120135015 - Induction of pancreatic stem cells by transient overexpression of reprogramming factors and pdx1 selection: Methods for generating pancreatic stem cells from a pancreatic tissue of 24-week old mice by transient overexpression of reprogramming factors combined with Pdx1 selection is described herein. The generated cells were designated as iPaS (induced pancreatic stem) cells and exhibit the same morphology as the pancreatic stem cells previously established... Agent: Baylor Research Institute

20120135014 - Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction: This application discloses methods, systems and kits for correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. Tolerance can be induced by solo or repeated administration of antigen, including soluble antigens administered either intravenously or... Agent: The University Of Tennessee Research Foundation

20120135017 - Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making: The present invention relates to embedding live or dead microorganisms and/or bioactive materials in a protective dry formulation matrix, wherein the formulation includes the bioactive microorganism or material, a formulation stabilizer agent, and a protective agent. The formulation is prepared by dispersing all the solid components in a solution, with... Agent:

20120135018 - Erg monoclonal antibodies: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In... Agent: The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.

20120135019 - Fviii peptides for immune tolerance induction and immunodiagnostics: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with... Agent: Baxter International Inc.

20120135020 - Ttk peptides and vaccines including the same: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical... Agent: Oncotherapy Science, Inc.

20120135022 - Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essentially consisting of vp3: The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for... Agent: Deutsches Krebsforschungszentrum

20120135021 - Cell penetrating peptides and its use fused to biomolecules with therapeutic action: The present invention relates to use of a new cell penetrating peptides (CPP) and in particular to the region 32-51 of protein Limulus antilipopolisacárido (LALF) and its analogous. This invention refers to compositions containing these peptides associated to biomolecules with therapeutics properties. This invention consist of compositions comprise the covalent... Agent:

20120135023 - Influenza hemagglutinin and neuraminidase variants: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.... Agent: Medlmmune, LLC

20120135025 - Chlamydia antigens and uses thereof: The present invention provides novel chlamydia antigens, nucleic acids encoding the antigens, and immunogenic compositions including the antigens. The present invention further provides methods of using the antigens to elicit immune responses (e.g., T cell-mediated and/or B cell-mediated immune responses). The present invention provides methods of prophylaxis and/or treatment of... Agent: Genocea Biosciences, Inc.

20120135026 - Combination neisserial compositions: Compositions comprising a first biological molecule from a Neisseria bacterium and a second biological molecule from a Neisseria bacterium. The term “biological molecule” includes proteins and nucleic acids. Preferred Neisseria species are N. meningitidis and N. gonorrhoeae.... Agent: Novartis Vaccines And Diagnostics Srl

20120135024 - Neisseria meningitidis antigens and compositions: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.... Agent: J. Craig Venter Institute, Inc.

20120135027 - Proteins used for the diagnosis of lyme borreliosis: Chimera proteins including: (i) at least one sequence of a DbpA protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and B. garinii, and (ii) at least one sequence of an OspC protein of a Borrelia species selected from B. afzelii, B. burgdorferi sensu stricto and... Agent: Biomerieux

20120135028 - Vaccine: The present disclosure provides immunogenic compositions that include at least two paramyxovirus F protein antigens selected from human metapnuemovirus (hMPV), paarainfluenza virus (PIV) and respiratory syncytial virus (RSV). The antigens of the disclosed compositions are recombinant F protein polypeptides, which have been modified to stabilize the trimeric prefusion conformation. Nucleic... Agent: Biomedical Corporation Of Quebec

20120135029 - Method for the purification of protein complexes: The present invention provides an improved method for the purification of a mixture of complexes comprising a stress protein complexed to a peptide or peptide fragment from a source mixture, typically a cell lysate. The method of the invention provides for protein complexes to be purified using ion exchange chromatography... Agent: Immunobiology Limited

20120135030 - Method of producing protein-carbohydrate vaccines reduced in free carbohydrate: This invention is directed to processes for reducing the level of free carbohydrate from a solution of protein-linked carbohydrate (conjugate) and non-linked carbohydrate. In this process, the conjugate is adsorbed to a hydrophobic membrane while the carbohydrate is not. The conjugate is then desorbed from the membrane, yielding a solution... Agent: Fina Biosolutions, LLC

20120135032 - Generation of a broad t-cell response in humans against hiv: The present invention relates to a recombinant Modified Vaccinia virus Ankara (MVA) comprising in the viral genome one or more expression cassettes for the expression of HIV proteins selected from Gag, Pol, Tat, Vif, Vpu, Vpr, Rev and Nef or a part or a derivative thereof or selected from Gag,... Agent: Bavarian Nordic A/s

20120135031 - Method of enhancing an immune response: A method of enhancing an immune response to an antigen is provided. The method involves augmenting the level of a TAP molecule in a target cell bearing the antigen. Preferably, the TAP molecules enhanced by administering a nucleic acid sequence encoding a TAP-1 and/or TAP-2 molecule. The method is useful... Agent: Tapimmune, Inc.

20120135033 - Multiple delivery system for heterologous antigens: The invention is directed to an episomal recombinant nucleic acid encoding at least two heterologous antigens each fused to a PEST-endogenous polypeptide, vaccines comprising the same, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering the same.... Agent:

20120135034 - Non-integrating retroviral vector vaccines: This invention relates to non-integrating, non-replicating retroviral vectors that cause an immune response in an animal host when administered to the host. The vectors transduce cells in the host, where they produce virus-like particles (VLPs), which stimulate an additional immune response in the host when they are released from the... Agent:

20120135035 - Induction of an immune response against dengue virus using the prime-boost approach: The invention relates to methods for the induction of an immune response to dengue virus. The method of inducing an immune response against dengue virus comprises administration of a non-replicating immunogen followed by a boost with a tetravalent live attenuated viral vaccine. Another aspect of the inventive subject matter is... Agent:

20120135036 - Bacterial composition and its use: The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is... Agent:

20120135037 - Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same: The present invention is based, in part, on flagellin adjuvant used to enhance immune responses directed against Streptococcus pneumoniae, in particular, to enhance immune responses to polypeptide antigens (e.g., PspA) and capsular polysaccharide from S. pneumoniae. In representative embodiments, the invention provides a fusion protein comprising a flagellin adjuvant and... Agent:

20120135038 - Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines: Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark,... Agent:

20120135039 - Oral vaccines for producing mucosal immunity: Embodiments of this invention include lipid-based immunogenic compositions (adjuvants or carriers) useful for oral or gastrointestinal administration for improving mucosal immune responses in animals vaccinated for a variety of bacterial infections. In certain embodiments, lipid compositions of this invention include a mixture of fatty acids having different chain lengths, thereby... Agent:

20120135040 - Temperature sensitive vaccine strain of mycoplasma hyopneumoniae and uses thereof: The present invention relates to a Mycoplasma hyopneumoniae vaccine strain comprising a mutation in at least one of the genes listed or as deposited with the National Measurements Institute (Australia) under accession number NM04/41259, which strain is temperature sensitive and attenuated, a vaccine comprising such strains and methods and uses... Agent:

20120135043 - Immunomodulatory properties of multipotent adult progenitor cells and uses thereof: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response.... Agent:

20120135041 - Immunosuppressor based on the blockage of tcr-nck interaction: The present invention relates to a compound of structural formula (I) and its derivatives for use as medicinal drugs. They are preferably immunosuppressive agents, with mechanism of action based on the blockage of TCR-Nck interaction.... Agent: Consejo Superior De Investigaciones Cientificas

20120135042 - Methods using immunomodulatory compounds for treatment of certain leukemias: Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention. The invention further relates to methods of treatment using an immunomodulatory compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms... Agent:

20120135044 - Instant thickener comprising probiotics for hot or cold foods and beverages to be administered to dysphagic patients: The present invention relates to the fields of hydration and nutrition for dysphagic patients. In particular, the present invention relates to thickeners comprising probiotic microorganisms and to compositions comprising such thickeners. The probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic microorganisms.... Agent: Nestec S.a.

20120135048 - novel formulation of indomethacin: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way... Agent: Iceutica Pty Ltd

20120135045 - Antimicrobial collagenous constructs: Bioengineered collagen constructs with antimicrobial properties are provided. The bioengineered collagen constructs comprise a sheet-like layer of purified collagenous tissue matrix derived from a tissue source, such as the tunica submucosa of small intestine or a processed intestinal collagen layer derived from the tunica submucosa of small intestine, treated with... Agent: Organogenesis, Inc.

20120135046 - Corticosteroid particles and method of production: A new particle morphology of glucocorticosteroids is described. The forms have a particle morphology that is particularly well suited for use in an inhaled corticosteroid drug suspension formulation for delivery from a next generation nebulizer device. Use of the new glucocorticosteroid particles enables enhanced drug delivery efficiency and increased residence... Agent: Map Pharmaceuticals, Inc.

20120135049 - Decellularized tissue engineered constructs and tissues: Methods for producing tissue engineered constructs and engineered native tissues include producing a tissue engineered construct by growing cells in vitro on a substrate and then decellularizing the construct to produce a decellularized construct consisting largely of extracellular matrix components. The construct can be used immediately or stored until needed.... Agent: Duke University

20120135055 - Dry powder inhaler formulations: A dpi formulation comprises a solvate of beclomethasone and is substantially free of excipient and free of carrier. The solvate particles are of size 0.5 to 10 microns and are obtained by crystallization of the steroid in the presence of ultrasound.... Agent: Breath Limited

20120135050 - Extended-release formulation for reducing the frequency of urination and method of use thereof: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount... Agent: Wellesley Pharmaceuticals, LLC

20120135051 - Generation of vascularized human heart tissue and uses thereof: The present invention relates to the generation of vascularized human heart tissue from human primordial Islet1-positive (ISL1+) progenitors, and more particularly the generation of vascularized human heart tissue from human primordial Islet1+ cardiovascular stem cells which are positive for markers ISL1+/NKX2.5−/KDR−. One aspect of the invention relates to isolation of... Agent: The General Hospital Corporation

20120135052 - Method for preparing an organic-compatible and water-compatible composition of metal nanocrystals, and resulting composition: A method for preparing a composition of metal nanocrystals from at least one organometallic precursor in a solvent medium in the presence of a PEG ligand, including a carbon chain, at least one end of which is functionalized by a coordination grouping including at least one hetero atom, and having... Agent:

20120135053 - Nanoparticulate telmisartan compositions and process for the preparation thereof: The present invention is directed to nanostructured (nanoparticulated) Telmisartan compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Telmisartan according to the invention have an average particle size of less than about 600 nm. Telmisartan is an angiotensin II receptor antagonist (ARB) used in the... Agent:

20120135047 - Novel formulation of diclofenac: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way... Agent:

20120135054 - Poly (ester ether amide)s and uses thereof: Cationic poly(ester ether amide)s (PEEAs) and compositions comprising PEEAs and biomolecules such as nucleic acids and proteins. Also, a method for intracellular delivery of biomolecules using complexes of the PEEAs and biomolecules. For example, PEEAs can be used as transfection agents for nucleic acids such as DNA and RNA.... Agent: Cornell University

20120135057 - Antiperspirant compositions and products having a dispersed cooling sensation agent and methods for making the same: A personal care product comprises an antiperspirant product that is housed within a container. The antiperspirant product comprises a dispersed cooling sensation agent that is adsorbed onto surfaces of silica particles that are dispersed throughout the antiperspirant product, absorbed into pores of the silica particles or a combination thereof.... Agent: The Dial Corporation

20120135056 - Antiperspirant compositions and products having predetermined effects and methods for making the same: A personal care product comprises an antiperspirant product housed within a container. The antiperspirant product comprises a first portion comprising a first ingredient. A second portion is macroscopically separated from the first portion. The second portion has a composition different from the first portion and comprises a second ingredient effective... Agent: The Dial Corporation

20120135058 - Nanodispersions: (ii) freeze-drying the mixture to remove solvent (a) and thereby obtain the carrier material (b) in solid form with payload (c) dispersed therein as nanoparticles.... Agent: Iota Nanosolutions Limited

20120135059 - Preparation for oral cavity: Object of the present invention is to provide a preparation for oral cavity that is appropriately usable as a prophylactic agent for dental caries, a therapeutic agent for dental caries at early stage, a prophylactic and/or therapeutic agent for dentinal hypersensitivity, a preparation for the lining of a dentin cavity... Agent: Nippon Shika Yakuhin Co., Ltd.

20120135060 - Compositions and methods for cell killing: Provided herein are biocidic compositions including an ion exchange material, wherein when said material is in an environment capable of transporting H+, said ion exchange material is adapted to cause the death of at least one cell within or in contact with said environment. A selectively permeable barrier layer may... Agent:

20120135061 - Pary-xylene based microfilm elution devices: This invention is in the field of controlled elution devices for therapeutic delivery. There exists a need for a stand-alone capable device for the localized and extended delivery of a therapeutic. This need is overcome by the present invention having an exemplary embodiment comprised of a microfilm base (12), a... Agent: Cute Lovable Teddy Bear, LLC

20120135062 - Wound dressing materials: A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressing comprising the materials, methods of treatment with the materials, and methods of making the materials.... Agent: Systagenix Wound Management (us),inc.

20120135065 - Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome: An amphoteric liposome composed of a mixture of lipids, said mixture comprising a cationic amphiphile, an anionic amphiphile and optionally one or more neutral amphiphiles, at least one of said cationic and anionic amphiphiles being chargeable and the respective amounts of said cationic and anionic amphiphiles being selected such there... Agent: Marina Biotech, Inc.

20120135064 - Conjugated nanodelivery vehicles: Anti-angiogenesis agent-linked liposomes and micelles, methods of making such liposomes and micelles, and methods of using such liposomes and micelles, such as for delivery of therapeutic and detection agents to tumor cells, are described.... Agent: Northeastern University

20120135063 - Glucuronic acid-containing glucan, process for production of same, and use of same: An object of the present invention is to provide a uronic acid-containing glucan or a modified product thereof. The glucuronic acid-containing glucan of the present invention is a glucuronic acid-containing glucan in which a glucuronic acid residue is bound to at least one non-reducing end of a glucan, and the... Agent: Ezaki Glico Co., Ltd.

20120135068 - Liposome-encapsulated glutathione for oral administration: The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related... Agent:

20120135066 - Regulators of the hedgehog pathway, compositions and uses related thereto: The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.... Agent:

20120135067 - Vaccine for mycoplasma infection: Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria.... Agent: National Institute Of Infectious Diseases

20120135071 - Abuse-proofed dosage form: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from... Agent: Grunenthal Gmbh

20120135070 - Copolymers: The invention provides a block copolypeptide comprising a hydrophilic heteropolypeptide block (A) and a hydrophobic homopolypeptide block (B). There is also provided a polymersome comprising a block copolypeptide of the invention. The invention further provides a method for preparing a copolymer comprising ring-opening polymerisation (ROP) of an amino acid N-carboxyanhydride... Agent: Universiteit Leiden

20120135069 - Nanonized testosteron formulations for improved bioavailability: Nanonized formulations of testosterone esters, especially testosterone undecanoate, and of testosterone are prepared which show an enhanced oral bioavailability compared to the existing oral products on the market. The drug is dissolved in a melted lipid phase, which is subsequently nanonized. The drug is associated with the lipid. The drug... Agent: Pharmasol Gmbh

20120135072 - Oral drug delivery system: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.... Agent:

20120135073 - Oral drug delivery system: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.... Agent:

20120135074 - High-strength testosterone undecanoate compositions: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the present invention provides for a pharmaceutical composition that includes a therapeutically effective amount of testosterone undecanoate and a solubilizer. The testosterone undecanoate is solubilized... Agent:

20120135075 - Dosage form: The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising: melt-extruded particulates comprising a drug; and a matrix; wherein said melt-extruded particulates are present as a discontinuous phase in said matrix.... Agent: Euro-celtique S.a.

20120135076 - Intrabuccally rapidly disintegrating tablet and a production method of the tablets: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter,... Agent:

20120135077 - Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings: A sustained release formulation for opioid drugs is described. The formulation contains an opioid-ion exchange resin complex having a hybrid coating. The hybrid coating contains a cured polyvinylacetate polymer and a pH-dependent enteric coating layer mixed therein. Also provided are methods of making and using same.... Agent: Tris Pharma, Inc.

20120135078 - Angina treatment: A xanthine oxidase inhibitor for use in the treatment of angina is described. The angina may be stable angina pectoris and the treatment may be to eliminate, reduce or alleviate one or more symptoms of angina pectoris (such as chest pain), or may be prophylactic. The xanthine oxidase inhibitor may... Agent: University Of Dindee

20120135079 - Modified release tranexamic acid formulation: A modified release dosage form for the oral administration of tranexamic acid.... Agent: Watson Pharmaceuticals, Inc.

20120135080 - Core-shell magnetic particles and related methods: The invention provides core-shell magnetic particles comprising a magnetic core and a functional shell, methods for making same, methods of separation using same, methods for using same, and devices comprising same. The particles and methods of the invention are useful for targeting and removing substances of interest that may be... Agent: Massachusetts Institute Of Technology

20120135081 - Hydrophobins for dispersing active agents: In the field of drug or nutrient administration novel particles and formulations thereof are provided. Said particles each have a core comprising active agent and at least partial coating comprising proteins, selected from hydrophobins. Preferable hydrophobins belong to class I or class II. Said particles exhibit enhanced characteristics, for example... Agent: Teknologian Tutkimuskeskus Vtt

20120135082 - Extended release compositions comprising as active compound venlafaxine hydrochloride: The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with polymeric layer which enables the controlled release of the Venlafaxine Hydrochloride.... Agent: Lycored Bio Ltd.

20120135083 - Dried product and a process for manufacturing the product: A dried product of an extract from inflammatory rabbit skin inoculated with vaccinia virus having an inhibitory activity for the production of a kallikrein-like substance is produced by admixing the extract with a saccharide, sugar alcohol or ascorbic acid before reaching dryness, and then drying the admixture to a solid... Agent: Nippon Zoki Pharmaceutical Co., Ltd.

20120135085 - Method and composition for disinfection and purification: A method and composition for a non-toxic aqueous silicon solution.... Agent:

20120135084 - Use of deuterium oxide for treating viral diseases of the eye: The invention relates to the use of deuterium oxide for the prophylaxis and/or therapy of viral diseases of the eye.... Agent: D2 Bioscience Group Ltd

20120135086 - Method of tissue repair using a composite material: A composite biocompatible hydrogel material includes a porous polymer matrix, the polymer matrix including a plurality of pores and providing a Young's modulus of at least 10 GPa. A calcium comprising salt is disposed in at least some of the pores. The porous polymer matrix can comprise cellulose, including bacterial... Agent: Ut-battelle, LLC

20120135087 - Topical compositions designed to maintain or restore the integrity of the mucous membranes: The present invention relates to topical compositions containing choline alfoscerate for use in maintaining and restoring the integrity of the mucous membranes.... Agent: Ricerfarma S.r.l.

20120135088 - Fungicidal composition and method for controlling plant diseases: wherein X is a halogen atom, a nitro group, a substitutable hydrocarbon group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group, a hydroxyl group, a substitutable alkylthio group, a cyano group, a carboxyl group which may be esterified or amidated, or a substitutable amino group, n... Agent: Ishihara Sangyo Kaisha, Ltd.

20120135089 - E3 ligase inhibitors: The present invention provides, e.g., compounds having the structure of formula (I): The present invention also provides pharmaceutical compositions that include such compounds, and methods for modulating murine double minute 2 protein (Mdm2) E3 ligase activity, particularly the Mdm2-MdmX hetero-complex E3 ligase activity, using such compounds.... Agent:

20120135090 - Solutions comprising polyethylene glycol and electrolytes: The invention provides a solution in water comprising the following components at the following concentrations: (a) N×(70 to 130) g/L polyethylene glycol (PEG) having an average molecular weight of 2500 to 4500; (b) N×(1.6 to 4.0) g/L sodium chloride; (c) N×(0.2 to 0.6) g/L potassium chloride; (d) N×(0.6 to 2.2)... Agent:

20120135091 - Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides: The present invention concerns the use of active compounds, including chalcogenides and sirtuin-modulating compounds, either alone or in combination for increasing or enhancing survivability and/or longevity in biological matter. In general aspects, the chalcogenides and other active compounds may modulate one or more sirtuin proteins. It includes compositions, methods, articles... Agent:

20120135092 - Inhibitors of reca activities for control of antibiotic-resistant bacterial pathogens: Compounds for modulating RecA protein activity are provided. In some embodiments, the compounds modulate RecA activity by interfering with assembly of monomeric RecA protein subunits into a nucleoprotein filament. In some embodiments, the compounds modulate RecA activity by interfering with adenosine triphosphate hydrolysis by the RecA protein. In some embodiments,... Agent:

20120135093 - Soap composition for treating acne containing absolute ginseng essential oil: The present invention discloses a soap composition containing a ginseng absolute oil, based on the finding that a ginseng extract, particularly a ginseng absolute oil, has a potent effect on the treatment of acne. A soap composition for treating acne according to one embodiment of the present invention was used,... Agent: Soonchunhyand University Industry Academy Cooperation Foundation

20120135094 - Oregano and mint anti-inflammatory compositions and methods: The present invention relates to bioactivity-guided isolation and identification of bioactive compounds from oregano and mint plants, in particular, rosmarinic acid, oleanolic acid and ursolic acid, and use of these compounds or combinations thereof as anti-inflammatory agents for the treatment of conditions related to pain and inflammation and/or as ingredients... Agent: Rutgers, The State University Of New Jersey

20120128580 - Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status: The present invention provides methods for the preselection of a subject for therapeutic treatment with elesclomol based on modulated levels of hypoxia in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with elesclomol based on modulated levels of lactate dehydrogenase... Agent: Synta Pharmaceuticals Corp.

20120128581 - Sincalide formulations: The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations as well as methods for treating, preventing, and diagnosing gall bladder-related disorders using... Agent: Bracco Suisse S.a.

20120128582 - Methods and compositions of [32p]-labeled adenine nucleotides for the treatment of atherosclerosis, vascular arterial diseases and coronary artery diseases: A method for the treatment of atherosclerosis. The method includes the administration of a 32P-labeled agent as a beta emitter, such as 32P-labeled ATP or other 32P-labeled adenine nucleotides, whereby the 32P-labeled agent seeks and then permeates the atherosclerotic plaque en bloc without prior degradation. The accumulation of the 32P-labeled... Agent:

20120128583 - Dtpa derivative, metal complex, mr and ct contrast agent and method for manufacturing same: The present invention relates to DTPA derivatives capable of forming complexes by combining with metals and the like, metal complexes formed by combining with the DTPA derivatives, MR and CT contrast agents including gold (Au) nano-particles of which surfaces are coated with the metal complexes, and a method for manufacturing... Agent: Kyungpook National University Industry Academic Cooperation Foundation

20120128584 - Anti-cdh3 antibodies labeled with radioisotope label and uses thereof: The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present... Agent: Oncotherapy Science, Inc.

20120128586 - Method for treating chronic lymphocytic leukemia: The present invention provides a method for treating a subject having chronic lymphocytic leukemia (CLL) comprising administering to the subject one or more agents that target cell surface membrane antigens expressed preferentially on cells of the proliferative compartment of a CLL clone of the subject to treat chronic lymphocytic leukemia... Agent: The Feinstein Institute For Medical Research

20120128585 - Method of diagnosing the presence of a tumor in a mammal by assessing cdo expression level: The present invention provides for a method of using BOC/CDO hedgehog antagonists to inhibit hedgehog signaling, as well as treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders, as well as other conditions affected by hedgehog signaling such... Agent: Genentech, Inc.

20120128587 - Folate-targeted diagnostics and treatment: Methods of detecting and assessing functionally active folate receptors on tumors and treatment associated with those tumors are described. Also described are methods of selecting ovarian and lung cancer patients for therapy with a folate-vinca conjugate by identifying functionally active folate receptors on the tumors of the patient. Also described... Agent: Endocyte, Inc.

20120128588 - Isotope labeled 2-arylpropionic acid compounds and process for production of same, and molecular probe for positron emission tomography and method for imaging of cyclooxygenase and the like using same: Disclosed are: labeled NSAIDs compounds which can be produced within a short time, can be used suitably for a PET method, and enable the imaging of cyclooxygenase-2; and a process for producing the labeled NSAIDs compounds. Specifically disclosed are isotope-labeled 2-arylpropionic acid compounds, each of which is a compound represented... Agent:

20120128589 - Perfluoro compounds for use in imaging: Described is the use of perfluoro-t-butyl cyclohexane in a contrast agent for molecular imaging, notably F MRI. Particularly, the perfluoro-t-butyl cyclohexane is present in the form of an aqueous emulsion of nanoparticles comprising the perfluoro compound as a core, and an emulsifying agent, such as a phospholipid, as a shell.... Agent: Koninklijke Philips Electronics N.v.

20120128591 - Anti-fap antibodies and methods of use: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.... Agent:

20120128590 - Nanoparticle delivery systems for membrane-integrating peptides: Compositions which comprise emulsions of nanoparticles for delivery of membrane-integrating peptides are described. The nanoparticles comprise a liquid hydrophobic core coated with a lipid/surfactant layer which contains the membrane-integrating peptides. Methods to use such compositions are also described.... Agent: Washington University

20120128592 - Surface enhanced raman spectroscopy (sers) compounds and methods of their preparation: m

20120128594 - Selective infarcted-tissue-targeting bacteria and use thereof: The present invention relates to bacteria which specifically target infracted tissue and use thereof. The present invention provides a selective infracted tissue-targeting bacterium for the first time, and can be used in selectively delivering drugs to the infracted tissue or in selectively imaging the infracted tissue. The infracted tissue-targeting bacterium... Agent: Industry Foundation Of Chonnam National University

20120128593 - Use of a magnetic resonance imaging medium comprising hyperpolarized 13c pyruvate for the detection of inflammation or infection: The invention relates to a method of 13C-MR imaging, 13C-MR spectroscopy and/or 13C-MR spectroscopic imaging of inflammation or infection using an imaging medium which comprises a hyperpolarized 13C-substance.... Agent:

20120128595 - Preparation of a lipid blend and a phospholipid suspension containing the lipid blend: The present invention describes processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent.... Agent: Lantheus Medical Imaging, Inc.

20120128596 - Fluorescent phospholipid ether compounds, compositions, and methods of use: The invention generally relates to novel fluorescent phospholipid compounds, compositions comprising these compounds, and diagnostic methods utilizing these compounds. A preferred compound of the present invention has the following structural formula: (I)... Agent: Cellectar, Inc.

20120128597 - Composition for prevention and treatment of allergic and/or inflammatory diseases: A prophylactic antiallergenic composition includes at least one arabinogalactan or arabinogalactan protein. The arabinogalactan or arabinogalactan protein is isolated from a grass or corresponds in its structural arrangement to an arabinogalactan that can be isolated from a grass.... Agent: Protectimmun Gmbh

20120128598 - Topical pharmaceutical foam composition: A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an oil-in-water emulsion which contains one or more hydrofluoroalkane (HFA) propellants and one or more keratolytic agents. The keratolytic agent may be present in either phase of the emulsion or dispersed in... Agent: Precision Dermatology, Inc.

20120128599 - Oral care composition: Disclosed are oral care compositions and the use of such oral care compositions for treating conditions caused by biofilm formation. Also disclosed are methods for inhibiting biofilm formation and/or degrading biofilm. The oral care composition includes a sesquiterpenoid and an antimicrobial agent, in which the sesquiterpenoid and the antimicrobial agent... Agent: Colgate-palmolive Company

20120128600 - Dental care product: A dental care product comprises an orally acceptable carrier or excipient, and a bacterial resistance copolymer, which comprises a zwitterionic block and a charged anchoring block, wherein the anchoring block binds to tooth surfaces by electrostatic attraction, and the zwitterionic block extends outwardly to reduce the attachment of bacteria to... Agent:

20120128601 - Alkyl sulfosuccinate mixtures, and use thereof: The invention relates to mixtures of alkyl sulfosuccinate monoesters of general formulas (I) and/or (II), in which R represents a linear or branched, saturated or unsaturated alkyl group having 6 to 22 C atoms, and X and Y independently represent a hydrogen atom or a cation that can form a... Agent:

20120128605 - Compositions comprising a skin-lightening resorcinol and a skin darkening agent: The present invention relates to a composition comprising a skin-lightening resorcinol and a skin darkening agent. The composition may be topically applied to the skin, such as to treat signs of aging.... Agent:

20120128603 - Cosmetic compositions: A cosmetic composition comprises a) an N-acyl amino acid compound selected from the group consisting of N-acyl amino acid, its isomers, its salts, derivatives thereof, and mixtures thereof, and b) hexyldecanol.... Agent:

20120128607 - Extract of whole seeds of morninga sp, and use thereof in cosmetic and/or dermatological compositions: The present invention relates to an extract of whole seeds of Moringa sp. containing oil (including triglycerides, fatty acids, and polar lipids) and polyphenols and to the use thereof in cosmetic and/or dermatological compositions.... Agent: Pierre Fabre Dermo-cosmetique

20120128608 - Hybrid copolymer compositions: Hybrid copolymer compositions include a hybrid copolymer including at least one ethylenically unsaturated monomer and a naturally derived hydroxyl containing chain transfer agent as an end group; and a hybrid synthetic copolymer including one or more synthetic polymers derived from the at least one ethylenically unsaturated monomer with at least... Agent: Akzo Nobel N.v.

20120128606 - Luna creme: The invention provides a product line features Skin Beautifying Milk, Body Creme, Fade Creme and Maxi Tone. Ingredients include, but are not limited to: water, pentylene glycol, glyceryl stearate, mineral oil, PEG-100 stearate, glycerin, palmitic acid, sodium dihydroxycetyl phosphate, ehtylhexyl palmitate, stearic acid, petrolatum, xanthan gum, beeswax, cetearyl alcohol, phenoxyethanol,... Agent:

20120128604 - Method for manufacturing highly iridescent titanium oxide composition: A highly iridescent titanium oxide composition, which not only produces new and outstanding luster as well as color brightness within a recognized color range by interference colors but also retains clear complementary colors. The highly iridescent titanium oxide composition is a coating composition forming a coating layer over the surface... Agent: Nihonkoken Kougyo Kabushiki Kaisha

20120128602 - Skin compositions containing low levels of colorants: A composition for providing enhanced skin appearance, particularly in terms of providing the appearance of reduced dryness and flakiness for an extended period of time, is disclosed. The compositions include low levels of skin coloring agents, including self-tanning compounds, such as DHA and/or erythrulose, in a topical cosmetic base. The... Agent: Kao Corporation

20120128610 - Cosmetic or dermatological preparation: The invention relates to a cosmetic or dermatological preparation comprising: a) one or more chemical light protection filters, selected from the group of 2,4,6-Trianilino-p-(carbo-2′-ethylhexyl-1′oxy)-1,3,5-triazine (ethylhexyl triazon), 1-(4-tert-butylphenyl)-3-(4-methoxyphenyl)-propane-1,3-dion (butyl methoxydibenzoyl-methane), bisoctyloxyphenol-methoxy-phenyl-triazine (bis-ethylhexyloxyphenol methoxyphenyl triazine) and 2-[-4-(diethylamino)-2-hydroxybenzoyl] benzoic acid hexylester (diethylamino hydroxybenzoyl hexyl benzoate); and/or one or more light protection filters selected... Agent:

20120128609 - Cosmetic use of natural emulsifiers: The use of natural emulsifiers for the preparation of cosmetics comprising a wax, an active ingredient and an emulsifier which allows the formation of an oil-in-water emulsion is disclosed. Preferably, said natural emulsifier is olive oil transesterified with cetearyl alcohol and/or sorbitol.... Agent:

20120128611 - Uv filter combinations comprising benzylidene malonates: Disclosed is the use of a UV filter combination, comprising (a) a first UV filter selected from benzylidene malonates of formula (1), wherein R1 methyl; ethyl; propyl; or n-butyl; if R1 is methyl, then R is tert. butyl; formula (II); formula (III); a radical of formula (1a); or a radical... Agent: Basf Se

20120128612 - Azole antifungal compositions: The present invention relates generally to antifugal compositions. In an embodiment, the antifungal compositions are effective for application to nails and surrounding skin, and comprise at least one volatile solvent, at least one film forming substance, and at least one pyrimidone derivative of formula I, such as albaconazole. These compositions... Agent: Palau Pharma, S.a.

20120128613 - Compositions comprising a skin-lightening resorcinol and a skin darkening agent: The present invention relates to a composition comprising a skin-lightening resorcinol and a skin darkening agent. The composition may be topically applied to the skin, such as to treat signs of aging.... Agent:

20120128614 - Solvent, solution, cleaning composition and methods: A cleaning composition can comprise aqueous, nonaqueous liquid, or solid formulations The formulations can contain a surfactant and a solvent The solvent has been shown to have utility in promoting removal, solubilizing or cleaning undesirable soil residues from a number of substrates The solvent materials can be used as a... Agent: Segetis, Inc.

20120128617 - Hair treatment agents comprising polyether-modified organic compounds and hair styling polymers: Hair treatment agents that, in addition to at least one hair-setting polymer, additionally contain polyether-modified organic compounds having at least three polyether substituents, the polyethers comprising a polyalkylene chain made up of ethylene oxide units or ethylene oxide units and propylene oxide units, having a maximum proportion of 50 wt... Agent:

20120128618 - Cosmetic cleaning agent having novel mixture of active agents: A cosmetic cleaning and care agent having good foaming properties includes a) at least one mild anionic surfactant and at least one mild amphoteric/dipolar ionic surfactant, wherein the total quantity of mild anionic and mild amphoteric/dipolar ionic surfactant is 3 to 20% by weight, b) 0.005 to 5% by weight... Agent: Henkel Ag & Co, Kgaa

20120128619 - Cosmetic agent: A cosmetic agent particularly useful for the styling of keratin fibers such as human hair is disclosed. The cosmetic agent of the present invention contains a unique combination of specific amphoteric polymers with an amphiphilic anionic polymer that imparts optimized properties to the agent without additional active ingredients. Styling agents... Agent: Henkelstrasse 67

20120128615 - Hair treatment composition: Provided is a hair treatment composition capable of imparting good manageability and excellent hair feel to the hair upon finishing permanent wave or hair dye treatment. The hair treatment composition has the following components (A) and (B): (A) a compound represented by the following formula (1): R1O-(PO)n(EO)m-R2 (1) wherein R1... Agent: Kao Corporation

20120128616 - Cosmetic composition comprising at least one elastomeric polyurethane and at least one cationic polymer: Provided is a cosmetic composition comprising, in a cosmetically acceptable medium, at least one film-forming elastomeric, anionic polyurethane, and at least one cationic polymer, as well as a method for the styling of the hair comprising applying this composition to the hair.... Agent:

20120128620 - Animal litter: An animal litter is provided. The animal litter includes zeolite, a sub-blend comprising organic proteins, amino acids, carbohydrates, surfactants, and oxidizers, and a blend of bacteria that functions as a biological inhibitor, wherein the zeolite and the sub-blend are coupled together by the application of the blend of bacteria. Under... Agent:

20120128621 - Long-wearing cosmetic composition: The present invention relates to a cosmetic composition particularly useful for the application of color such as in a foundation, lip gloss, lip stick, mascara, eye shadow, blush, and nail polish, for example. A cosmetic composition according to the present invention includes a film-forming silicone-containing polyurethane having a viscosity from... Agent: Avon Products, Inc.

20120128622 - Mrsa bactericidal topical gel: The present invention is directed to an enhanced wound healing composition, including a gel containing vancomycin, useful for the prevention of the spread of resistant-type bacteria. Preferably, the drug is one or more antibiotic agents in therapeutically effective concentrations to reduce or eliminate MRSA. The composition is based on a... Agent:

20120128623 - Surface anti-biomolecule agent: This invention discloses a surface anti-biomolecule agent for an artificially or naturally charged substrate. The anti-biomolecule agent comprises a copolymer employing anchoring blocks or domains to binds sites of the substrate via electrostatic attractive force, and employing zwitterionic blocks or domains extended outwardly to reduce the attachment of biomolecules to... Agent:

20120128624 - Recombinant human albumin-granulocyte macrophage colony stimulating factor fusion protein with long-lasting biological effects: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and... Agent:

20120128626 - Anti-il-6 antibodies for the treatment of anemia: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat anemia (e.g., anemia associated with chemotherapy) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head... Agent: Alder Biopharmaceuticals, Inc.

20120128625 - Compounds, compositions, and methods for preventing metastasis of cancer cells: Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.... Agent:

20120128627 - Il-17 homologous polypeptides and therapeutic uses thereof: The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies... Agent:

20120128630 - 1-(6 members azo-heterocyclic)-pyrrolin-2-one compounds as inhibitors of hepatitis c ns5b polymerase, the pharamaceutical composition thereof and their therapeutic use: The present invention concerns a 1-(6 members azo-heterocyclic)-pyrrolin-2-one compound of the following formula I or a salt, solvate, tautomer, isotope, enantiomer, diastereoisomer or racemic mixture thereof: the pharmaceutical composition thereof and their therapeutic use as inhibitors of Hepatitis C NS5B polymerase.... Agent: Vivalis

20120128628 - Combination of a nucleoside polymerase inhibitor with a macrocyclic protease inhibitor and use thereof in the treatment of hepatitis c, liver fibrosis and impaired liver function (as amended): Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease... Agent:

20120128629 - Method of labelling interferons with peg: A method of site specific labelling of an interferon molecule is provided. The method comprises the steps: a) providing a label molecule comprising a PEG moiety having an aldehyde or ketone moiety; b) providing an interferon molecule having a C terminal hydrazide moiety; and c) allowing the aldehyde or ketone... Agent: Almac Sciences (scotland) Limited

20120128631 - Compositions and methods for kinase-mediated cytoprotection and enhanced cellular engraftment and persistence: Disclosed are methods of protecting cells, especially non-vascular system, non-hematopoietic cells and tissues, from apoptosis and enhancing their engraftment, survival, and/or persistence by providing enhanced levels of PIM activity for the cell, including PIM-1 activity. Also disclosed are cells that have been engineered to express enhanced levels of PIM kinase,... Agent: San Diego State University (sdsu) Foundation, Dba San Diego State University (sdsu) Research

20120128643 - Gene vector: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC... Agent: Fondazione Centro San Raffaele Del Monte Tabor

20120128632 - Identity markers: Methods for identifying trichogenic dermal cells, including dermal papilla cells and dermal sheath cells, capable of inducing hair follicle formation when injected into skin are provided. It has been discovered that EGF latrophilin and seven transmembrane domain-containing protein 1 (ELTD1). Transmembrane Protein 108 (TMEM1 08), Hyaluronan and proteoglycan link protein... Agent:

20120128633 - Use of collinsella aerofaciens for reducing bloating: The invention relates to compositions comprising Collinsella aerofaciens for use for reducing bloating, in particular in subjects suffering from irritable bowel syndrome.... Agent: Campagnie Gervaise Donone

20120128634 - Use of collinsella aerofaciens for reducing bloating: The invention relates to compositions comprising Collinsella aerofaciens for use for reducing bloating, in particular in subjects suffering from irritable bowel syndrome.... Agent: Campagnie Gervaise Donone

20120128644 - Use of bacteria to treat and prevent respiratory infections: The invention provides methods for treating respiratory infections by administering compositions comprising one or more isolated, non-pathogenic, hydrogen peroxide-producing bacterial species or strains to the mouth, oropharynx, larynx, nasal cavity, fauces of a subject.... Agent: Oragenics, Inc.

20120128645 - Prophylactic, ameliorating or therapeutic agent for oral diseases: A prophylactic, ameliorating or therapeutic agent for an oral disease, which contains a lactic acid bacterial cell of one or more kinds selected from the group consisting of Lactobacillus rhamnosus strain KO3, Lactobacillus casei strain YU3 and Lactobacillus paracasei strain YU4 or a culture of the cell, or an extract... Agent: Hiroshima University

20120128648 - Novel biopesticide compositions and method for isolation and characterization of same: The present invention describes the isolation and characterization of the novel biopesticide compositions and/or biopesticide formulations obtained from Eucalyptus species capable of serving as effective biocontrol agents and/or pest control management agents. The invention focuses on the isolation of these biopesticide compositions and formulations that are known to possess pesticidal... Agent: The Energy And Resources Institute (teri)

20120128635 - Methods and compositions for treating hemophilia b: Disclosed herein are methods and compositions for insertion of Factor IX (FIX) sequences into the genome of a cell for treating hemophilia B.... Agent:

20120128637 - Cellular seeding and co-culture of a three dimensional fibroblast construct: The present invention provides methods for cellular seeding onto three-dimensional fibroblast constructs, three-dimensional fibroblast constructs seeded with muscle cells, and uses therefore.... Agent: Arizona Board Of Regents On Behalf Of The University Of Arizona

20120128636 - Gingiva derived stem cell and its application in immunodulation and reconstruction: The present invention relates to gingiva derived messenchymal stem cells (GMSCs). More specifically, the invention provides compositions and methods of using GMSCs to regulate inflammatory response in the setting of normal versus pathological wound healing and to treat inflammatory and/or autoimmune diseases.... Agent: University Of Southern California

20120128640 - Heterocyclic compounds and expansion agents for hematopoietic stem cells: An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells containing a compound represented by the formula (I) (wherein X, Y, Z, Ar1, R1, R2, R3, R4, R5, R6 and R7 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a... Agent: Nissan Chemical Industries Ltd.

20120128639 - In vitro production of oligodendrocytes from human umbilical cord stem cells: The invention provides a method of producing oligodendrocytes by in vitro differentiation of human multi-potent progenitor cells (MLPCs). The method comprises culturing isolated MLPCs on a first surface in a serum-free defined culture medium; replacing the culture medium with serum-free culture medium supplemented with bFGF, EGF and PDGF-AA for approximately... Agent: University Of Central Florida Research Foundation, Inc.

20120128641 - Methods and compositions for improving the viability of cryopreserved cells: The present invention provides polymers and methods for increasing the viability of cryopreserved cells after thawing. Thawing cryopreserved cells in the presence of a polymer such as poloxymer P1 88 or other non-ionic polymers is thought to stabilize the membranes of the cells leading to increased post-thaw viability. Such methods... Agent: The General Hospital Corporation D/b/a Massachusetts General Hospital

20120128638 - Pharmaceutical composition for the treatment of heart diseases: The present invention is related to a pharmaceutical composition comprising cells committed to the generation of heart tissue and at least one pharmaceutically acceptable excipient produced according to internationally recognized standards for pharmaceutical product manufacture, a process for the manufacture of such a pharmaceutical composition and a kit for the... Agent: Cardio3 Biosciences S.a.

20120128642 - Potency markers: Methods for identifying trichogenic dermal cells, including dermal papilla cells and dermal sheath cells, capable of inducing hair follicle formation when injected into skin are provided. Biomarkers have been discovered that can be used to detect, identify, and distinguish trichogenic dermal cells, i.e., that are able to induce hair follicle... Agent:

20120128646 - Methods and compositions for the treatment of autoimmune disease: The present invention is related to the development and treatment of autoimmune disease. Autoimmune diseases can result from tissue damage caused by the activation of autoreactive T cells by autoantigens. For example, peptide fragments of naturally occurring proteins (i.e., for example, chromogranin A) may activate autoreactive T cells that result... Agent:

20120128647 - Delivery of compounds with rehydrated blood cells: Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets.... Agent: University Of North Carolina At Chapel Hill

20120128649 - Modified non-cytotoxic proteases: The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage... Agent: Syntaxin Limited

20120128650 - Extended acting oxygen generating composition for treating microbial infections: A medicament for the treatment or prevention of a microbial infection or an associated condition in a low oxygen environment characterised in that the medicament includes an extended acting oxygen generating system.... Agent: Dec International Nz Limited

20120128651 - Acute lymphoblastic leukemia (all) biomarkers: The present invention concerns the use of biomarkers for acute lymphoblastic leukemia (ALL) to prognose or evaluate a patient with ALL who is Ph+. Methods and compositions are provided that concern these ALL biomarkers. In specific embodiments, methods for determining whether an ALL patient should be treated with standard chemotherapy... Agent:

20120128652 - Endolysin plyp40: The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO:1. The present invention further relates to the nucleic acid molecules comprising a nucleotide sequence coding for the polypeptide, vectors comprising the nucleic acid molecules, and host cells for the expression of the polypeptides.... Agent:

20120128654 - Allantoin administration for the treatment of neurodegenerative disease and neurotrauma: Methods for inhibiting the progression of neurodegenerative diseases and treating neurotrauma-induced damage and cerebrovascular disease are provided herein, the methods including the administration of a safe and effective amount of allantoin to a patient in need thereof. Also provided are pharmaceutical compositions including allantoin for the inhibition of the progression... Agent: University Of Cincinnati

20120128653 - Process for making dry and stable hemostatic compositions: t

20120128655 - Induced pluripotent stem cells: The present invention concerns the delivery of certain reprogramming factor proteins into cells, such as differenti-atedsomatic cells, in order to induce the epi-genetic reprogramming of the cell so it becomes a pluripotent stem cell. The reprogramming factor protein(s) may be Sox2, Klf4, Oct3/4, c-Myc, Lin28, Nanog, or any protein with... Agent: The Mclean Hospital Corporation

20120128659 - Agents capable of downregulating an msf-a - dependent hif-1alpha and use thereof in cancer treatment: Methods and pharmaceutical compositions for the treatment of cancer or acute ischemia are provided. Also provided are methods of identifying agents capable of preventing the formation of or dissociating the MSF-A-HIF-1alpha protein complex, and methods of determining the prognosis of an individual having cancer by identifying the presence or absence... Agent: Medical Research Fund Of Tel Aviv Sourasky Medical Center

20120128660 - Diagnosis of restenosis in patients undergoing percutaneous coronary intervention: The present invention relates to compounds, compositions, methods and/or kits for determining and/or predicting and/or diagnosing and/or treating restenosis in a patient.... Agent: University Of Saskatchewan

20120128658 - Rage g82s-related methods and compositions for treating inflammatory disorders: This invention provides methods, compositions and articles of manufacture for inhibiting the onset of and treating inflammatory disorders such as rheumatoid arthritis. The instant invention is based on the blockade of RAGE G82S function.... Agent: The Trustees Of Columbia University In The City Of New York

20120128657 - Synthetic macrocyclic compounds and methods for treating cancer: Disclosed herein are macrocyclic compounds that are effective to inhibit cell migration. In one embodiment, the compounds have the structure: or any pharmaceutically acceptable salt or solvate thereof, wherein: m is 0 or 1; R1, R2 and R3 independently are H, aralkyl, acyl, lower alkyl or silyl; X is —C(O)N(R4)—... Agent:

20120128656 - Vaccine compositions and methods: The present invention relates to pharmaceutical vaccine compositions comprising at least one vaccine antigen together with living immune cells. These immune cells include at least a portion of activated T-cells and act as an adjuvant. Methods for using these pharmaceutical compositions to prevent or treat diseases, such as cancer, infectious... Agent: Immunovative Therapies, Ltd.

20120128663 - Fc variants that extend antibody half-life: The invention relates generally to compositions and methods for altering the serum half-life in vivo of an antibody.... Agent: Xencor, Inc.

20120128664 - Glycosylated antibodies: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1%... Agent:

20120128668 - Method of promoting bone growth by an anti-activin antibody: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.... Agent: Acceleron Pharma, Inc.

20120128666 - Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid: Methods are provided for increasing neuronal differentiation of neuronal stem cells using antibodies that bind lysophosphatidic acid (LPA). Particularly preferred antibodies to LPA are monoclonal antibodies, including humanized monoclonal antibodies to LPA. Such antibodies, and derivatives and variants thereof, can be used in increasing neuronal differentiation, and in treatment and/or... Agent: Lpath, Inc.

20120128669 - Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections: Amino acid sequences are provided that are directed against and/or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and... Agent: Ablynx N.v.

20120128670 - Mtor inhibitor and angiogenesis inhibitor combination therapy: Cancer therapy comprising treatment with an mTOR inhibitor, such as a dual mTORC1/mTORC2 inhibitor, such as OSI-027, in combination with an angiogenesis inhibitor.... Agent: Osi Pharmaceuticals, LLC

20120128667 - Pentamidine combinations for treating cancer: The present invention relates to the treatment of cancer, e.g., ovarian cancer, breast cancer, pancreatic cancer or colon cancer, with pentamidine and (a) oxaliplatin, (b) gemcitabine, (c) taxol, (d) 5-fluorouracil or (e) CPT 11.... Agent: Oncozyme Pharma Inc.

20120128661 - Polynucleotide and polypeptide sequences involved in cancer: The present invention relates to polynucleotide and polypeptide sequences which are differentially expressed in cancer cells compared to normal cells. The present invention more particularly relates to the use of these sequences in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells.... Agent: Alethia Biotherapeutics Inc.

20120128665 - Preselection of subjects for therapeutic treatment based on hypoxic status: The present invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on... Agent: Synta Pharmaceuticals Corp.

20120128662 - Substituted imidazoquinoxalines: The present invention relates to substituted imidazoquinoxaline compounds of general formula (I) as inhibitors of Mps-1 Kinase or TTK, and being active against inflammation and cancer.... Agent: Bayer Pharma Aktiengesellschaft

20120128673 - Modulation of pilr receptors to treat microbial infections: The present invention provides methods of using agonists and antagonists of PILRα and PILRβ, respectively, to treat S. aureus infection, in particular, S. aureus infections of the lungs. Also provided are use agonists and antagonists of PILRα and PILRβ, respectively, to prevent such infections.... Agent: Schering Corporation

20120128671 - Neutralizing molecules to influenza viruses: The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, and methods and means for making such antibodies.... Agent:

20120128672 - Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins: The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be... Agent: Five Prime Therapeutics, Inc.

20120128674 - C3b antibodies and methods for the prevention and treatment of complement-associated disorders: The present invention concerns antibodies to C3b and the prevention and treatment of complement-associated disorder using such antibodies.... Agent:

20120128675 - Anti-fgf19 antibodies and methods using same: The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4.... Agent:

20120128676 - Muc1 antibodies: The present invention pertains to anti-mucin antibodies having improved antigen binding and/or recognition properties as well as a method for improving the antigen binding and/or recognition of an anti-mucin antibody. In particular, the present invention is directed to anti-MUC1 antibodies which are useful in the treatment of cancer.... Agent: Glycotope Gmbh

20120128681 - Anti-ck8 antibodies to be used for treating colorectal cancers and identifying metastatic and/or invasive phenotypes: The invention relates to antibodies specific to human CK8 and to pharmaceutical compositions for preventing and treating colorectal cancers. The invention also relates to methods for identifying colorectal cancers with an invasive and/or metastatic phenotype including detecting the cleavage of the C-terminal portion of human CK8 on the surface of... Agent: Hospices Civils De Lyon

20120128682 - Apolipoprotein l- i variants and their use: An isolated human Apolipoprotein L-I corresponding to a wild type human Apolipoprotein sequence is modified by a deletion at its C-terminal end.... Agent: Universite Libre De Bruxelles

20120128680 - Biomarker antibody and diagnosis device for detecting certain autoimmune diseases: Antibodies which specifically bind to a peptide having the sequence Ala-Ala-Ala-Pro-Ala-Lys-Ala-Ala-Ala-Ala-Pro-Ala-Lys-Thr-Ala-Ala-Ala-Pro-Val (SEQ ID No1), and which are not induced in a host following an infection of the host with T. cruzi.... Agent: Hospices Civils De Lyon

20120128678 - Diagnosis and treatment of cancer using anti-tmprss11e antibody: The present inventors have obtained a monoclonal antibody against TMPRSS11E and found that this antibody binds to a native form of TMPRSS11E, and TMPRSS11E is highly expressed on the cell membranes of cancer cell lines in flow cytometry. This antibody exhibits antibody-dependent cell-mediated cytotoxicity activity (ADCC activity) and antitumor effect... Agent: The University Of Tokyo

20120128679 - Human antibodies to the glucagon receptor: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and... Agent: Regeneron Pharmaceuticals, Inc.

20120128677 - Pancreatic cancer targets and uses thereof: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as... Agent: Celera Corporation

20120128683 - Autism treatment: A safe and effective treatment to curtail and cure autism spectrum disorders has been described in this invention using insulin, IGF-1, with multiple known adjuvant therapeutic agents, as well as other pharmaceutical, biochemical, nurticeuticals, and biological agents or compounds delivered through the olfactory mucosal region of the nose and external... Agent:

20120128684 - Conserved hemagglutinin epitope, antibodies to the epitope and methods of use: Disclosed are antibodies that bind to the stem region of influenza hemagglutinin in the neutral pH conformation, hemagglutinin epitopes in the stem region, and methods of making and using both.... Agent: Dana-farber Cancer Institute, Inc.

20120128685 - Use of high-dose oxazaphosphorine drugs in combination with monoclonal antibodies for treating immune disorders: The present invention relates to methods of treating an autoimmune disorder, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, monoclonal antibodies that selectively bind B-cell specific antigens.... Agent: The Johns Hopkins University

20120128688 - Anti-cxcl13 and anti-cxcr5 antibodies for the prevention and treatment of cancer and cancer cell migration: Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CXCL13 and/or the chemokine receptor CXCR5. Another method comprises the step of... Agent: Morehouse School Of Medicine

20120128689 - Anti-il-23 immunoglobulins: The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA).... Agent: Glaxo Group Limited

20120128690 - Methods for determining agents that treat or prevent obesity and/or obesity related diseases and methods for treatment therewith: The present invention provides methods for determining a putative agent that treats or prevent obesity and/or obesity related diseases comprising contacting cells with the putative agent and measuring the activity and/or level of Maf1 and/or the activity and/or level of KIAA1875. The present invention also provides the agent identified by... Agent: Albert Einstein College Of Medicine Of Yeshiva University

20120128687 - Novel antibody formulation: Pharmaceutical liquid formulation of an antibody against human OX40L, a process for the preparation and uses of the formulation.... Agent: Hoffmann-la Roche.inc.

20120128686 - Thienopyrimidines for pharmaceutical compositions: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity... Agent: Boehringer Ingelheim International Gmbh

20120128691 - Human cytomegalovirus neutralizing antibodies and use thereof: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes... Agent: Institute For Research In Biomedicine

20120128692 - Human cytomegalovirus neutralizing antibodies and use thereof: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes... Agent: Institute For Research In Biomedicine

20120128693 - Cadherin-11 inhibitors and methods of use thereof: Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis.... Agent: Georgetown University

20120128698 - Diagnosis and treatment of autoimmune demyelinating diseases: The present invention concerns the diagnosis and treatment of autoimmune demyelinating diseases, such as multiple sclerosis (MS), by means of a CLM-I agonist.... Agent:

20120128696 - Methods for detecting and inhibiting angiogenesis: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue. The invention further provides methods of reducing or inhibiting angiogenesis in... Agent: The Regents Of The University Of California

20120128697 - Notch inhibition in the treatment or prevention of atherosclerosis: The present invention is directed to methods of treating or preventing atherosclerosis and other cardiovascular diseases by administering agents that inhibit or modulate the NOTCH signaling pathway. In addition, the invention encompasses methods for assaying compounds for their ability to treat atherosclerosis based upon their effects on NOTCH signaling, and... Agent: The Brigham And Women's Hospital, Inc.

20120128695 - Teneurin c-terminal associated peptides (tcap) and methods and uses thereof: The invention provides a novel family of biologically active neuropeptides and the nucleic aid molecules coding for same. The peptides are derived for the C-terminus of the teneurin family peptides (Ten M1-4). These novel peptides, referred to as teneurin C-terminal associated peptides (TCAPs) are active in neuronal communication and are... Agent:

20120128694 - Therapeutic agents for alzheimer's disease and cancer: e

20120128699 - Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These TROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an... Agent: Idera Pharmaceuticals, Inc.

20120128700 - Constructs for delivery of therapeutic agents to neuronal cells: A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a HN domain of a clostridial toxin and... Agent: Syntaxin Limited

20120128703 - Aminopterin dosage forms and methods for inflammatory disorders: There is disclosed dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Specifically, there is disclosed a method for treating an inflammatory disorder in a patient with uninterrupted... Agent:

20120128701 - Compositions and methods for the removal of biofilms: Methods of breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of a polypeptide that has one or more HMG-box domains to a subject suffering from the infection or having the biofilm. By competing with microbial proteins that... Agent: University Of Southern California

20120128702 - Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer: The present invention relates to methods for predicting the effect of an immunotherapy against cancer in a patient based on new biomarkers. The present invention furthermore relates to a prognosis regarding the outcome based on said biomarkers. The present invention furthermore relates to panels of biomarkers for use in the... Agent: Immatics Biotechnologies Gmbh

20120128705 - C6orf167 peptides and vaccines containing the same: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the C6orf167 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical... Agent: Oncotherapy Science, Inc.

20120128706 - Immune adjuvant comprising atp: This invention relates to an immunoadjuvant, which has an excellent antibody production enhancing function and is highly safe, and a vaccine composition comprising the immunoadjuvant. More specifically, the present invention relates to an immunoadjuvant comprising ATP or its pharmaceutically acceptable salt, its solvate, or its derivative having a physiological function... Agent:

20120128704 - Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof: The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three... Agent: Helmholtz Zentrum Muenchen Deutsches Forschungszen Trum Fuer Gesundheit Und Umwelt (gmbh)

20120128708 - Diagnostic mycobacterium tuberculosis test: A method of diagnosing Mycobacterium tuberculosis infection in a human, or of determining whether a human has been exposed to Mycobacterium tuberculosis, comprising (i) contacting T-cells from said human with one or more of (a) a peptide having the sequence shown in SEQ ID NO 20, (b) a peptide having... Agent:

20120128709 - Expression of recombinant proteins: The invention provides auto-inducible systems for expressing recombinant proteins of interest which take advantage of elements of quorum sensing (QS) systems of certain bacteria. These systems can be used to produce commercial quantities of proteins such as antigens, which can be used to prepare pharmaceutical compositions.... Agent:

20120128707 - Streptococcus pneumoniae proteins and nucleic acids: The invention provides proteins and nucleic acid sequences from Streptococcus Pneumoniae, together with a genome sequence. These are useful for the development of vaccines, diagnostics, and antibiotics.... Agent: Novartis Vaccines And Diagnostics Srl

20120128710 - Enhancement of pathogen-specific memory th17 cell responses: Compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses are disclosed herein. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with... Agent: Baylor Research Institute

20120128711 - Anti-inflammatory approach to prevention and suppression of post-traumatic stress disorder, traumatic brain injury, depression and associated disease states: A composition and methods of use are disclosed for prevention and control of inflammation and oxidative stress and various associated medical conditions, including PTSD, chronic depression and traumatic brain injury. A composition providing a phytonutrient and enriched mushrooms having enhanced Vitamin D and ergothioneine are disclosed. The combined use of... Agent: Total Nutraceutical Solutions, Inc.

20120128712 - Vaccine directed against porcine pleuropneumonia and a method to obtain such a vaccine: The present invention pertains to a vaccine directed against porcine pleuropneumonia, comprising lipopolysaccharide, wherein the vaccine comprises a polymyxin to reduce symptoms of an endotoxic shock arising from the lipopolysaccharide. The invention also pertains to a method to obtain such a vaccine and a method for administering the vaccine to... Agent:

20120128714 - Alphavirus replicon particles expressing trp2: The immune response to melanoma cells and tumors can be induced or significantly increased by administering to a subject a pharmaceutical composition comprising alphavirus particles, especially Venezuelan equine encephalitis virus replicon particles, which express the melanoma antigen dopachrome tautomerase (DCT, TRP2) in cells of the subject, with the result of... Agent:

20120128713 - Replication-defective flavivirus vaccine vectors against respiratory syncytial virus: Replication-defective vaccine vectors against respiratory syncytial virus (RSV) are disclosed. Corresponding compositions and methods employing the vaccine vectors are also disclosed.... Agent: Sanofi Pasteur Biologics Co.

20120128715 - Method for stimulating the immune response of newborns: The present invention is based on the surprising discovery that agonists of TLR8 are uniquely efficacious in enhancing (e.g. inducing) the immune response of newborns. Thus, agonists of TLR8 serve as both vaccine adjuvants and as adjunctive therapies for acute infection in newborns, preferably the agonist is a TLR8-selective agonist.... Agent: Children's Medical Center Corporation

20120128717 - Influenza virus vaccine composition and methods of use: The present invention is directed to compositions and methods for enhancing the immune response of a human in need of protection against influenza virus (IV) infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an... Agent: Vical Incorporated

20120128716 - Vaccine compositions: Vaccine compositions, useful for eliciting an immune response in subjects which is protective against influenza type A virus, comprise influenza type A virus antigen and a bacterial sialidase. An intranasal vaccine against highly pathogenic subtype H5N1 virus, for use in the treatment of poultry, preferably comprises inactivated H5N1 antigen, sialidase... Agent:

20120128718 - Attenuated fnr deficient enterobacteria: The invention provides an attenuated enterobacterium comprising an attenuating mutation in the fnr gene, and optionally further comprising a heterologous nucleic acid encoding a foreign antigen. Also provided are pharmaceutical formulations comprising the attenuated enterobacteria of the invention. Further disclosed are methods of inducing an immune response in a subject... Agent:

20120128719 - Streptococcus vaccine compositions and methods of using the same: The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides immunogenic nanoemulsion compositions and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against a bacterial species... Agent: The Regents Of The University Of Michigan

20120128720 - Mycobacterium mutants for vaccines with improved protective efficacy: Tuberculosis (TB) is a major health problem and currently, the only licensed TB vaccine is Mycobacterium bovis Bacille Calmette-Guerin (M. bovis BCG). In the present invention, mutation of mycobacterial components reportedly involved in phagosome maturation inhibition was evaluated for vaccine purposes, as such mutations should result in better vaccine antigen... Agent:

20120128721 - Schistosoma vaccine: The method for large scale production of a full length Schistosomal paramyosin coiled coil dimer composition is carried out by providing a composition comprising recombinant paramyosin, contacting the composition with a strand separation agent to remove paramyosin fragments and other contaminants. The purified paramyosin is used in vaccines for humans... Agent:

20120128722 - Novel monensin derivatives for the treatment and prevention of protozoal infections: This invention relates to novel polyether ionophores, formulations comprising same, and to methods of making and using these compounds and formulations for the treatment and/or prevention of parasitic infection in animals and humans. These compounds exhibit improved safety profiles and/or efficacies as compared to parent compounds.... Agent:

20120128723 - Cancer specific antibody and cell surface proteins: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses... Agent: Viventia Biotechnologies Inc.

20120128724 - Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In preferred embodiments, the... Agent: The Regents Of The University Of Colorado, A Body Corporate

20120128725 - Detection/measurement of malaria infection disease utilizing natural immunity by hemozoin induction, screening of preventative or therapeutic medicine for malaria infection disease, and regulation of natural immunity induction: The instant invention is to provide a method for detecting and measuring malaria infection utilizing the induction by hemozoin (HZ); a method for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection using the method for detecting and measuring; and a means for regulating... Agent: Osaka University

20120128727 - Bacterial expression of an artificial gene for the production of crm197 and its derivatives: The present invention relates to polynucleotide sequences comprising the SEQ ID N° 1 encoding CRM197 and optimised for its expression in E. coli. The invention consequently concerns a method for the production of CRM197 in E. coli via a fusion protein CRM197-tag.... Agent:

20120128726 - Infant feeding formulas comprising probiotic micro-organisms: The present invention relates to the field of infant nutrition. In particular, the present invention relates to infant feeding formulas comprising probiotic micro-organisms. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic micro-organisms, for example.... Agent: Nestec S.a.

20120128731 - Biocompatible carrier and method for fabricating the same: The invention provides a biocompatible carrier and method for fabricating the same. The biocompatible carrier includes: a gel, and a plurality of metal nanoparticles, an organic compound or combinations thereof embedded in the gel, wherein the metal nanoparticles, the organic compound or combinations thereof are uniformly distributed in the gel.... Agent: National Sun Yat-sen University

20120128732 - Combinations and modes of administration of therapeutic agents and combination therapy: The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least... Agent:

20120128730 - Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron: Compositions for once-daily administration of ondansetron are described. Compositions include a core, a semi-permeable membrane disposed generally around the core, an orifice in the semi-permeable membrane in fluid communication with the core, and a coating having a first therapeutically effective dose of ondansetron or a pharmaceutically acceptable salt disposed generally... Agent:

20120128728 - Compositions comprising amphotericin b: The present invention comprises compositions and formulations comprising amphotericin B comprising less than 10% degradants, compositions and formulations comprising amphotericin B with one or more excipients, methods of making amphotericin B compositions and formulations, as well as systems for using amphotericin B compositions and formulations. Also provided are pharmaceutical compositions... Agent: Novartis Pharma Ag

20120128737 - Compositions for treating degenerative joint diseases: In order to provide a composition for the treatment of degenerative joint diseases with an improved efficacy, it is proposed that the composition comprises collagen hydrolysate and rosehip powder and/or extract, wherein the weight ratio of collagen hydrolysate to rosehip powder and/or extract, in each case in relation to dry... Agent: Gelita Ag

20120128729 - Gallium formulation for the treatment and prevention of infectious diseases: A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such as Staphylococcus aureus, Rhodococcus equi, Mycobacterium tuberculosis, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas... Agent: Aridis Pharmaceuticals

20120128735 - Methods of treatment using a gastric retained gabapentin dosage: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.... Agent: Depomed, Inc.

20120128741 - Modified hyaluronic acid polymer compositions and related methods: The present application provides compositions comprising hyaluronic acid having low levels of functional group modification, mixtures formed by controlled reaction of such lightly modified hyaluronic acid with suitable difunctional or multi-functional crosslinkers, and hydrogel precursor compositions and the resulting hydrogels. The compositions are lightly cross-linked and possess low pro-inflammatory properties... Agent: Carbylan Biosurgery, Inc.

20120128740 - Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them: The present invention is directed to nanostructured (nanoparticulated) Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them according to the invention have an average... Agent:

20120128736 - Oil-in-water emulsion of mometasone: Novel pharmaceutical compositions of mometasone or a pharmaceutically acceptable derivate thereof in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect. The compositions contain mometasone in micronised form, butylene glycol and water and the weight ratio between the butylene glycol and water... Agent: Galenica Ab

20120128734 - Oral delivery product: An oral delivery product comprising a semi-permeable pouch designed for delivery of an active agent in the oral cavity of a subject. The pouch encloses multiple particles, and the particles are alginate matrices that comprise an active agent, e.g. nicotine. The alginate is e.g. sodium alginate, such as Protanal LFR... Agent:

20120128733 - Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same: The present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may comprise progestogen-only contraceptives (“POC”), such as Drospirenone.... Agent:

20120128742 - Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein: The present disclosure relates to crystalline form of (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, salts and hydrates thereof. This disclosure also relates to solid oral formulation of (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, pharmaceutically acceptable salts, solvates (including hydrates) thereof, as well as methods of treatment using the same.... Agent:

20120128738 - Theobromine for the treatment of cough: The present invention is theobromine as an active agent to be delivered via the inhaled route, for the treatment of cough.... Agent:

20120128739 - Three-dimensional nanostructured hybrid scaffold and manufacture thereof: A method of making a three-dimensional biocompatible scaffold capable of supporting cell activities such as growth and differentiation, the method includes providing a supporting grid that forms an open network and provides mechanical support of a second biocompatible material. The second biocompatible material has interconnected cavities that allow nutrients, metabolites... Agent: Aarhus Universitet

20120128745 - Benzylidene malonates: m

20120128747 - Core-shell material, method for preparing same, and use thereof for the thermostimulated generation of substances of interest: The present invention relates to a material in the form of solid particles consisting of a continuous shell including at least one silicon oxide, said shell confining at least one oil phase, said material being characterized in that said oil phase is solid at the storage temperature of said material... Agent:

20120128746 - Cosmetic nanocomposites based on in-situ crosslinked poss materials: A cosmetic composition for caring for and/or making up the skin, lips and/or body in the form of a film, which is non-transferable, long-lasting with a comfortable feeling of use to consumers over long periods of wear time. The composition contains graftable POSS which forms a film when it cures... Agent: Avon Products, Inc.

20120128744 - Mixture containing menthol: The present invention relates to d,l-menthol and optionally additionally l-menthol-containing mixtures, which are liquid at normal pressure and a temperature of 20° C. or higher. The present invention further relates to products that comprise such a mixture or that are preparable by mixing or contacting such a mixture with further... Agent: Symrise Ag

20120128748 - Organic-inorganic composite particles, process for producing the same, dispersion containing the particles, and cosmetic containing the particles: Organic-inorganic composite particles includes inorganic oxide particles each of which has a cationic charge on the particle surface and polymer gel molecules which are derived from a natural substance, have an anionic functional group and one or more hydroxyl groups in a molecule and have both a shrinking and a... Agent: Jgc Catalysts And Chemicals Ltd.

20120128743 - Polymer particles: g

20120128749 - Composition and process for production thereof: Disclosed are: a composition which enables the more effective development of the efficacy of a water-soluble drug in a solution containing the drug; and a dispersion in which a hydrophobic drug can be dispersed stably without requiring the use of any surfactant. Specifically disclosed are: a composition comprising ultra-fine bubbles... Agent:

20120128750 - Process for preparing an aqueous suspension of an organic pesticide compound: The present invention relates to a process for preparing an aqueous suspension of an organic pesticide compound, which has a solubility in water of not more than 2 g/l at 20° C. and a melting point of not more than 110° C. and which is capable of forming at least... Agent: Basf Se

20120128751 - Preservation of liquid foods: Anti-spoilage inserts and methods are provided for inhibiting the spoilage of liquid foods.... Agent:

20120128752 - Multi-phase microparticles and method of manufacturing multi-phase microparticles: The invention relates to a method of manufacturing multi-phase microparticles. The method comprises dissolving at least three different polymers in a volatile organic solvent to obtain a first solution. The first solution comprises at least two cloud points, wherein the second cloud point is higher than the first cloud point.... Agent: Nanyang Technological University

20120128753 - Meditowel pre-packaged medicated muscle and joint pain relief wipe: Single use, substrate uniformly impregnated with an anhydrous muscle and joint pain relief solution for the use of aseptically delivering a single dose of a muscle and joint pain relief solution to the area of pain. Solution and substrate is contained encapsulated within a heat sealed foil enclosure that is... Agent:

20120128754 - Treatment of eye discomfort by topical administration of a cooling agent to the external surface of the eyelid: The present invention pertains generally to the field of ocular treatment, and more specifically to the use of a liquid cooling agent composition comprising a cooling agent for the treatment of (e.g., the alleviation of symptoms of; the amelioration of) eye discomfort. The preferred cooling agent is (1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarboxylic acid 2,3-dihydroxy-propyl... Agent:

20120128758 - Formulation for inducing broadly reactive neutralizing anti-hiv antibodies: The present invention relates in general, to a formulation suitable for use in inducing anti-HIV-1 antibodies, and, in particular, to a formulation comprising Toll Like Receptor (TLR) agonists with HIV-1 gp41 membrane proximal external region (MPER) peptide-liposome conjugates for induction of broadly reactive anti-HIV-1 antibodies. The invention also relates to... Agent:

20120128760 - Lipid compositions: Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is (F). Also disclosed are methods of producing the cationic lipid of formula (I).... Agent: Alnylam Pharmaceuticals, Inc.

20120128761 - Lipophilic polynucleotide conjugates: Disclosed are lipophilic polynucleotide conjugates including polynucleotide-cholesterol conjugates and methods of delivering therapeutic polynucleotides to a mammalian cell or patient in need of treatment using said conjugates. The disclosure further provides methods of synthesizing the lipophilic polynucleotide conjugates. The conjugates are designed to mimic or target cellular miRNAs. The lipophilic... Agent: Miragen Therapeutics, Inc.

20120128763 - Lubricant for the ocular surface: A formulation has been developed for treatment of the symptoms of dry eye which incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear and eyedrop as well as stabilize the eyedrop. The improved performance of the jojoba wax supplemented tear relieves irritation... Agent: Melbj Holdings, LLC

20120128757 - Method of manufacture of liposome composition: The present invention provides a method of manufacture of a liposome composition including a step in which: a liposome dispersion liquid containing a liposome, and further containing cyclodextrin in the liposome internal phase is provided and a step in which an active compound is introduced into said liposome internal phase,... Agent: Eisai R&d Management Co., Ltd

20120128759 - Method to inhibit airway hyperresponsiveness using aerosolized t cell receptor antibodies: Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflammation, is effective at extremely low doses of antibody, and does not have... Agent: National Jewish Health

20120128755 - Personal care composition containing yeast extract and hexapeptide: A personal care composition comprising (a) a yeast extract, (b) Hexapeptide-11 (Phe-Val-Ala-Pro-Phe-Pro) (SEQ ID NO:1), and (c) a determatologically-acceptable carrier, wherein the total amount of components (a) and (b) is from about 2 wt % to about 6 wt %, preferably from 4-6% based on the total weight of the... Agent:

20120128756 - Skin permeating and cell entering (space) peptides and methods of use thereof: The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.... Agent:

20120128762 - Sphingomyelin liposomes for the treatment of hyperactive bladder disorders: The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20120128764 - Controlled-release compositions comprising a proton pump inhibitor: The present invention relates to pharmaceutical compositions, and methods of preparing such compositions, comprising one or more populations of controlled-release particles comprising one or more proton pump inhibitors. The present invention also relates to pharmaceutical dosage forms, including orally disintegrating tablets, tablets, capsules, and methods for their preparation.... Agent: Aptalis Pharmatech, Inc.

20120128765 - Method and device for producing soft capsules: The claimed subject matter relates to a rotary die device for producing soft capsules, comprising a capsule forming unit for forming a soft-capsule shell and a dosing unit for feeding a filling material into the capsule forming unit, characterized in that the dosing unit comprises a conveying apparatus of viscous... Agent: Swiss Caps Rechte Und Lizenzen Ag

20120128766 - Self-breaking tablets: Self-breaking core tablets and functionally coated tablets and capsule formulations are provided. Methods for production of these tablet and capsule formulations and their administration are also provided.... Agent: Aptapharma, Inc.

20120128768 - Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity: The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity and at least one compound with 5-HT6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.... Agent: Laboratorios Del Dr. Esteve S.a

20120128767 - Therapeutic calcium phosphate particles and methods of making and using same: The present invention provides novel calcium phosphate nanoparticles suitable for efficient encapsulation of biologically active molecules. The invention further provides pharmaceutical compositions comprising these nanoparticles, as well as methods of making such nanoparticles and using them as carriers for therapeutic delivery of biologically active macromolecules.... Agent:

20120128769 - Solubilized coq-10: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.... Agent: Soft Gel Technologies, Inc.

20120128770 - Treatment of insulin resistance and obesity by stimulating glp-1 release: The present invention relates to 1 or 2 C16-C18 acyl glycerol based compounds which are capable of activating G-protein coupled receptor 119 and thereby stimulate GLP-1 release. Compounds of the present invention are useful in the prophylaxis and/or treatment of metabolic disorders and complications thereof, such as, type 2 diabetes... Agent: Kobenhavns Universitet

20120128772 - Controlled release pharmaceutical compositions of milnacipran: A controlled release pharmaceutical composition comprising Milnacipran or pharmaceutically acceptable salts thereof and hydrophobic release controlling agent. The composition releases 90% of the total amount of Milnacipran or pharmaceutically acceptable salts thereof between 8 to 20 hours when dissolution is carried out in 900 ml 0.1N HCl, USP apparatus Type... Agent: Lupin Limited

20120128771 - Timed, pulsatile release systems: A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time... Agent:

20120128773 - Desfesoterodine in the form of a tartaric acid salt: The invention concerns desfesoterodine in the form of a tartaric acid salt, in particular in the polymorphic “R form”, as well as a process for its production. In a second aspect, the invention concerns the desfesoterodine of the invention in a microencapsulated form.... Agent: Ratiopharm Gmbh

20120128774 - Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix: The present invention provides effective new methods and materials for maxillofacial bone augmentation, particularly alveolar ridge augmentation, that are free of problems associated with prior art methods. In one embodiment, these materials include human recombinant platelet derived growth factor (rhPDGF-BB) and a biocompatible matrix. In another embodiment, these materials include... Agent: Biomimetic Therapeutics, Inc.

20120128775 - Biocarrier and method of using the same: The present invention discloses a biocarrier for delivery of a bioactive substance near/into a target cell, comprising a bioactive substance-loaded core with a first electricity, and one or more block copolymer, each block copolymer comprising a zwitterionic block and an anchoring block with an initial electricity opposite to the first... Agent:

20120128776 - Method for the preparation of microparticles with efficient bioactive molecule incorporation: The present invention relates to relates to a method for the preparation of drug filled polymer microparticles comprising a gas core and shell, which particles are suitable as part of a therapeutic composition, especially for drug delivery. By using this method, polymeric microparticles are obtained that combine high incorporation efficiency... Agent: Koninklijke Philips Electronics N.v.

20120128778 - Compositions and methods for once-daily administration of a trilayer osmotic tablet: A trilayer osmotic tablet is described. The tablet includes a core, a semi-permeable membrane disposed generally around the core, and an orifice in the semi-permeable membrane in fluid communication with the core. The core includes first, second, and third layers. The first layer is in fluid communication with the orifice.... Agent:

20120128777 - Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles: The invention is related to compositions which can be used as dermal formulations for supporting the skin to restore normal conditions in case of e.g. irritated skin, or to support medical therapy of skin with atopic dermatitis symptoms, atopic dermatitis, psoriasis or related diseases (e.g. accompanied by distorted barrier function... Agent: Pharmasol Gmbh

20120128779 - Process for producing protein microparticles: The present invention relates to a process for producing protein microparticles in dilute organic acid solutions and in the absence of an alcohol such as ethanol. The microparticles are formed by dissolving a cereal prolamin protein in a concentrated organic acid solution with agitation and then diluting the solution with... Agent: University Of Pretoria

20120128780 - Nanoparticulate bisphosphonate compositions: Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal.... Agent: Elan Pharma International Ltd.

20120128781 - Functionalization of nanoparticles by glucosamine derivatives: The present invention relates to oligomeric or polymeric saccharide derivatives comprising glucosamine moieties, e.g. derivatives of oligomeric or polymeric glucosamines such as chitosan oligomers or polymers, in which one or more amine groups are substituted by anchoring groups that chemisorb to the surface of a nanoparticle or form an interdigitated... Agent:

20120128782 - Multicomponent degradable cationic polymers: Degradable polymers were synthesized that self-assemble with DNA to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure provides significant changes to efficacy in a cell-type dependent manner. Polymers presented here are more effective than commercially available materials, such... Agent: The Johns Hopkins University

20120128783 - Compositions and methods for delivery of frozen particle adhesives: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least... Agent: Searete LLC, A Limited Liability Corporation Of The State Of Delaware

20120128784 - Composition containing bee venom as an active ingredient for preventing and treating acne: The present invention relates to a composition for preventing and treating acne, comprising a material which has excellent antibacterial activity against Propionibacterium acnes known as acne-causing bacteria and which shows strong antibacterial activity against skin floras that enlarge the site of inflammation to worsen acne, in which the material also... Agent: Korea Rural Development Administration

20120128785 - Biological nasal bridge implant and method of manufacture: A nasal bridge implant is made according to a method that includes the steps of collecting animal material from a bovine or porcine source, the animal material being either a tendon or a ligament, removing cells from the animal material, shaping the animal material to provide a desired shape for... Agent: Grandhope Biotech Co., Ltd.

20120128786 - Delivery system comprising a silicon-containing material: A composition comprising nanoparticles of a hydrolysable silicon-contain material for use as a delivery system for a bioactive ingredient, wherein surface of the silicon-containing material is associated with a stabilizing agent which modifies the rate of hydrolysis of the silicon-contain material and/or inhibits the rate of orthosilicic acid polymerisation and... Agent:

20120128787 - Homeopathic composition comprising hypericum perforatum extract and essential oils for the treatment of neuropathic pain: The present invention provides a method of treating neuropathic pain by administering a topical homeopathic composition to a mammalian subject. The homeopathic formulation contains homeopathic active ingredients comprising Hypericum perforatum in a base of essential oils which facilitate delivery of the homeopathic ingredient through the skin.... Agent: Origin Biomed Inc.

20120128788 - Collagen production enhancer: A collagen production enhancer for increasing the amount of collagen contained in the skin tissues, comprising calcium phosphate fine particles as effective ingredients.... Agent: Sofsera Corporation

20120128789 - Use of xenon for treating hypersensitivity to pain: The invention relates to a gaseous mixture containing oxygen (O2) and a volume proportion of 20 to 70% of xenon (Xe) for use as an inhalable drug for preventing or treating hypersensitivity to pain in humans or animals, in particular hypersensitivity to pain expressed as hyperalgesia or allodynia.... Agent: L'air Liquide Societe Anonyme Pour L'etude Et Exploitation Des Procedes Georges Claude

20120128790 - Granular antimicrobial agent for water processing: [Means for Solving the Problems] A granular antimicrobial agent for water processing which has a solubility at 25° C. of preferably 0.1 mg/g·L·hour to 1 mg/g·L·hour, comprises 0.5 wt % to 4 wt % of Ag2O, 2 wt % to 10 wt % of K2O, 35 wt % to 50... Agent: Toagosei Co., Ltd.

20120128791 - Ammoniacal copper zinc arsenate concentrates and methods of preparation: Disclosed herein is a composition concentrate that is suitable for treating wood upon dilution with water in a weight ratio of concentrate to water of between 1:10 and 1:100. The concentrate contains copper ammonium cations, zinc ammonium cations, arsenate and/or hydrogen arsenate anions; carbonate and/or bicarbonate anions, ammonia and water,... Agent:

20120128792 - Trace elements: The inventions discloses a trace element solution, which comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at... Agent:

20120128793 - Implantable or insertable medical device resistant to microbial growth and biofilm formation: Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer... Agent: Boston Scientific Scimed, Inc.

20120128794 - Methods and compositions for the sustained release of chromium: Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting”... Agent: Nutrition 21, Inc.

20120128795 - Colorless, non-fuming, hazardless and stable aqua-regia, its preparation method and use in treating medical disorders: A method for production of colorless, non-fuming, hazardless and stable aqua-regia solution is provided. The method includes heating a dry mixture of potassium nitrate, potassium chloride and potassium aluminum sulphate to obtain vapors of aqua-regia and condensing the vapors obtained to form a colorless, non-fuming, hazardless and stable aqua-regia solution.... Agent:

20120128796 - Extracts and compounds from ficus benghalensis for increasing hair growth and decreasing hair loss: This application discloses natural product extracts and compounds from an aerial root of a Ficus plant, such as Ficus benghalensis. The application also discloses the use of natural product extracts and compounds from Ficus plants for increasing hair growth and decreasing hair loss. Methods of producing the extracts and isolating... Agent:

20120128797 - Method for treatment of constipation-predominant irritable bowel syndrome: The present invention provides methods for treating constipation-predominant irritable bowel syndrome comprising administering to a patient in need thereof, a polymeric proanthocyanidin composition from a Croton species or Calophyllum species in an amount sufficient to treat constipation-predominant irritable bowel syndrome (c-IBS). Treatment of c-IBS includes the treatment of the constipation... Agent: Napo Pharmaceuticals, Inc.

20120128798 - Method of treating neurological conditions with extract of nerium species or thevetia species: A method of treating neurological condition in a subject by administration of an extract, or fraction or sub-fraction thereof, of Nerium species or Thevetia species is provided, wherein the extract, or fraction or sub-fraction thereof, excludes oleandrin and neriifolin. Alzheimer's disease, Huntington's disease or stroke are treated by administering a... Agent: Phoenix Biotechnology, Inc.

20120128799 - Soft dried marshmallow and method of preparation: Dried soft aerated confections and methods of their preparation are provided having a water activity of about 0.1 to 0.4 and a glass transition temperature of less than 20° C. The confections comprise sugars, a foaming and a structuring ingredient, preferably each gelatin, and about 5 to 15% softening agent.... Agent: General Mills, Inc.

20120128800 - Dietary supplements containing extracts of aronia and method of using same to promote weight loss: A dietary supplement composition comprising aronia extract containing at least 20% anthocyanins by dry weight. The aronia extract is derived from the aronia melanocarpa plant. The aronia extract comprises approximately 10%-30% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is provided in the composition.... Agent: Fhg Corporation D/b/a Integrity Nutraceuticals

20120128802 - Bitterness suppressant: The present invention relates to a bitterness suppressant derived from a juice of a stone fruit, and more specifically to a bitterness suppressant characterized by being derived from a juice of a stone fruit wherein a low molecular weight saccharide has been removed.... Agent: Kirin Holdings Kabushiki Kaisha

20120128801 - Combination herbal product to benefit respiratory tract in people exposed to smoke: An herbal composition for providing a beneficial effect to the respiratory tract. The composition includes Thyme Leaf, Wild Cherry Bark, Cocoa Extract, Mullein Leaf Extract, and Boswellia Serrata. In particular, the composition may prevent or treat cough, specifically caused by exposure to smoke. Also described are methods of using the... Agent:

20120128803 - Process for preparing water extract of cinnamon: This invention relates to an improved process for preparing water extract of cinnamon in a large scale. The process comprises the steps of: (a) adding an aqueous solvent such as water to at least 5 kg of a cinnamon raw material at a water to material ratio of 1:1 to... Agent:

20120128804 - Process for preparing water extract of cinnamon: This invention relates to an improved process for preparing water extract of cinnamon in a large scale. The process comprises the steps of: (a) adding an aqueous solvent such as water to at least 5 kg of a cinnamon raw material at a water to material ratio of 1:1 to... Agent:

20120128805 - Long-lasting gustatory and/or olfactory aversion veterinary compositions for behavior modification: Disclosed herein are gustatory and/or olfactory aversion compositions comprising one or more bitterants and appropriate adhesives or tackifiers, and the like, which provide a long-lasting effect. The compositions are useful for behavior modification, especially in animals, such as pets or livestock.... Agent: Vet Planet, LLC

20120128807 - Composition for preventing or treating irritable bowel syndrome: The present invention relates to a composition or a method for treating or preventing irritable bowel syndrome. The present invention uses Atractylodes japonica rhizome extract, preferably the ethanol water solution extract of Atractylodes japonica rhizome, more preferably the 35-65 v/v % ethanol water solution extract of Atractylodes japonica rhizome for... Agent: Sk Chemicals Co., Ltd.

20120128806 - Weight reduction system and method: A method of topically applying natural plant product for dissipation of human adipose tissue, comprising: (a) topically applying an inner portion of a natural plant product to an epidermal layer exterior to adipose tissue to be dissipated of a user's body for a period of time, upon which a percentage... Agent:

20120128808 - Agents from ficus hispida for the amelioration of metabolic syndrome and related diseases: The invention discloses herbal ingredient(s) derived from Ficus hispida comprising herb powder(s), extract(s), fraction(s), pure compound(s) or mixtures thereof and their compositions for alleviating metabolic disorders selected from metabolic syndrome, obesity, diabetes, atherosclerosis, endothelial dysfunction and other metabolic disorders or conditions; the for amelioration of different biological marker proteins and... Agent: Laila Nutraceuticals

20120121501 - Hmgn2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells: The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor... Agent: Sanford-burnham Medical Research Institute

20120121502 - Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof: The present invention relates to novel pyrimidine hydroxy amide compounds, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.... Agent: Acetylon Pharmaceuticals

20120121504 - B cell surface reactive antibodies: The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL.... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Svcs.

20120121503 - Inhibition of cd69 for treatment of inflammatory conditions: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same.... Agent: National University Corporation Chiba University

20120121506 - Targeting of bone marrow neovasculature: Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).... Agent:

20120121505 - Therapeutic compositions and methods: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.... Agent:

20120121507 - Peptide ligands for clusterin and uses thereof: Peptides are disclosed that are useful for molecular imaging or diagnosis of a disease state, such as cancer, in which clusterin is upregulated.... Agent:

20120121508 - Radiolabeled cgrp antagonists: The present invention is directed to radiolabeled CGRP receptor antagonists which are useful for the quantitative imaging of CGRP receptors in mammals.... Agent: Merck Sharp & Dohme Corp.

20120121509 - Vital fluorochrome conjugates and methods of use: The present invention provides compositions and methods based on vital fluorochrome conjugates that are useful for imaging dying and dead cells.... Agent: The General Hospital Corporation

20120121511 - Infection detection methods and systems and related compounds and compositions: e

20120121510 - Localized therapy following breast cancer surgery: Particles providing prolonged release of chemotherapy are injected or implanted into surgical sites in the breast following removal of cancerous tissue. In one embodiment, the particles are designed to not release formulation for approximately two to three weeks after surgery so as to not inhibit healing; in another embodiment particles... Agent:

20120121512 - Monoclonal antibodies and their use: Isolated monoclonal antibodies are disclosed herein that specifically bind a cell surface antigen expressed on the human pancreatic endocrine cells or a subset thereof, and/or a precursor thereof. Isolated monoclonal antibodies are also disclosed herein that specifically bind a cell surface antigen expressed on human pancreatic exocrine cells or human... Agent: Oregon Health & Science University

20120121514 - Needle array assembly and method for delivering therapeutic agents: A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to... Agent:

20120121513 - Platform technologies for spontaneously occurring diseases: The invention provides platform technologies for spontaneously occurring diseases that can be used for translational medicine. Non-human companion animals, such as dogs, spontaneously develop diseases that mirror human diseases. Using companion animals that develop spontaneously occurring diseases can benefit the time and cost for translational medicine by allowing for testing... Agent: Oatmeal Biotechnologies Group LLC

20120121515 - Methods and compositions for cell-proliferation-related disorders: Methods of treating and evaluating subjects having neoactive mutants are described herein.... Agent:

20120121518 - Multifunctional imaging and therapeutic nanoparticles: Multifunctional nanoparticles for imaging and therapeutic drug delivery made from amphiphilic block copolymers having a hydrophobic block and one or more hydrophilic blocks, and at least one internal and one terminal chelating agent units having a paramagnetic metal ion associated therewith.... Agent:

20120121517 - Biodegradable and thermosensitive poly(organophosphazene)-superparamagnetic nanoparticle complex, preparation method and use thereof: The present invention relates to a poly(organophosphazene)-superparamagnetic nanoparticle complex including a biodegradable and thermosensitive poly(organophosphazene) and a iron oxide (Fe3O4, Magnetite)-series ferrite superparamagnetic nanoparticle, a preparation method, and uses of carrying a physiologically-active material, a bio-material and a biomaterial for cancer hyperthermia. The iron oxide is used as a MRI... Agent: Korean Institute Of Science And Technology Of Seoul, Republic Of Korea

20120121516 - Emulsion activatable by ultrasounds and method for producing same: The invention relates to an emulsion that can be activated by ultrasounds, comprising, in an emulsion in an aqueous solution, microparticles having a diameter of less than 10 μm and containing an active agent and a gaseous precursor in a liquid form, encapsulated by a first emulsifier. The microparticles contain... Agent: Centre National De La Recherche Scientifique- Cnrs

20120121519 - Natural polymeric emulsifiers and method for use: Polymeric emulsifiers include polysaccharides modified with at least one cross-linking reagent and with from about 1 mol % to about 10 mol % of at least one ionic reagent, methods for preparing the same, and emulsions including the polymeric emulsifiers.... Agent: Akzo Nobel Chemicals International B.v.

20120121520 - Functional formulation in chewing gum: Nutraceutical gum or functional food compositions comprise Ashwagandha (Withania somnifera) and L-theanine in a sublingual formulation. Methods of making suitable sublingual formulations are described. Also provided is a method for reduction of stress and/or enhancement of energy and mental clarity, comprising administering to an individual in need thereof an effective... Agent:

20120121523 - Compositions having hase rheology modifiers: A monomer compound that contains at least one polymerizable functional group per molecule, and at least one bicycloheptyl-, bicycloheptenyl-, or branched (C5-C42)alkyl-polyether radical per molecule, wherein the bicycloheptyl- or bicycloheptenyl-polyether radical may optionally be substituted on one or more of the ring carbon atoms by one or two (C1-C6)alkyl groups... Agent: Rhodia Operations

20120121521 - Cosmetic coating to protect unclothed skin from thermal injury: A hydrogel composition and a method for protecting a surface from thermal injury is disclosed. The method comprises applying a hydrogel composition to the surface to protect the skin from exposure to a heat flux, wherein the hydrogel is of a type and applied in an amount effective to reduce... Agent: Texas Research International, Inc.

20120121522 - Metabolized conditioned growth medium and methods of use: Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used... Agent: Skinmedica, Inc.

20120121524 - Photo-stable cosmetic or dermatological compositions: m

20120121525 - Antiperspirant compositions containing triethylhexanoin:

20120121526 - Antiperspirant compositions containing triethylhexanoin: A mild reducing composition and method for straightening human hair are described. The composition contains cysteamine hydrochloride in the range of 5-10% by weight at a pH range of 7.0-9.0. The composition is applied to hair and processed for 15-45 minutes. The hair is rinsed with water, dried with a... Agent:

20120121527 - Novel biaromatic compounds that modulate ppary type receptors and cosmetic/pharmaceutical compositions comprised thereof: m

20120121529 - Hair conditioners comprising selected cationic silicones and dimethicone: Hair preparations containing selected cationic silicones and dimethicone are used for the treatment of keratin fibers, in particular human hair.... Agent: Henkel Ag & Co. Kgaa

20120121528 - Hair care agent containing acetylpyridinium salts: Cosmetic hair treatment agent free from hydrogen peroxide and/or the addition products thereof to organic and inorganic compounds and having, in a cosmetic carrier, at least one surface-active agent chosen from anionic, amphoteric and/or zwitterionic surfactants, and at least one acetylpyridinium derivative of formula (I) for improving the general condition... Agent:

20120121531 - Biocomposite for artificial tissue design: The present invention concerns a biocomposite useful in artificial tissue replacement, methods for its production, and methods of use. The biocomposite can be implanted into humans or animals as an artificial tissue for treatment of a tissue defect. The biocomposite can be formed or manipulated into a desired shape for... Agent: University Of South Florida

20120121530 - Vasoprotective and cardioprotective antidiabetic therapy: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.... Agent: Boehringer Ingelheim International Gmbh

20120121532 - Process for making dry and stable hemostatic compositions: d) finishing the final container to. a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.... Agent: Baxter International Inc.

20120121533 - Nucleic acid ligands to ll37: The present invention is directed to nucleic acid ligands to LL37, methods for producing said nucleic acid ligands, and methods for utilizing said nucleic acid ligands. In one exemplary embodiment, for example, this invention relates to nucleic acid ligands exhibiting high specific binding affinity to LL37 peptides, precursors and/or portions... Agent: Biotex, Inc.

20120121534 - Injectable composition combining a filling agent and a fibroblast growth medium: The invention relates to a composition that can be subcutaneously or intradermally injected, comprising: a filling agent; and a fibroblast growth medium.... Agent: Jean-noel Thorel

20120121535 - Agent for preventing recurrence of leukemia: The present invention provides a drug capable of initiating the progression of the cell cycle of leukemia stem cells to overcome the resistance of the leukemia stem cells to cell cycle-dependent chemotherapeutic agents, and a drug for suppressing recurrence of leukemia containing the same, and the like, an agent containing... Agent: Riken

20120121538 - Combined measles-malaria vaccine: A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and... Agent: Cadila Healthcare Limited

20120121536 - Compositions and methods for glucose transport inhibition: Glucose deprivation is an attractive strategy in cancer research and treatment. Cancer cells upregulate glucose uptake and metabolism for maintaining accelerated growth and proliferation rates. Specifically blocking these processes is likely to provide new insights to the role of glucose transport and metabolism in tumorigenesis, as well as in apoptosis.... Agent: Ohio University

20120121537 - Methods and compositions for inhibiting hepatitis c virus replication: Compositions and methods for reducing hepatitis C virus (HCV) replication are provided. Also provided are compositions and methods of treating an HCV infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral... Agent:

20120121539 - Programming of cells for tolerogenic therapies: Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease.... Agent: President And Fellows Of Harvard College

20120121540 - Certain nitrogen containing bicyclic chemical entities for treating viral infections: Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).... Agent:

20120121541 - 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof: The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective... Agent: Anadys Pharmaceuticals, Inc.

20120121542 - Red-shifted opsin molecules and uses thereof: The invention, in some aspects relates to compositions and methods for altering cell activity and function and the use of light-activated ion pumps (LAIPs).... Agent:

20120121543 - Anti-microbial agent from paenibacillus sp. and methods and uses thereof: The present invention provides, in part, a Paenibacillus sp. isolate, designated Paenibacillus polymyxa JB05-01-1, as well as an anti-microbial agent obtained from the bacterium or cell culture supernatant thereof. Compositions, methods and uses are also provided.... Agent: Best Environmental Technologies Inc.

20120121558 - Compositions and methods for treating plasma protein deficiency disorders: The disclosure of the present application provides compositions and methods for treating a blood disorder. In at least one embodiment of a method for treating a patient with a plasma protein deficiency disorder, the method comprises the steps of administering a cell-based composition to a patient with a plasma protein... Agent:

20120121560 - Methods of expanding and redifferentiating islet beta cells: A method of ex-vivo increasing insulin content in progenitor cells which express SLUG is provided. The method comprises downregulating an amount or activity of SLUG in the progenitor cells. Cell populations generated thereby and uses thereof are also provided.... Agent:

20120121559 - Treatment and prevention of pathological conditions using iduna related techniques and compositions: Research into neuroprotective mechanisms has at its heart the goal of developing new therapeutic strategies to treat patients. For example, the compositions and induction strategies disclosed herein have use for acute injuries such as stroke or trauma, and would be extremely useful in treating patients undergoing cardiac bypass surgery, neurosurgery... Agent:

20120121561 - Dry whole milk preparations containing probiotic micro-organisms: The present invention relates to the field of nutrition for young children. In particular, the present invention relates to dry whole milk preparations comprising probiotic micro-organisms to be administered to young children older than 12 months. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic... Agent: Nestec S.a.

20120121562 - Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients: The present invention relates to a nutritional supplement compositions for breast-fed infants or pets which comprise at least one probiotic and at least one nutrient. The compositions are aimed at preserving exclusive breast feeding in infants. The compositions of the invention are also for use in improving the health of... Agent: Nestec S.a.

20120121563 - Specialized nutritional formula for adult patients with gastrointestinal intolerance containing probiotics: The present invention relates to the field of nutrition for adults. In particular, the present invention relates to the nutritional compositions intended for adults with an impaired function of the gastro-intestinal tract. One embodiment of the present invention relates to a nutritional composition to be administered to adults with an... Agent: Nestec S.a.

20120121564 - Use of selected lactic acid bacteria for reducing infantile colic: The invention herein provides certain strains of lactic acid bacteria selected for their capability of promoting production of IL-10 and consequently proliferation of CD4+CD25+ TR cells, for prophylaxis and/or treatment of infant colic, a method of selecting such strains, and products containing such strains.... Agent: Biogaia Ab

20120121565 - Protein recovery: A process for recovering a protein-containing fermentation agent, comprising (i) forming an aqueous mixture of an organic material and a protein-containing fermentation agent capable of fermenting the organic material to produce ethanol, (ii) fermenting the aqueous mixture to produce ethanol, (iii) recovering from the fermented aqueous mixture an ethanol stream... Agent: Ab Agri Limited

20120121551 - Compositions and methods for immunostimulatory rna oligonucleotides: The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IFN-α-inducing activity to a RNA oligonucleotide. The present invention also provides RNA oligonucleotides, including siRNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for... Agent:

20120121555 - Compositions and methods of using living and non-living bioactive devices with components derived from self-renewing colony forming cells cultured and expanded in vitro: The invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone... Agent: Garnet Biotherapeutics, Inc.

20120121554 - Hmg-coa secondary metabolites and uses thereof: The present invention is directed, among other things, to using secondary metabolites in the mevalonate pathway (such as, for example, HMG) and/or structurally related compounds to mediate biological activities (e.g., for therapeutic applications) and/or as diagnostic agents. In some embodiments, the biological activities comprise one or more pleiotropic effects of... Agent: Edenspace Systems Corporation

20120121549 - Induced pluripotent stem cells and methods of use: The invention relates to the field of stem cells and, specially, to the reprogramming of adult somatic cells; to obtain pluripotent cells by the transfection of specific genes. Thus, the invention provides induced pluripotent stem cells (iPS) and methods of obtaining and using them.... Agent: Salk Institute For Biological Studies

20120121544 - Method for efficiently proliferating and differentiating natural killer cells from umbilical cord blood: The present invention relates to a method for efficiently proliferating and differentiating natural killer cells (NK cells) from umbilical cord blood, more precisely a method for efficiently proliferating and differentiating natural killer cells from umbilical cord blood comprising the following steps: 1) preparing CD3 negative cells by eliminating CD3 positive... Agent: Medicell Corporation

20120121546 - Method of producing progenitor cells from differentiated cells: The present invention provides a method of producing progenitor cells, such as cells capable of being differentiated into a plurality of different cell types, from differentiated cells. Methods of using progenitor cells in differentiation and/or tissue or organ repair and/or regeneration and/or building are also provides. Methods of using progenitor... Agent:

20120121547 - Methods and compositions for treating chronic wounds: The invention is directed to novel methods for treating wounds, in particular, chronic wounds such as diabetic ulcers. Such methods utilize novel cell and cell-product compositions in combination with insulin.... Agent:

20120121552 - Methods for purifying hematopoietic stem cells: Described herein are methods for purifying hematopoietic stem cells. Also described herein are methods for purifying EPCR+ cells. The invention also provides substantially pure isolated hematopoietic stems cells, including EPCR+ hematopoietic stem cells.... Agent: Children's Medical Center Corporation

20120121556 - Methods of using regenerative cells to promote wound healing: Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the... Agent: Cytori Therapeutics, Inc.

20120121557 - Neuregulin induced proliferation of cardiomyocytes: The present invention provides methods for inducing division of postmitotic mammalian differentiated cardiomyocytes. The invention can be used to repair heart tissue damaged by, for example, myocardial ischemia, hypoxia, stroke, myocardial infarction or chronic ischemic heart disease in vivo. In addition, the methods of the invention can be used to... Agent: Children's Medical Center Corporation

20120121545 - Pharmaceutical composition for bone disease treatment or countering inflammation, comprising cartilage stem cells as an active principle: Disclosed is a pharmaceutical composition for treating bone disease or countering inflammation containing cartilage stem cells as an active ingredient. The present disclosure provides a novel cell treatment regimen for bone disease and inflammatory disease using the cartilage stem cells as an active ingredient. When the cartilage stem cells of... Agent: Corestem Co., Ltd.

20120121550 - Production of oligodendrocytes from placenta-derived stem cells: The present invention provides methods and compositions for the production of glial cells and oligodendrocytes from placenta stem cells. The invention further provides for the use of these glia and oligodendrocytes in the treatment of, and intervention in, for example, trauma, ischemia and degenerative disorders of the central nervous system... Agent:

20120121548 - Production of reprogrammed pluripotent cells: The present invention provides a method of producing a reprogrammed cell, said method comprising exposing Stro-1+ multipotential cells and/or progeny cells thereof to one or more potency-determining factors under conditions sufficient to reprogram the cells. The present invention also provides cells produced by such a method and cells differentiated therefrom... Agent:

20120121553 - Selection and propagation of progenitor cells: A population of progenitor cells and methods for obtaining and culturing the progenitor cells, that are useful in fields including regenerative medicine (tissue regeneration), transplantation, and cancer research.... Agent: Organ Recovery Systems, Inc.

20120121567 - Ophthalmic solution for protecting internal structures of the eyeball against uv-a rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique: An ophthalmic solution containing riboflavin and at least a compound chosen in the group composed of essential and conditionally essential amino acids, coenzyme Q, L-proline, glycine, lysine hydrochloride, L-leucine, L-arginine and compounds intended to stimulate the production of metalloproteinase MMP9 for the protection of internal structures of the eyeball against... Agent:

20120121566 - Solubilized coq-10: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.... Agent: Soft Gel Technologies, Inc.

20120121568 - Superoxide dismutase variants and methods of use thereof: The present disclosure provides variant superoxide dismutase polypeptides, compositions comprising the polypeptides, and nucleic acids comprising nucleotide sequences encoding the polypeptides. The present disclosure provides methods of reducing oxidative damage in a cell, tissue, or organ. The present disclosure provides methods of identifying agents that increase superoxide dismutase activity.... Agent:

20120121571 - Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus... Agent: The Regents Of The University Of Michigan

20120121569 - Methods of treating infections originating from viruses in the herpesviridae family: Three RNases (ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2) are tested against identified herpesviridae infections. With some exceptions, quantitative PCR assays indicate that the RNases have anti-viral activity against many of these viruses.... Agent: Tamir Biotechnology, Inc.

20120121570 - Test for predicting neutralization of asparaginase activity: Method of in vitro measurement of the presence of factors that are able to neutralize asparaginase activity in a sample of blood, plasma, serum or derived medium that may contain asparaginase neutralizing factors, obtained from a patient, comprising mixing of said sample with asparaginase, incubation of said mixture, then measurement... Agent:

20120121572 - New medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of... Agent: Fidia Farmaceutici S.p.a.

20120121573 - Treatment of pulmonary vascular remodeling with neprilysin: The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.... Agent:

20120121576 - Actriia binding agents and uses thereof: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIA and uses for same.... Agent:

20120121577 - Antibodies as t cell receptor mimics, methods of production and uses thereof: Antibodies are produced that recognize peptides displayed in the context of MHC molecules and thus mimic the specificity of a T cell receptor (TCR). The antibodies are produced by immunizing a host with at least one peptide/MHC complex to elicit an immune response thereto. The desired antibodies can differentiate the... Agent:

20120121574 - Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore: Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.... Agent:

20120121580 - Methods for producing high concentration lyophilized pharmaceutical formulations: The present invention relates to methods of producing lyophilized pharmaceutical compositions comprising a high concentration of therapeutic protein or antibody prior to lyophilization, wherein the lyophilized formulation can be reconstituted with a diluent in about 15 minutes or less. The invention also relates to the high concentration lyophilized formulations produced... Agent: Merck Sharp & Dohme Corp.

20120121578 - Methods of using immunoglobulin aggregates: The current invention provides a method of treating a mammal in need of such treatment with aggregated IgG derived from pooled human plasma. The invention further provides using the discarded fraction obtained during the course of standard IgG fractionation as the source of the aggregated IgG. The methods of the... Agent: Gliknik Inc.

20120121575 - Prohibitin as target for cancer therapy: The present invention relates to pharmaceutical compositions comprising inhibitors of Prohibitin (PHB) for the prevention or/and treatment of hyperproliferative disorders.... Agent: Dr. Thomas Rudel

20120121579 - Treatment of oncostatin m receptor beta mediated heart failure: The present invention relates to an inhibitor of the oncostatin M receptor β or an inhibitor of an activator of the oncostatin M receptor β for use in the treatment and/or prevention of heart failure. The present invention also relates to a method of treating and/or preventing heart failure comprising... Agent: Max-planck-gesellschaft Zur Forderung Der Wissenschaften E.v.

20120121587 - Anti-axl antibody: An objective of the present invention is to decrease the immunogenicity of mouse-derived anti-AXL antibodies in humans by humanizing them. The present invention provides antibodies that can bind to a specific region in Anexelekto (AXL) and humanized antibodies that are produced based on such antibodies. The anti-AXL antibodies of the... Agent: Chugai Seiyaku Kabushiki Kaisha

20120121581 - Anti-botulism antibody coformulations: This invention relates to stable formulations of multiple antibodies comprising a plurality of anti-botulism antibodies and an effective amount of a succinate buffer, an effective amount of arginine, wherein the antibodies are present in substantially equal concentrations and the pH of the formulation is between about 5 and about 6.5.... Agent: Xoma Technology Ltd.

20120121583 - Antibodies against human tweak and uses thereof: The invention provides antibodies binding to TWEAK, including anti-TWEAK antibodies comprising a heavy chain variable domain CDR3 (CDR3H) selected from the group consisting of SEQ ID NO: 8, 16 or 24. The invention provides anti-TWEAK antibodies which are useful for the treatment of cancer, autoimmune diseases, rheumatoid arthritis, psoratic arthritis,... Agent: Genentech, Inc.

20120121589 - Modified egfr ectodomain: A protein that attenuates EGFR and/or EGFR family members comprises a modified EGFR ectodomain. The protein inhibits signaling via the EGFR and/or EGFR family members. The protein includes a portion of the EGFR (or EGFR family member) and the “U” region epitope of EGFR related protein (ERRP), wherein the portion... Agent: Wayne State University

20120121588 - Modulation of pilr receptors to treat sepsis: The present invention provides methods of using agonists and antagonists of PILRα and PILRβ, respectively, to treat immune mediated sepsis. Also provided are methods of prophylactically treating with agonists and antagonists of PILRα and PILRβ respectively, to prevent the development of sepsis.... Agent: Schering Corporation

20120121586 - Modulators for her2 signaling in her2 expressing patients with gastric cancer: The present invention relates to means and methods for the identification of responders for or a patient sensitive to a modulator of the HER2/neu (ErbB2) signaling pathway. Also described herein are corresponding methods of treatment of a group of patients determined and defined in accordance with the identification method of... Agent:

20120121582 - Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease: The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of non-neoplastic hyperproliferative epithelial and/or endothelial cell disorders, including but not limited to disorders associated with increased deposition of extracellular matrix components (e.g., collagen, proteoglycans, tenascin and fibronectin) and/or aberrant angiogenesis. Non-limiting examples of... Agent: Medimmune, LLC

20120121584 - Monoclonal antibodies against extracellular loops of c5ar: The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5a... Agent:

20120121585 - Silent fc variants of anti-cd40 antibodies: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.... Agent: Novartis Ag

20120121594 - Anti-il-6 antibodies for the treatment of arthritis: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat rheumatoid arthritis.... Agent: Alder Biopharmaceuticals, Inc.

20120121593 - Method for determining predisposition to pulmonary infection: Provided herein are methods and materials for diagnosing a subject's predisposition for pulmonary infection in a CF subject by detecting a pulmonary infection genetic marker. Pulmonary infection markers have been identified in the IL-1 gene cluster and may be useful in predicting CF disease progression and assessing a CF subject's... Agent:

20120121590 - Methods of inhibiting adverse cardiac events and treating atherosclerosis and coronary artery disease using galectin-3 binding protein (gal-3bp, btbd17b, mac-2 binding protein): The invention provides Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptide sequences and compositions that include Gal-3BP polypeptide sequences, and methods of using Gal-3BP polypeptide sequences, including modified forms and wild type (native) forms of Gal-3BP polypeptide, such as in treatment, diagnostic, detection and prognostic methods.... Agent:

20120121591 - Selective and potent peptide inhibitors of kv1.3: Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a... Agent: Amgen Inc.

20120121592 - Targeting antigens to human dendritic cells via dc-asialoglycoprotein receptor to produce il-10 regulatory t-cells: Compositions and methods for targeting protein antigens to human DCs via DC-asialoglycoprotein receptor (DC-ASGPR) are disclosed herein. The DC-ASGPR carries an intracellular tyrosine-based and dileucine motif, resulting in the generation of such IL-10 Tregs both in vitro and in vivo. The methods of the present invention can be used for... Agent: Baylor Research Institute

20120121595 - Fragment of secreted heat shock protein-90alpha (hsp90alpha) as vaccines or epitope for monoclonal antibody drugs or target for small molecule drugs against a range of solid human tumors: The invention provides methods for treating HIF-1α-overexpressing human tumors, inhibiting HIF-1α-overexpressing tumor invasion and preventing tumor metastasis, and/or promoting tumor prophylaxis, using various types of inhibitors against the Hsp90α from the tumors.... Agent: University Of Southern California

20120121596 - Bispecific anti-her antibodies: The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.... Agent:

20120121599 - Compositions and methods for stem cell delivery: This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cells, methods of production, and kits.... Agent:

20120121598 - Compositions containing antibodies for treating cd5+hla-dr+b or t cell related diseases: The present invention relates to compositions containing antibodies for treating CD5+ HLA-DR+ B OR T cell related diseases such as B or T cell malignances (leukaemia and lymphoma), autoimmune diseases and T cell related diseases as transplantation and graft rejection.... Agent:

20120121597 - Fusion proteins for hiv therapy: Disclosed herein are fusion antibodies created to provide both an antigen-binding site that targets the CD4 receptor and an antigen-binding site that targets the HIV envelope. The fusion antibodies disclosed herein provide improved potency and breadth against HIV as compared to monospecific antibodies, and additionally provide high barrier against viral... Agent: The Rockefeller University

20120121600 - Pharmaceutical antibody compositions with resistance to soluble cea: The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” and... Agent: Micromet Ag

20120121601 - Mammalian receptor proteins; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.... Agent: Schering Corporation

20120121602 - Novel proteins: Provided herein are four polypeptides, named PRT5, PRT6, PRT7 and PRT8, the nucleic acids encoding the same, compositions comprising the proteins, as well as their uses in therapeutic and diagnostic methods. Antibodies which specifically recognize the polypeptides are also provided, as well as their uses. Characterization of each protein showed... Agent: Two To Biotech Ltd.

20120121604 - Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. Such Compositions comprise inter alia an anti-CTLA-4 agent, e.g. ipilimumab or tremelimumab in combination with other chemotherapeutic agents such as dasatinib, imatinib, paclitaxel, gemcitabine, cisplatin or etoposide.... Agent: Bristol-myers Squibb Company

20120121603 - Compositions and methods for the therapy and diagnosis of influenza: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.... Agent: Theraclone Sciences, Inc.

20120121605 - Anti sulfatides and anti sufated proteoglycans antibodies and their use: Accordingly, the invention provides pharmaceutical compositions comprising MAbs of the invention or fragments thereof for the therapeutic and diagnostic use associated with cardiovascular diseases. Particularly, the present invention relates to the fragments derived from the MAbs that recognize sulfatides and sulfated proteoglycans, which can be used in the therapy or... Agent: Centro De Inmunologia Molecular

20120121606 - Antibodies that immunospecifically bind to b lymphocyte stimulator protein: The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or... Agent: Human Genome Sciences, Inc.

20120121607 - Antibodies to clostridium difficile toxins: The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of C. difficile infection wherein the antibodies bind to a C. difficile toxin.... Agent: Health Protection Agency

20120121609 - Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof: The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (EGFR)-1(IIIb), EGFR-1(IIIc), and/or EGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing EGFR-1 or EGFR-4... Agent: Imclone LLC

20120121610 - Therapeutic agent and assay: The present invention relates to an agent that is useful in the treatment of a cell proliferative disease or disorder, and an assay for identifying such an agent.... Agent:

20120121608 - Use of sam68 for modulating signaling through the tnf receptor: Sam68 plays a role in TNF-dependent signaling, including NF-kB signaling and extrinsic activation of apoptosis. In some embodiments, inhibitors of Sam68 are administered to inhibit TNF-dependent signaling, for example to inhibit NF-kB signaling or apoptosis in a patient in need. In some embodiments, functional Sam68 is administered to increase TNF-dependent... Agent:

20120121611 - Method of treating autoimmune disease with mesenchymal stem cells: Methods and compositions for treating an autoimmune disease, such as new onset type 1 diabetes (T1D) in a subject using autologous or allogeneic mesenchymal stem cells administered to the subject prior to autoimmune-induced complete depletion of insulin-producing pancreatic beta cells, e.g., within six months of new onset type 1 diabetes... Agent: Genzyme Corporation

20120121612 - Fermented wheat germ proteins (fwgp) for the treatment of cancer: The present invention provides compositions comprising the component of fermented wheat germ extract (“FWGE”) active in reducing, inhibiting or preventing the proliferation of cancer cells and/or tumors, and methods of making and using such compositions. The active component from FWGE comprises polypeptides having a molecular weight in the range of... Agent: Regents Of The University Of California

20120121614 - Methods and compositions for bi-specific targeting of cd19/cd22: Methods and composition involving genetically engineered targeting conjugates with reversed orientation of VL and VH chains are provided. For example, in certain aspects targeting conjugates comprising VL and VH chains of anti-CD22 and anti-CD19 are described. In a further aspect, the invention provides methods and targeting conjugates comprising therapeutic agents... Agent: Daniel A. Vallera

20120121613 - Protein conjugate having an endopeptidase- cleavable bioprotective moiety: The invention is directed to a procoagulant conjugate having an endopeptidase-activatable procoagulant protein moiety and one or more bioprotective moieties, which are conjugated to one another by a linker that is cleaved by an endopeptidase in situ to release the bioprotective moiety. The invention is also directed to therapeutic uses... Agent: Bayer Healthcare LLC

20120121615 - Alaninyl maytansinol antibody conjugates: e

20120121620 - Anti-estrogen and immune modulator combinations for treating breast cancer: Compositions for treating cancers of mucosal tissues including breast, prostate, ovary, colon are disclosed which include various combinations of new or conventional anti-estrogen compounds, aromatase inhibitors, immune modulators, immune inhibitors, immune inhibitor mimicking compounds and steroid or thyroid hormones. Methods of predicting susceptibility of a cancer of mucosal origin to... Agent:

20120121622 - Biodegradable immunomodulatory formulations and methods for use thereof: The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or nanocarrier.... Agent: Dynavax Technologies Corporation

20120121619 - Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate: A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of determining whether the human subject is a glatiramer acetate responder by evaluating a biomarker... Agent:

20120121624 - Hepatitis c virus ns3 protease inhibitors: The present invention relates to macrocyclic compounds of Formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.... Agent: Merck Sharp & Dohme Corp

20120121616 - Immune balance-regulating agent: Disclosed is a novel use of superheated stream-treated material. Disclosed is an immune balance-regulating agent comprising a superheated steam-treated product of crown daisy (Chrysanthemum coronarium). This immune balance-regulating agent, which comprises, as the active ingredient, a superheated stream-treated product of crown daisy that has been used as a food for... Agent:

20120121623 - Novel antipathogenic peptides: The present invention relates to monomeric and multimeric peptidic compounds which have antipathogenic, in particular antiviral or/and antibacterial activity. In a preferred aspect, the peptide compounds of the invention have an activity in respect of a broad spectrum of viruses, both DNA and RNA viruses, irrespective of whether they possess... Agent: Spiderbiotch S.r.l.

20120121618 - Predicting and treating prostate cancer: The disclosure features methods and compositions for determining whether a male subject has, or is at an increased risk of developing, an aggressive form of prostate cancer. The disclosure also features methods for adjusting a treatment regimen (e.g., discontinuing a therapy comprising an antioxidant) or administering a therapy that does... Agent: Dana-farber Cancer Institute, Inc.

20120121617 - Promoters for recombinant viral expression: The invention relates to a promoter selected from a group of nucleic acids consisting of (a) a nucleic acid having the nucleotide sequence of SEQ ID NO:1; (b) a nucleic acid having a nucleotide sequence derived from SEQ ID NO:1, wherein not more than 10 nucleotides have been added, deleted,... Agent: Bavarian Nordic A/s

20120121621 - Synergistic prebiotic compositions: The invention relates to synergistic compositions comprising prebiotic components selected from fructose polymers GFn and Fm, either containing a glucose (G) end-group, or without a glucose end-group, and one or more component of a group of prebiotics consisting of modified or unmodified starch and partial hydrolysates thereof, partially hydrolysed inulin,... Agent:

20120121626 - Chimeric vegf peptides: Compositions for and methods of treating patients with malignancies associated with overexpression of VEGF, particularly ovarian cancer are provided herein. The compositions include but are not limited to certain VEGF epitopes, multivalent peptides comprising the epitopes, and chimeric peptides comprising one or more of the epitopes and a T cell... Agent: The Ohio State University Research Foundation

20120121625 - Peptide: The present invention provides peptides at least partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognised by a factor VIII specific T cell. In particular, the present invention provides a peptide comprising or consisting of the sequence... Agent: Apitope Technology (bristol) Limited

20120121627 - Peptides for active anti-cytokine immunization: Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said... Agent: Vaxconsulting

20120121628 - Lipidated polyepitope vaccines: This invention relates to, inter alia, an isolated lipidated polypeptide including a lipid moiety at the N-terminus and a plurality of epitopes, and methods of making and using the polypeptide.... Agent: National Health Research Institutes

20120121629 - New human rotavirus vaccine strains and diagnostics: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an... Agent:

20120121630 - Recombinant ectodomain expression of herpes simplex virus glycoproteins in yeast: The present invention provides Herpes Simplex Virus (HSV) gD, gC, gB and/or gE recombinant glycoproteins having a particular pre-selected N-linked glycosylation pattern as the predominant N-glycoform. The present invention also provides methods of producing these recombinant glycoproteins in yeast, preferably Pichia pastoris, which may be glycoengineered to provide particular glycosylation... Agent:

20120121635 - Expression in plants of hiv-related proteins: Plants are engineered to express HIV related surface protein genes. The plants can be used as a source of the protein for a variety of purposes. Plant tissue can be orally administered to animals to elicit an immune response or provide protection from viral infection. The protein can be extracted... Agent: Prodigene, Inc.

20120121633 - Hiv cd4 binding site based covalent immunogen compositions: Provided are immunogenic compositions based on the highly conserved, core CD4 binding site of the gp120 protein of the human immunodeficiency virus. One embodiment includes an antigenic conjugate of an electophilic derivative of HIV gp120 peptide 416-433, designated E-416-433, covalently linked to an immunogenic carrier protein. The compositions are effective... Agent:

20120121631 - Polyvalent vaccine: The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens... Agent: Duke University

20120121634 - Soluble pd-1 variants, fusion constructs, and uses thereof: The subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are therapeutic compositions comprising the sPD-1 proteins, nucleic acids, and fusion constructs of the subject invention. In a preferred embodiment, the therapeutic composition is... Agent: The University Of Hong Kong

20120121632 - Tat protein for preventing or treating aids: The invention relates to a method of preventing or treating acquired immunodeficiency syndrome (AIDS) in a patient, wherein the patient is administered with a Tat protein comprising amino acid sequence SEQ ID NO: 1 or 2, or a variant thereof capable of stimulating an immune response against Tat proteins.... Agent: Universite De La Mediterrannee

20120121636 - Tat-based vaccine compositions and methods of making and using same: A Tat-based vaccine composition comprising at least one antigen coupled to at least one immunostimulatory lentivirus trans-activator of transcription (Tat) molecule wherein the antigen is a cancer antigen an infectious disease antigen or a fragment thereof and methods to treat disease by administering the Tat-based vaccine composition. An additional Tat-based... Agent: Nanirx, Inc.

20120121637 - Chimeric factor h binding proteins (fhbp) and methods of use: Chimeric fHbps that can elicit antibodies that are bactericidal for different fHbp variant strains of N. meningitidis, and methods of use, are provided.... Agent:

20120121638 - Polypeptide derived from enterococcus and its use for vaccination: A medicament for the treatment or the prevention of a bacterial infection is disclosed which contains a polypeptide having a contiguous sequence of at least six amino acids of SEQ ID NO:1. Said polypeptide can be used for the preparation of a vaccine against an Enterococcus infection.... Agent:

20120121639 - Proteins with repetitive bacterial-ig-like (big) domains present in leptospira species: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3... Agent: The Regents Of The University Of California

20120121640 - Ox40/trail fusion proteins: Fusion proteins which act on the OX40/TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, and alloimmune diseases, as well as cancer.... Agent: The Trustees Of The University Of Pennsylvania

20120121641 - Mhc oligomer and method of making the same: The invention discloses MHC oligomers and methods for making the same comprising at least two functional MHC complexes having a peptide binding groove, each MHC complex having a peptide bound in the peptide binding groove of the MHC complex, wherein each peptide has a modification which allows highly specific oligomerisation... Agent:

20120121642 - Anti-inflammatory hydrolysate of c. versicolor: Methods and compositions for reducing and/or inhibiting inflammation by topical application of dermatocosmetic compositions comprising effective amounts of extracts of Coriolus versicolor that have been hydrolyzed by an acid protease, preferably Rhizomucor miehei, and thereafter rendered substantially devoid of acid-protease activity.... Agent: Active Organics, Inc.

20120121643 - Engineered listeria and methods of use thereof: The invention provides a bacterium containing a polynucleotide comprising a nucleic acid encoding a heterologous antigen, as well as fusion protein partners. Also provided are vectors for mediating site-specific recombination and vectors comprising removable antibiotic resistance genes.... Agent:

20120121644 - Sticky soft gel for treating poultry: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling... Agent:

20120121645 - Supralingual vaccines and applicators: Solid and semi-solid formulations are used for supralingual administration of vaccines to animals. The formulations, which comprise antigens dispersed in a solid or semi-solid matrix, or paste, are delivered via supralingual applicators. The supralingual applicators are designed so as to position the antigen-containing matrix directly on the dorsal surface of... Agent: The Board Of Regents For Oklahoma State University

20120121646 - Vaccine: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner... Agent: Isis Innovation Limited

20120121647 - Influenza vaccine, composition, and methods of use: The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal... Agent: Institut Pasteur De Lille

20120121648 - Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles: Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immunostimulatory RNA motifs and the polymers incorporating such motifs are potent and selective inducers of TLR7 and the TLR7-associated... Agent: Coley Pharmaceutical Gmbh

20120121649 - Compositions and methods for the prevention and treatment of cancer: Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class I and/or class II molecules presenting tumor-specific antigens... Agent: Uti Limited Partnership

20120121650 - Chimeric virus vaccines: The present invention provides novel self-replicating and self-propagating chimeric viral vectors and chimeric virus particles comprising a modified genome of a carrier RNA virus packaged within structural proteins of a second virus. Also provided are pharmaceutical formulations comprising the chimeric viral vectors and virus particles and methods of inducing an... Agent:

20120121651 - Pyrazolopyridines and analogs thereof: Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, and prodrugs thereof, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.... Agent: 3m Innovative Properties Company

20120121652 - Complete liquid nutrition for children at the age of 1-10 years comprising probiotics: The present invention relates to the field of nutrition for children. In particular, the present invention relates to the nutritional compositions intended for children with an impaired function of the gastro-intestinal tract. One embodiment of the present invention relates to a nutritional composition to be administered to children with an... Agent: Nestec S.a.

20120121660 - Bone void fillers: A bone void filler composition is described containing an acidic mineral component that contains a calcium source and a phosphate source or a lower alkyl carboxylate source; an osteoinductive component that contains demineralized bone; and a three-dimensional, osteoconductive biologically acceptable carrier component that contains a collagenous material. The bone void... Agent: Zimmer Orthobiologics, Inc.

20120121668 - Compositions for oral adminstration of active principles requiring masking of taste: A process for the preparation of a composition intended for the oral administration of active principles with unacceptable taste, which comprises from about 15% to about 30% of organoleptically unpleasant active ingredient (principle) that is mixed with from about 60% to about 80% of an ester of glycerol or of... Agent: Aventis Pharma S.a.

20120121666 - Compositions of particles: Method of making particle compositions exhibiting improved floodability and/or flowability properties. The compositions generally contain particles and non-surface modified nanoparticles.... Agent: 3m Innovative Properties Company

20120121661 - Devices with multiple surface functionality: Phosphorus-based coatings having a plurality of phosphate moieties, a plurality of phosphonate moieties, or both, covalently bonded to an oxide surface of an implantable substrate exhibiting one or more of the following characteristics: (a) the surface phosphorus-containing group density of the coated regions of the substrate is at least about... Agent: The Trustees Of Princeton University

20120121657 - Enhancing biocompatibility of a medical device: The present invention relates to a medical device comprising both pyrolytic carbon and an NO generator, methods of making same, and methods of using same.... Agent: St. Jude Medical, Inc.

20120121658 - Functionalized rgd peptidomimetics and their manufacture, and implant having a coating containing such functionalized rgd peptidomimetics: At least some embodiments of the invention relates to an implant having a coating that contains or is composed of a functionalized RGD peptidomimetic RGD-P1 having the formula (1) and/or a functionalized RGD peptidomimetic RGD-P2 having the formula (2), and an associated manufacturing method.... Agent: Biotronik Ag

20120121659 - Functionalized rgd peptidomimetics and their manufacture, and implant having a coating containing such functionalized rgd peptidomimetics: At least some embodiments of the invention relates to an implant having a coating that contains or is composed of a functionalized RGD peptidomimetic RGD-P1 having the formula (1) and/or a functionalized RGD peptidomimetic RGD-P2 having the formula (2), and an associated manufacturing method.... Agent: Biotronik Ag

20120121664 - Gastric acid secretion inhibiting composition: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in... Agent: Orexo Ab

20120121665 - Implantable or insertable medical device resistant to microbial growth and biofilm formation: Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer... Agent: Boston Scientific Scimed, Inc.

20120121656 - Methods and compositions for protecting against neurotoxicity of a neurotoxic agent, and improving motor coordination associated with a neurodegenerative condition or disease: Provided are methods for protecting against or reducing neurotoxicity of exposure to a neurotoxic agent, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for neuroprotection against the neurotoxic agent, preferably where protecting against or reducing loss of motor coordination in the subject... Agent: Revalesio Corporation

20120121654 - Nanoparticle isoflavone compositions & methods of making and using the same: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.... Agent: Humanetics Corporation

20120121653 - Novel mometasone compositions and methods of making and using the same: The present invention is directed to mometasone furoate compositions comprising mometasone furoate and at least one surface stabilizer. The mometasone furoate particles of the composition preferably have an effective average particle size of less than about 2000 nm.... Agent: Elan Pharma International Limited

20120121667 - Pharmaceutical composition: Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the... Agent: Alpharma Pharmaceuticals, LLC

20120121662 - Treatment using dantrolene: Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of... Agent: Lyotropic Therapeutics, Inc.

20120121663 - Treatment using dantrolene: Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of... Agent: Lyotropic Therapeutics, Inc.

20120121655 - Chewable formulation comprising alginate, bicarbonate and carbonate: The present invention relates to a solid, ingestible composition comprising: a) an alginate; b) a bicarbonate; and c) a carbonate wherein the composition is in the form of a chewable core, a process for preparing said composition, and its use in the treatment of reflux oesophagitis, gastritis, dyspepsia or peptic... Agent: Reckitt Benckiser Healthcare (uk) Limited

20120121675 - Compounds which inhibit muscle contraction: Peptides of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-Yp—Zs—R2 their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, their preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of conditions, disorders and/or diseases that are a consequence of muscle contraction.... Agent: Lipotec, S.a.

20120121671 - Control of fluid migration in non-latex bonded wet-wipes: The present invention describes wet-wipe composition with a liquid portion that is impregnated in a substrate, wherein the liquid portion contains a thickening or gelling polymer along with a thickening or gelling agent which substantially reduces fluid migration of the liquid portion within a wet-wipes stack during storage wherein the... Agent: Hercules Incorporated

20120121677 - Fragrance-containing compositions: An antiperspirant or deodorant composition comprising i) an antiperspirant or deodorant active, ii) a liquid carrier for the antiperspirant or deodorant active, and iii) fragrance in which the fragrance comprises a mixture of first and second fragrances, respectively (iiia) and (iiib), the first fragrance (iiia) being free from encapsulation and... Agent:

20120121676 - Method for manufacturing capsules, resulting capsules, and use of said capsules: The invention relates to a one-step process for manufacturing capsules from 1 to 100 microns with a polydispersity index of less than 10%, to suspensions of capsules obtained via this process, and to the use of these suspensions of capsules.... Agent: Centre National De La Recherche Scientifique

20120121674 - Nonwoven fabric products with enhanced transfer properties: The present invention relates to the field of non-woven textile products, and is applied to the manufacture of non-woven fabric products or generally nonwovens for various applications such as household use and personal care. In particular, the present invention relates to a wet nonwoven fabric product impregnated with a substance... Agent:

20120121669 - Oral care composition comprising capsules: Oral care compositions comprising a capsules comprising flavoring and/or one or more active ingredients, and/or flavours, said capsules distributed in an orally acceptable vehicle or carrier.... Agent: Colgate-palmolive Company

20120121672 - Particles that disrupt or impede bacterial adhesion, related compositions and methods: Oral care and other compositions comprising particles having cores attached to bioadhesive polymers for inhibition of pellicle formation, plaque formation, biofilm formation, biofouling, and microbial adhesion or attachment are described. Methods using said compositions to treat surfaces, such as oral surfaces.... Agent: Colgate-palmolive Company

20120121670 - Polyarginine nanocapsules: The present invention relates to a system for administering active ingredients comprising nanocapsules with a diameter less than 1 μm comprising a polyarginine salt, a negative phospholipid and an oil. The invention also relates to methods for obtaining said nanocapsule system, the pharmaceutical and cosmetic compositions thereof, as well as... Agent:

20120121673 - Topical compositions comprising inorganic particulates and an alkoxylated diphenylacrylate compound: A topical composition of improved spreadability and aesthetical appeal is provided, which contains inorganic particulates in combination with an alkoxylated diphenylacrylate compound. Preferably, the topical composition is a sunscreen composition that contains inorganic or physical sunscreen agents in combination with an alkoxylated α-cyanodiphenylacrylate compound, which is characterized by improved photo-protection... Agent:

20120121678 - Vapor-phase application of spinosyn for the control of pest, and formulations and products utilizing the same: The present invention relates to the vapor-phase application of at least one spinosyn to treat pests including, for example, vadult mosquitoes and houseflies.... Agent: Entarco Sa

20120121679 - Viricidal and microbicidal compositions and uses thereof: The present disclosure encompasses compositions comprising a surfactant, and an acid such as, but not limited to, levulinic acid, that together have a synergistic effect in reducing the viability of a virus population compared to the efficacy of the individual compounds. This synergy allows the formulation of compositions where the... Agent: University Of Georgia Research Foundation, Inc.

20120121680 - Animal repelling deicer: Deicing products designed to deter ungulates are provided, along with methods of using those products to treat iced surfaces. The deicing product comprises a mixture of a deicer along with an ungulate repellent. The repellent can repel based on conditioned avoidance, fear, chemical irritation, and/or bad taste. The deicer can... Agent: North American Salt Company

20120121681 - Insecticidal polymer matrix comprising pbo and dm: An insecticidal polymer matrix containing Piperonyl Butoxide (PBO) and deltamethrin (DM), wherein the ratio between the content of PBO and the content of DM in terms of weight is higher than 3.... Agent: Vestergaard Frandsen Sa

20120121682 - Crgd peptide derivative and its manufacture, and implant having a coating containing a crgd peptide derivative:

20120121684 - coating comprising a poly(ethylene glycol)-poly(lactide-glycolide-caprolactone) interpenetrating network: Implantable medical devices are disclosed. The devices comprise a coating comprising an interpenetrating network or semi-interpenetrating network. The interpenetrating network or semi-interpenetrating network comprises poly(ethylene glycol) and an aliphatic polyester copolymer. A method of using the implantable device is also provided.... Agent: Abbott Cardiovascular Systems Inc.

20120121683 - Functional nanoparticle filled nanotubes and methods of their production: Carbon nanotubes with a suspension or colloidal solution of functional nanoparticles and methods for production of carbon nanotubes loaded with functional nanoparticles are provided.... Agent: Drexel University

20120121685 - Breakfast cereals containing probiotic micro organisms: The present invention relates to the field of nutrition. In particular, the present invention relates to a breakfast cereal composition comprising probiotic micro-organisms. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic micro-organisms, for example.... Agent: Nestec S.a.

20120121686 - Biodegradable compositions having pressure sensitive adhesive properties: A composition comprising the reaction product of (a) an isocyanate group-containing component having an average functionality of at least 2; and (b) an active hydrogen group-containing component having an average functionality of at least 2. The composition is biodegradable, a solid at 22° C. and below, and has pressure sensitive... Agent: Cohera Medical, Inc.

20120121687 - Wound healing material and method for fabricating the same: The present invention provides a wound healing material and method for fabricating the same. The wound healing material comprises a hydrophobic fluoro-containing membrane having a first surface and a second surface opposing to each other; and at least one biocompatible polymer covalently bonded to at least one part of the... Agent: Chung Yuan Christian University

20120121695 - Acoustically sensitive drug delivery particles comprising non-lamellar forming phosphatidylethanolamine: Novel acoustically sensitive drug carrying particles comprising non-lamellar forming lipids are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their pay-load upon exposure to acoustic energy.... Agent: Epitarget As

20120121694 - Compositions and kits for ocular treatment: Embodiments of the invention provide eyelid preparations, methods, and kits, for treating ocular conditions. The eyelid preparations comprise a mixture of tea tree oil and sea buckthorn oil in a pharmaceutically acceptable carrier.... Agent: Ocusoft Inc.

20120121697 - Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease: Compositions and methods are disclosed for the treatment and diagnosis of inflammatory diseases and disorders, including pulmonary diseases and fibrotic disorders, including COPD.... Agent:

20120121692 - Compounds and compositions comprising cdk inhibitors and methods for treating cancer: Disclosed herein are compounds suitable for use as antitumor agents, methods for treating cancer wherein the disclosed compounds are used in making a medicament for the treatment of cancer, methods for treating a tumor comprising, administering to a subject a composition comprising one or more of the disclosed cytotoxic agents,... Agent: Georgia State University Research Foundation

20120121691 - Method for increasing the production of a specific acyl-chain dihydroceramide(s) for improving the effectiveness of cancer treatments: A method to improve the effectiveness of cancer treatments by increasing the production of specific ACYL-chain dihydroceramide(s). Increase of native chain-length dihydroceramides is directly cytotoxic to human acute lymphoblastic leukemia cell line MOLT-4 ALL cells with a cytotoxic potency that is dependent upon the specific fatty acid acyl-chain length and... Agent: Texas Tech University System

20120121690 - Method to enhance an immune response of nucleic acid vaccination: A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The... Agent: Lipoxen Technologies Limited

20120121693 - Methods for generating new hair follicles, treating baldness, and hair removal: The present invention provides methods of treating baldness in a subject and generating new hair follicles, comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell. The present invention also provides methods for hair removal and inducing hair... Agent:

20120121688 - Preventative or therapeutic agent and method for immune disease: More particularly, the present invention provides a pharmaceutical (e.g., a preventive or therapeutic agent for immune diseases such as allergic disease and autoimmune disease) containing a CD1d ligand and a target antigen (e.g., allergen, autoantigen). Preferably, the pharmaceutical contains a drug delivery vehicle including the CD1d ligand and the target... Agent: Rinken

20120121689 - Small interfering rna delivery: A liposomal siRNA composition is described. The liposomes are formed of neutral liposome forming components, and the composition comprising additionally sugar. The composition provides reduced expression of target gene, without causing systemic toxicity. The composition is produced by a dehydration-rehydration technique to provide high yields and good control of liposome... Agent: Lipoxen Technologies Limited

20120121696 - Terpene glycosides and their combinations as solubilizing agents: Several terpene glycosides (e.g., mogroside V, paenoiflorin, geniposide, rubusoside, rebaudioside A, steviol mono-side and stevioside) were discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds, including but not limited to, paclitaxel, camptothecin, curcumin, tanshinone HA, capsaicin, cyclosporine, erythromycin, nystatin, itraconazole, celecoxib, clofazimine, digoxin, oleandrin, nifedipine,... Agent:

20120121699 - Lycopene and resveratrol dietary supplement: A dietary supplement is disclosed comprising lycopene and resveratrol in a range of ratio of lycopene:resveratrol from 1:10 to 10:1. Preferably, the ratio is 1:2 to 1:4. Lycopene is preferably of ≧95% purity and resveratrol is of ≧98% purity. Both lycopene and resveratrol may preferably comprise of nano-sized particles in... Agent: Hsiehs Biotech (singapore) Pte Ltd

20120121698 - Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same: The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same.... Agent: Amarin Pharma, Inc.

20120121701 - Pharmaceutical composition of peptide drug and enzyme-inhibition compounds: The invention relates to a method of co-administering a peptide or protein drug with an enzyme-resistant PGA-complexone compound orally so to mitigate enzyme attack in the gastrointestinal tract of an animal subject.... Agent:

20120121700 - Pharmaceutical formulations comprising valganciclovir: Pharmaceutical formulations prepared by granulating valganciclovir or a salt thereof, using a nonaqueous solvent or hydro-alcohol.... Agent:

20120121702 - Controlled release azithromycin solid dosage forms: A solid dosage form for oral administration comprising azithromycin in an amount below that which causes gastrointestinal side effects, which dosage form is a controlled release dosage form.... Agent: Dow Pharmaceutical Sciences, Inc.

20120121703 - Tablet containing ferric citrate: The present invention provides a new preparation which is a tablet containing (1) ferric citrate, (2) a polyvinyl alcohol-polyethylene glycol graft copolymer, and (3) a polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer.... Agent: Japan Tobacco Inc.

20120121704 - Aliphatic amine polymer salts for tableting: The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater... Agent: Genzyme Corporation

20120121705 - Pharmaceutical or cosmetic or dietetic composition suitable for promoting a hair pigmentation effect: The invention relates to the use of spermidine or a pharmaceutically acceptable derivative thereof as the active principle in a pharmaceutical, cosmetic or dietetic composition. The composition is used for promoting pigmentation of the hair, particularly the shaft of the hair. The invention also relates to the composition which promotes... Agent:

20120121706 - Par-1 activation by metalloproteinase-1 (mmp-1): Matrix metalloproteases (MMPs) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (PAR-1) by endogenous platelet MMP-1 collagenase on the surface of platelets. Exposure of platelets to fibrillar collagen converts the surface-bound pro-MMP-1... Agent: Tufts Medical Center, Inc.

20120121708 - Acetazolamide microparticle and its preparation method and use: A method for preparing an acetazolamide microparticle having a mean particle size ranged between 0.36 μm and 18 μm is provided. The method includes steps of dissolving an acetazolamide in a solvent to form an acetazolamide solution; and mixing the acetazolamide solution with a supercritical fluid at a temperature and... Agent: National Taiwan University

20120121711 - Microsphere drug carrier, preparation method, composition and use thereof: A nanosphere or microsphere drug carrier, formulations comprising the drug carrier and the preparation method of the formulations and the use of the carrier are disclosed. The carrier comprises a biodegradable methoxy end-capped polyethylene glycol-polylactide block copolymersor a derivative thereof represented by formula (I) as the main carrier material: CH3O—[CH2—CH2—O]m—[C(O)—CH(CH3)—O]n—R... Agent: Xi'an Libang Medical Technology Co., Ltd.

20120121710 - Mucosal immunization: Methods and compositions for eliciting an immune response to an antigen are disclosed. In certain aspects, these methods concern eliciting an immune response in a subject by administering to the mucosa of the subject a composition comprising a virus-like particle (“VLP”) and Murabutide.... Agent: Arizona Board Of Regents For And On Behalf Of Arizona State University

20120121709 - Phase transition biopolymers and methods of use: The present disclosure describes environmentally responsive polypeptides capable of displaying stimuli-triggered conformational changes in a reversible or irreversible manner that may be accompanied by aggregation. Polypeptides include a number of repeated motifs and may be elastomeric or non-elastomeric. The polypeptides may be used to deliver therapeutics to a biological site... Agent:

20120121707 - Tolbutamide particle and preparing method thereof and method of reducing a blood glucose: A method for preparing a tolbutamide particle is provided. The method comprises steps of mixing a bulk drug of tolbutamide with a supercritical fluid to form a supercritical mixture; and expanding the supercritical mixture to obtain the tolbutamide particle.... Agent: National Taiwan University

20120121712 - Cellular electric stimulation mediated by piezoelectric nanotubes: Piezoelectric nanotransducers for use in an in vivo treatment of cell stimulation through electrical stimulation are described. The nanotransducers are localized in a target site, and an electrical stimulus is induced in the same site through external stimulation of the nanotransducers by ultrasonic waves.... Agent:

20120121713 - Chimeric therapeutics, compositions, and methods for using same: Chimeric therapeutics are disclosed that include a modified viral core protein comprising at least one mutation or modification in an immunogenic epitope and a therapeutic agent. The therapeutic agent may be associated with the modified viral core protein and may be a nucleic acid, a protein, or a small molecule.... Agent:

20120121714 - Compositions with antigens adsorbed to calcium phosphate: Calcium phosphate is used as an adjuvant, with a high degree of antigen adsorption to the adjuvant. The invention is particularly useful for adjuvanting conjugated capsular saccharide antigens. Buffers, such as phosphate or histidine buffers, can advantageously be used in combination with the calcium phosphate, and compositions may have a... Agent: Novartis Ag

20120121715 - Dna vaccine comprising il-6-encoding dna construct and applications thereof: A DNA vaccine, which comprises a DNA construct comprising an expression vector which is expressible in a eukaryotic cell, and a nucleotide fragment which comprises an IL-6-encoding sequence and an HPV E7(detox)-encoding sequence. A pharmaceutical composition and a method for preventing or treating HPV-related (-induced) diseases are included.... Agent: National Taiwan University

20120121716 - Pharmaceutical composition of an anthracycline: The present invention relates to pharmaceutical composition containing nemorubicin hydrochloride incorporated in microspheres. The compositions are useful for chemoembolisation, particularly for loco regional treatment of tumors.... Agent: Nerviano Medical Sciences S.r.l.

20120121717 - Drug-loaded polysaccharide-coated goldmag particles (dpgps) and its synthesis method: The invention relates to Polysaccharide-coated GoldMag particles (DPGPs) and the method of its synthesis, which characterized GoldMag particles as a core and natural or synthetic biodegradable polysaccharide such as dextran, cyclodextrin and derivatives as shell. DPGPs are synthesized by mixing Polysaccharide-coated GoldMag particles (DPGPs) with drug through physical bond. The... Agent: Xi'an Goldmag Nanobiotech Co. Ltd

20120121718 - Compositions and methods relating to reduced mucoadhesion: The present invention generally relates to reducing the mucoadhesive properties of a particle. In some embodiments, the particle is coated with and/or associated with a (poly(ethylene glycol))-(poly(propylene oxide))-(poly(ethylene glycol)) triblock copolymer. Methods for preparing inventive particles using a poly(ethylene glycol)-vitamin E conjugate as a surfactant are also provided. In some... Agent: The Johns Hopkins University

20120121719 - Methods of making and using three-dimensional extracellular matrices: Three-dimensional extracellular matrices lacking synthetic scaffolds are provided. Methods of making the three-dimensional extracellular matrices and methods of using the three-dimensional extracellular matrices are also provided.... Agent: University Of Utah Research Foundation

20120121720 - Modulation of beta 2 adrenergic receptors by inhibitors of egln3 or pvhl: This present invention relates to methods, compositions, and kits useful for treating a patient having or at risk for developing a disorder associated with decreased expression of β2 adrenergic receptors or need for increased 132 adrenergic receptor activity.... Agent:

20120121721 - Skin care products and compositions: Disclosed herein is a composition for treating maladies in humans or animals that includes from about 0.01% to about 40% by weight of a member of the curcuma genus, from about 0.01% to about 40% by weight of a member of the coffea genus and the balance being a pharmaceutically... Agent:

20120121722 - Atazanavir formulations: The present invention relates to formulations comprising atazanavir and a silicate, and the process of preparation thereof, wherein the silicate is present in the extragranular portion.... Agent:

20120121723 - Antimicrobial compositions: An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids,... Agent: Sterilex Technologies, LLC

20120121724 - Film comprising therapeutic agents: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin, as well as other therapeutic agents either with or without nitroglycerin, through the mucosal tissues of the oral cavity. The films include a water soluble... Agent:

20120121725 - Cosmetic composition for the treatment of acne comprising a peptide extract of schizandra: The present invention relates to a cosmetic, nutraceutical or dermatological composition for treating or preventing acne, comprising a peptide and oside extract of Schizandra fruit and a suitable excipient. Preferably, the extract is obtained from Schizandra sphenanthera. The composition may also comprise at least one anti-acne agent selected from a... Agent: Laboratoires Expanscience

20120121726 - Kits and methods for nutrition supplementation: The present invention relates to methods of co-administration of various vitamin and mineral compositions, and in a specific embodiment, said methods comprise co-administering one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids... Agent:

20120121727 - Substituted dihydropyrazolones for treating cardiovascular and hematological diseases: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.... Agent: Bayer Pharma Aktiengesellschaft

20120121728 - Stabilized and activated bromine solutions as a biocide and as an antifouling agent: The invention provides a process of removing or preventing biofouling, particularly on surfaces of industrial and agricultural equipment in contact with aqueous liquids. The process employs an antifouling composition of stabilized active halogen having a low pH.... Agent: Bromine Compounds Ltd.

20120121729 - Antitussive compositions comprising memantine: Memantine compositions and methods of use are described herein. In some embodiments, the compositions comprise memantine and an absorption enhancer, or memantine and an elimination enhancer, or memantine and an absorption enhancer and an elimination enhancer.... Agent:

20120121730 - Pharmaceutical and nutraceutical compositions for treating respiratory disease and associated phlegm: The present invention relates to pharmaceutical compositions comprising dextromethorphan or a physiologically acceptable salt thereof, quercetin, resveratrol, and hesperidin. The invention further relates to nutraceutical or dietary supplement composition comprising a physiologically acceptable salt of magnesium, quercetin, resveratrol, and hesperidin. Further provided are methods for treating respiratory disease in a... Agent: Trinity Laboratories, Inc.

20120121731 - Electrolytic system and method for generating biocides having an electron deficient carrier fluid and chlorine dioxide: A method for electrolytically generating a biocide having an electron deficient carrier fluid and chlorine dioxide, including providing a carrier fluid; providing a pair of electrodes interposed by a semi-permeable membrane within a vessel for creating a first passageway and a second passageway, an anode electrode of the pair of... Agent: Strategic Resource Optimization, Inc.

20120121732 - Composition for use in the prevention and treatment of cardiovascular diseases: The invention provides a composition the prevention and treatment of cardiovascular disease, wherein said composition compounds obtained from palm oil mill effluents, in particular from vegetative liquor from the milling of palm oil fruit.... Agent:

20120121733 - Deodorized edible oil or fat with low levels of bound mcpd and process of making using an inert gas: A process for making a deodorized edible oil or fat having a low level of bound MCPD (monochloro propanediol esters) and/or low level of bound 3-MCPD is described. The process comprises a step of stripping the vegetable oil or fat with an inert gas. The inert gas can be nitrogen.... Agent: Nestec S.a.

20120121735 - Composition and method for reducing food intake: The present invention features compositions and methods for suppressing appetite. The compositions of the invention are composed of a dietary fiber and a combination of selected herbal extracts, at least one of which is capable of inhibiting gastric emptying and one which increases metabolic rate.... Agent: Natures Remedies Ltd.

20120121734 - Compositions containing sucralose and application thereof: Novel utilization of sucralose which is a high intense sweetener. Compositions containing sucralose including: sweetening compositions having excellent sweetness qualities based on the characteristics of sucralose; foods with a masked unpleasant smell and unpleasant taste; performance food compositions (viscous food compositions, gel food compositions, emulsified food compositions); foods with improved... Agent: San-ei Gen F.f.i., Inc.

20120121736 - Composition for treating gastric ulcer and a process thereof: The present invention relates to a herbal composition for treating gastric ulcer, a method for preparing said herbal composition.... Agent:

20120121737 - Compositions comprising trans-tert-butyl cyclohexanol as skin irritation-reducing agent: The present invention primarily relates to the use of trans-tert-butyl cyclohexanol as skin irritation-reducing agent as well as compositions (formulations) having a skin irritation-reducing action comprising trans-tert-butyl cyclohexanol as skin irritation-reducing agent.... Agent: Symrise Ag

20120121738 - Bioactive botanical cosmetic compositions and processes for their production: The present invention is directed to bioactive botanical cosmetic compositions derived from membrane and cell serum fractions of plant cell juice. The present invention also relates to the methods for preparing these bioactive botanical cosmetic compositions and the uses of these compositions in various cosmetic formulations and as topical skin... Agent: Akzo Nobel Surface Chemistry LLC

20120121739 - Bioactive botanical cosmetic compositions and processes for their production: The present invention is directed to bioactive botanical cosmetic compositions derived from membrane and cell serum fractions of plant cell juice. The present invention also relates to the methods for preparing these bioactive botanical cosmetic compositions and the uses of these compositions in various cosmetic formulations and as topical skin... Agent: Akzo Nobel Surface Chemistry LLC

20120121740 - Compositions and methods for treating, inhibiting the onset, and slowing the progression of erectile dysfunction including naturally occurring age related erectile dysfunction: Compositions for treating erectile dysfunction (“ED”), including age related erectile dysfunction (ARED), comprise in a preferred embodiment ginger and an amino acid. Preferably the amino acid is L-arginine and/or L-citrulline. Additionally, the compositions may comprise guarana (Paullinia cupana), Muira puama cortex magnoliae officinalis (CMO) and/or fructus aurantil immaturus (FAI). The... Agent: K.l.r.m., LLC

20120121741 - Water soluble defructosylated pea extract, and use thereof as a prebiotic agent: The present invention relates to a water-soluble defructosylated pea extract, substantially free of proteins and peptides, as well as to an oligosaccharide composition such as that contained in said extract. It also relates to the method for preparing the same, and to the use thereof as a prebiotic agent.... Agent:

20120121742 - Plant extracts for use as phytochemicals: The invention concerns the use of grape (Vitis vinifera) seeds extracts as agents for the treatment and prevention of plant diseases caused by pathogens, particularly by fungi and oomycetes, as well as fungicidal compositions comprising Vitis vinifera extracts for application to plants affected or liable to be affected by a... Agent: Indena S.p.a.

20120121743 - Schisandra sphenanthera fruit extract and cosmetic, dermatological and nutraceutical compositions comprising same: The present invention relates to a cosmetic, dermatological or nutraceutical composition comprising a Schisandra sphenanthera fruit extract. Said Schisandra sphenanthera fruit extract is selected from a peptide and sugar extract, a crude oil, a refined oil, a refined oil concentrate or the unsaponifiable fraction of said concentrate. The invention also... Agent:

20120121745 - Agents for the control of limnoperna sp.: Compositions and methods for controlling Limnoperna sp., particularly, golden mussels are provided using Pseudomonas sp. suspension or compounds and compositions derived from said suspension.... Agent: Marrone Bio Innovations, Inc.

20120121744 - Pharmaceutical composition for inhibiting infection and replication of influenza a and b virus, and the manufacture thereof: Disclosed is a pharmaceutical composition for inhibiting infection and replication of influenza A and B virus, and the manufacture thereof. The pharmaceutical composition is produced by a manufacture of low-temperature disintegrating cyanobacteria, comprising the steps of: (a) mixing cyanobacteria and non-organic solvent to form a suspension containing cyanobacteria; (b) freezing... Agent: Far East Bio-tec Co., Ltd.

20120114554 - Engineered aerosol particles, and associated methods: An engineered aerosol particle for use in aerosol applications is provided. The engineered aerosol particle comprises a fabricated nanoparticle body member being non-spherical. The fabricated nanoparticle body member is configured to provide at least one of auto-rotation, tumbling, or lift when entrained in an airstream to thereby increase settling time... Agent: The University Of North Carolina At Chapel Hill

20120114556 - Immunotherapy of autoimmune disorders using antibodies which target b-cells: Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.... Agent: Immunomedics, Inc.

20120114555 - Method for treating immune disorders: The present invention relates to the treatment of B-cell mediated immune disorders such as rheumatoid arthritis, systemic lupus erythromatomus, diabetes mellitus, and multiple sclerosis. In particular, the present invention relates to the treatment of B-cell mediated immune disorders using antibodies which bind to membrane-bound free light chain expressed on the... Agent: Immune System Therapeutics Ltd

20120114557 - Methods for collagen imaging: Diagnostic compositions and methods for imaging and/or assessing collagen are described. The diagnostic compositions can include collagen binding peptides.... Agent: Collagen Medical, LLC

20120114558 - Aptamer-mediated drug release: The present invention relates to aptamer/drug conjugate complexes and the use of such complexes, together with a trigger compound, to inducibly release a drug. Through these complexes, the present invention provides a means for establishing a drug reservoir in a subject, whereby drug may be released as needed. One specific... Agent: The Trustees Of Columbia University In The City Of New York

20120114560 - Abeta binding molecules: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with Aη, including Alzheimer's disease, Down's syndrome, cerebral amyloid... Agent: Applied Molecular Evolution, Inc.

20120114559 - Nanoimprint lithography formation of functional nanoparticles using dual release layers: Functional nanoparticles may be formed using at least one nanoimprint lithography step. In one embodiment, sacrificial material may be patterned on a multilayer substrate including one or more functional layers between removable layers using an imprint lithography process. At least one of the functional layers includes a functional material such... Agent: Molecular Imprints, Inc.

20120114562 - Method for treating pervasive development disorders: A method of utilizing the chymotrypsin level of an individual as a measure of the success of neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD... Agent: Curemark, LLC

20120114561 - Methods for the treatment of neurodegenerative disorders: Methods for treating neurodegenerative disorders, including Parkinson's disease, are provided. The methods comprise administrating a therapeutically effective amount of oxytocin or oxytocin analogs to alleviate one or more symptoms of Parkinson's disease. Methods for determining the effectiveness of oxytocin therapy by itself or in addition to one or more adjunctive... Agent:

20120114564 - Mri t1 contrasting agent comprising manganese oxide nanoparticle: The present invention relates to the use of and method for using MnO nanoparticles as MRI T1 contrasting agents which reduces T1 of tissue. More specifically, the present invention is directed to MRI T1 contrasting agent comprising MnO nanoparticle coated with a biocompatible material bound to a biologically active material... Agent: Seoul National University Industry Foundation

20120114565 - Compounds modulators of vegf activity and uses thereof: Compounds of general formula (1): X1Y1X2Y2X3Y3X4Y4Y5X5X6Y6X7Y7X8X9X10 wherein X1-X10 are any natural or unnatural amino acids and Y1 is Gln; Y2 is Met or Leu; Y3 is He; Y4 is Pro or Ser; Y5 is His or Gly; Y6 is Gln or Pro; Y7 is He or Tyr or their homolog... Agent: Advanced Accelerator Applications S.a.

20120114563 - Optical imaging agents: The present invention relates to a method of in vivo optical imaging, of the margins around tumours, which comprises an optical imaging contrast agent. The optical imaging agents comprise conjugates of near-infrared dyes with synthetic polyethylene glycol (PEG) polymers having a molecular weight in the range 15-45 kDa. Also disclosed... Agent: General Electric Company

20120114566 - Lipoxin analogs and methods for the treatment of periodontal disease: This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms... Agent: Brigham And Women's Hospital, Inc.

20120114567 - Oral compositions containing oxidized camellia: Oral composition comprising a Camellia extract of semi-oxidized tissue from a member of the genus Camellia and an enhancing agent.... Agent: Colgate-palmolive Company

20120114568 - Beeswax and jojoba wax emulsion: A composition of matter and a method are disclosed including mixing pieces of solid beeswax and liquid jojoba wax at a predetermined temperature within a predetermined range of temperatures, filtering the mixture, and cooling the mixture to form a colloidal gel.... Agent:

20120114571 - Cationic comb copolymers, preparation thereof and use thereof in cosmetic, pharmaceutical and dermatological formulations: Copolymers are described, containing a) 20.0-99.9% by weight of one or more structural units resulting from polymerizable substances of the following structural formula (I) in which R2 is a linear or branched saturated alkyl radical having 6 to 200 carbon atoms or a linear or branched, mono- or, polyunsaturated alkenyl... Agent: Clariant Finance (bvi) Limited

20120114570 - Collagen extraction from aquatic animals: The present invention relates to the use of fish skin as novel industrial source of collagen. Advantageously, said skin is obtained after the filleting or cutting of the fresh fish and frozen immediately after filleting/cutting, thus guaranteeing a very good quality of the base material, both from the bacteriological standpoint... Agent: Universiti Putra Malaysia

20120114569 - Cosmetic composition with watertight fragrance: The present invention refers to a cosmetic composition which, in particular, enables the perfume component resist wash off by water and sweat and to remain fixed on the skin for a long time watertightly. The cosmetic composition comprises fragrance and a fragrance-fixing complex consisting of 0.01-10% by weight of a... Agent:

20120114573 - Oil-in-water emulsion having improved sensory properties: An oil-in-water emulsion includes, for 100 wt % thereof: a) 0.1 to 10 wt % of an emulsifying system including, for 100 wt % thereof: (i) 5 to 95 wt % of the mixture of the reaction products of a reducing sugar and 1,12-octadecanediol essentially consisting of hydroxyl-octadecyl polyglycosides of... Agent:

20120114572 - Photostabilization of coenzyme q compounds with alkoxycrylene compounds:

20120114574 - Compositions for nail and skin treatment: Novel topical compositions for the treatment of nail and skin afflictions comprising at least one active agent, at least one volatile solvent, at least one film-forming ingredient and at least one phospholipid, processes for their preparation and methods of treatment of nail and skin afflictions. Following application of the compositions... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

20120114576 - Method for preventing or treating yellowish discoloration of skin: This invention relates to a method for preventing or treating skin discoloration of a subject by inhibiting carbonylation of dermal proteins of the subject who is in need of prevention or treatment for skin discoloration.... Agent: Shiseido Company, Ltd.

20120114575 - Methods for inhibiting cutaneous inflammation and hyperpigmentation: This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treating contact dermatitis so as to thereby prevent or treat contact dermatitis... Agent: The Trustees Of Columbia University In The City Of New York

20120114577 - Peptide having activity of transforming growth factor and production method therefor: The present invention relates to a transforming growth factor-beta (TGF-β)-mimicking peptide containing a particular amino acid sequence and a composition for preventing or treating TGF-β-effective disorders or conditions using the same. The peptide of the present invention may be much higher stability than natural-occurring TGF-β and improve drawbacks caused by... Agent: Caregen Co., Ltd.

20120114582 - Antiperspirant compositions: Antiperspirant compositions containing a pigment often exhibit a dull colour if an inorganic pigment is employed, but if many bright organic pigments are used, the pigment is subject to photodegradation and accordingly fades. By incorporating selected types of polycyclic organic pigment, namely an organic pigment containing condensed aromatic or heterocyclic... Agent:

20120114581 - Malodor counteracting compositions and method for their use: The present invention relates to the field of perfumery and more particularly to the field of malodor counteractancy. In particular, it relates to a method for application of malodor counteracting (MOC) compositions capable of neutralizing in an efficient manner, through chemical reactions, malodors of a large variety of origins and... Agent: Firmenich Sa

20120114579 - Microorganisms inhibiting the formation of foot malodor: Described are microorganisms which are able to inhibit the formation of foot malodor by skin microorganisms. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.... Agent: Basf Se

20120114578 - Paste composition for use in coating films, fibers, and fabrics and method of manufacture: A paste composition for use in coating film, fiber, or fabric includes a dry grease having a discontinuous aqueous phase having a non-ionic alkoxylate surfactant portion and a polyorganosiloxane oil phase. The past further includes a dry-grease suspended powder. The surfactant portion is effective to suspend the powder forming a... Agent: Wacker Chemical Corporation

20120114580 - Sprayable perfume with an improved tenacity: An alcoholic perfume solution with an improved tenacity when applied onto a surface is described. The solution contains an effective amount of a single polymer capable of extending the diffusion of perfuming ingredients in the air.... Agent: Firmenich Sa

20120114583 - Use of dihydroquercetin and at least one amino acid to positively influence the natural pigmentation process: The present invention is a hair treatment agent comprising a combination of dihydroquercetin and/or a dihydroquercetin derivative with at least one amino acid. A preferred hair treatment agent comprises a combination of dihydroquercetin (taxifolin) with a six-amino acid mixture consisting of taurine, proline, valine, arginine, lysine, and glycine. The inventive... Agent: Henkel Ag & Co. Kgaa

20120114586 - Hair conditioners comprising selected cationic silicones and a b series vitamin: The invention relates to hair preparations containing selected cationic silicones and at least one B series vitamin as well as to the use of said preparations for the treatment of keratin fibers, in particular human hair.... Agent: Henkel Ag & Co. Kgaa

20120114584 - Relaxer gel activator: The present invention provides a relaxer gel activator composition, which includes a carbomer and guanidine carbonate as an alkaline neutralizing agent therefor, and a method for producing the relaxer gel activator. In some embodiments, the relaxer gel activator composition includes at least one conditioning agent, which may be PEG-2 dimeadowfoamamidoethylmonium... Agent: Alberto-culver Company

20120114585 - Semi-permanent mascara compositions: A semi-permanent mascara composition for use on eyelashes and/or eyelids that includes from 17% to 30%, by weight, of a film former selected from the group consisting of tall oil glyceride, pentaerythrityl rosinate, glyceryl rosinate, and the hydrogenated versions and mixtures thereof. Further there is from 0.1% to 14%, by... Agent:

20120114587 - Deodorizing system and method for use thereof: A system for producing a deodorizing or odor neutralizing fog includes a tank with an input port and an exit port, and a fogging portion located within the tank. A deodorizing or odor neutralizing liquid is added to the tank upon which the fogging portion is configured to float. Compressed... Agent:

20120114588 - Ibat inhibitors for treatment of metabolic disorders and related conditions: s

20120114592 - Hemostatic foams: Hemostatic foams Abstract The invention is directed to hemostatic foams and to the preparation of such foams. In a first aspect, the present invention provides a biodegradable hemostatic foam comprising a polymer blend of a water-soluble polymer and a phase-separated polyurethane comprising an amorphous segment and a crystalline segment, wherein... Agent: Polyganics B.v.

20120114591 - Treatment of chronic ulcerous skin lesions: The invention provides a method of treating a wound (for example, a chronic ulcerous skin lesion) in a human or non-human mammal (particularly a human). The wound is contacted with a topical hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, on... Agent: First Water Limited

20120114590 - Il28 and il29 truncated cysteine mutants and antiviral methods of using same: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc.

20120114589 - Swellable biodegradable polymeric matrices and methods: The invention provides biodegradable polymeric hydrogel matrices having excellent durability and swellability. The matrices are formed from a combination of poly-α(1→4)glucopyranose macromer and a biocompatible biostable hydrophilic macromer. The matrices can be used in association with a medical device or alone. In some methods the polymeric matrix is placed or... Agent:

20120114593 - Method and composition for altering a b cell mediated pathology: The present invention provides compositions for altering a B cell mediated pathology in a patient. The compositions may comprise at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the VH or VL region of a immunoglobulin molecule from particular B cells from... Agent: Mmr Global, Inc.

20120114594 - Muscle repair promoter: The present invention relates to muscle repair promoters for topical application that contain a colony-stimulating factor (CSF) as an active ingredient. The muscle repair promoters of the present invention exhibit their effect at low doses, particularly when they are administered intramuscularly.... Agent: Keiichi Fukuda

20120114595 - Sugar chain-added ailim extracellular domain and method for producing same: Disclosed is a synthetic AILIM extracellular domain which has high ligand-binding ability and a quality sufficient for a pharmaceutical product. Also disclosed is a method for synthesizing the synthetic AILIM extracellular domain. Specifically disclosed is a sugar chaim-added AILIM extracellular domain wherein a sugar chain is bound at a position... Agent: Otsuka Chemical Co., Ltd.

20120114597 - Cd4+cd25- t cells and tr1-like regulatory t cells: The invention provides CD4+CD25− T cells and Tr1-like regulatory T cells (i.e., contact-independent Type 1-like regulatory T cells), processes for their production and their use for regulatory purposes.... Agent: Argos Therapeutics, Inc.

20120114598 - Il-1alpha immunization induces autoantibodies protective against atherosclerosis: Immunization of a mammal with IL-1α, which causes the mammal to generate IL-1α autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease,... Agent: Xbiotech, Inc.

20120114596 - Tslp promotes immune evasion and persistence of viruses: It relates to the treatment or prevention of a chronic viral infection with a Thymic Stromal Lymphopoietin (TSLP) antagonist thereby avoiding immune evasion and persistence of the virus. It also provides a method of prognosing the evolution of a cervical dysplasia by TSLP expression in a sample of said cervical... Agent: Institut National De La Sante Et De La Recherche Medical (inserm)

20120114601 - New isothiazoloquinolones and related compounds as anti-infective agents: Certain compounds of Formula I and Formula II disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents.... Agent: Achillion Pharmaceuticals, Inc.

20120114600 - Novel inhibitors of hepatitis c virus: wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing... Agent: Theravance, Inc.

20120114599 - Opioid and opioid-like compounds and uses thereof: The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage.... Agent: Jenken Biosciences, Inc.

20120114602 - Process for the synthesis of conjugates of glycosaminoglycanes (gag) with biologically active molecules, polymeric conjugates and relative uses thereof: e

20120114604 - Combinations for hcv treatment: The present invention relates to co-administering a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The combination acts by interfering with the life cycle of the hepatitis C virus and is therefore useful as an antiviral therapy. As such, the combination may be used for treating... Agent: Vertex Pharmaceuticals Incorporated

20120114603 - Ifn-alpha/beta-independent mechanism of antiviral protection through a novel ligand-receptor pair: ifn- ligands engage a novel receptor ifn-rn (crf2-12) and il-10r2 (crf2-4) for signaling andinduction of biological activities: A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their... Agent: University Of Medicine And Dentistry Of New Jersey

20120114605 - Methods and compositions relating to hematologic malignancies: Methods of treating a subject having, or at risk of having, a myeloproliferative disorder are provided according to embodiments of the present invention which include administering a therapeutically effective amount of an arachidonate 5-lipoxygenase (5-LO) inhibitor to the subject. Combinations of therapeutic agents are administered according to embodiments of the... Agent: The Jackson Laboratory

20120114606 - Novel pasteuria strain and uses thereof: The subject invention provides a novel and advantageous strain of Pasteuria bacteria with nematicidal activity against lance nematodes. The subject invention provides the novel bacterial culture referred to as ATCC SD-5832, and mutants or variants thereof. Also provided are nematicidal compositions comprising the Pasteuria strain or its mutants or variants,... Agent:

20120114607 - Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules: The present application discloses a lentiviral transfer system which includes: (i) a self-inactivating transfer vector comprising: multiple gene units, wherein each gene unit includes a heterologous nucleic acid sequence operably linked to a regulatory nucleic acid sequence; and (ii) a helper construct which lacks a 5′ LTR, wherein the 5′... Agent:

20120114620 - Engineered dendritic cells and uses for the treatment of cancer: This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.... Agent: Intrexon Corporation

20120114619 - Protein with promoting effects for axonal growth of neurons of central nervous system: This invention comprises a polypeptide, a recombinant vector, a recombinant organism as well as RNA- and DNA-sequences. Furthermore, the use of polypeptides and recombinant vectors is described. Additionally the invention comprises methods for medical treatment.... Agent: Universitat Ulm

20120114609 - Biological material suitable for the therapy of osteoarthrosis, ligament damage and for the treatment of joint disorders: The present invention regards a biological material comprising: a) a liquid carrier comprising a viscous solution containing at least one natural and/or semisynthetic polysaccharide, and having a Dynamic viscosity measured at 20° C. and at shear rate of D=350 s−1, comprised between 100 and 250 c Poise and/or a Kinematic... Agent: Fidia Farmaceutici S.p.a.

20120114608 - Compositions, methods and kits for enhancing immune response to a respiratory condition: Disclosed herein are compositions for treating a respiratory condition, preferably by enhancing immune response in a mammal, the compositions including a therapeutic amount of a probiotic strain of bacteria and a therapeutic amount of an additional component. Also included are methods of treating a respiratory condition, preferably by enhancing immune... Agent:

20120114621 - Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same: The disclosure relates to a solid glass matrix of polysaccharide, saccharides and polyols as delivery vehicles for preservation and post gastric administration of a probiotic. The delivery vehicle is capable of releasing the probiotic at their site of action. The present invention further includes methods of making and using the... Agent:

20120114622 - Lactobacillus rhamnosus and weight control: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to treat obesity. One embedment of the present invention relates to the use of Lactobacillus rhamnosus CGMCC 1.3724 and/or Lactobacillus rhamnosus NCC 4007 for the preparation of a composition... Agent: Nestec S.a.

20120114624 - Nematocidal sulfonamides: e

20120114610 - Novel endophytic fungi and methods of use: This invention provides a novel endophytic fungus, Muscodor, that produces a mixture of volatile antibiotics with activity on specific plant pathogens, bacteria, nematodes and insects. Also provided is a method for treating or protecting plants, soil and seeds from microbial infections comprising applying an effective amount of a volatile antibiotic... Agent:

20120114611 - Bacteriophage-containing therapeutic agents: The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a... Agent:

20120114612 - Oncolytic viruses and methods for treating neoplastic disorders: The disclosure provides mutant ribonucleotide reductase strains of poxviruses including for example vaccinia viruses. The disclosure also provides methods and for the use of these mutant ribonucleotide reductase strains of vaccinia viruses in oncolytic virotherapy.... Agent:

20120114613 - Definitive endoderm cell populations: The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy.... Agent: Mount Sinai School Of Medicine Of New York University

20120114615 - Hydrolytically degradable polysaccharide hydrogels: Provided are polysaccharide compositions capable of controllable hydrolytic degradation and suitable for controlled release of therapeutic agents. Also provided are methods for synthesizing such compositions and a variety of applications in which the compositions may be used.... Agent: The Trustees Of The University Of Pennsylvania

20120114618 - Mesenchymal stem cells producing inhibitory rna for disease modification: Compositions and methods for delivering a siRNA, dsRNA, or miRNA polynucleotide into a target cell comprising contacting the target cell with a mesenchymal stem cell, which mesenchymal stem cell comprises an exogenous DNA sequence expressing the siRNA or dsRNA polynucleotide, thereby delivering the siRNA, dsRNA, or miRNA polynucleotide to the... Agent: The Regents Of The University Of California

20120114614 - Methods and compositions for long term hematopoietic repopulation: Methods for isolating a CD133+/CD45neg/GlyAneg subpopulation of umbilical cord blood cells are disclosed. In some embodiments, the methods include providing an initial population of umbilical cord blood cells; contacting the initial population of cells with a first antibody that is specific for CD133, a second antibody that is specific for... Agent:

20120114616 - Olfactory stem cells and uses thereof: Some aspects of this invention are based, at least in part, on the discoveries (i) pluripotent stem cell populations can be obtained from olfactory mucosa, (ii) that various regions of the olfactory mucosa contain pluripotent stem cells, (iii) that cells from these olfactory mucosa derived stem cell populations can be... Agent: King Faisal Specialist Hospital & Research Centre

20120114617 - Peptide promoting cell adhesion and migration: Synthetic peptide including the sequence KKLRIKSKEK (SEQ ID 1) or a sequence of identical size, in which the K residue (in position 1) and the R residue (in position 4) are conserved, the sequence being able to bind to the syndecan-1 receptor.... Agent: Centre National De La Recherche Scientifique

20120114623 - Antigen-specific long-term memory t-cells: The present invention provides compositions, methods, and systems for generating antigen-specific long-term memory T-cells using mTOR pathway inhibitors. The present invention provides compositions, systems, and methods for administering antigen-specific long-term memory T-cells to a subject (e.g., to a subject with cancer in adoptive transfer type of procedures).... Agent: The Regents Of The University Of Michigan

20120114625 - Shelf-stable fermented dairy products and methods of making same: Shelf-stable fermented dairy products and methods of making the shelf-stable fermented dairy products are provided. The shelf-stable fermented dairy products can be shelf-stable with improved taste, viscosity and texture profiles. In a general embodiment, the present disclosure provides a shelf-stable fermented dairy product including a shelf-stable fermented dairy component, a... Agent:

20120114626 - Method for treating pervasive development disorders: A method of utilizing the chymotrypsin level of an individual as a measure of the success of neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD... Agent: Curemark, LLC

20120114627 - Diagnosis, prevention and treatment of disorders characterized by undesirable cell proliferation: The present invention relates to compositions and methods for the reduction of atherosclerotic plaques and the decrease in the level of total serum cholesterol, triglycerides, serum LDL cholesterol, and serum HDL cholesterol. The present invention also relates to methods for the diagnosis, prevention and treatment of atherosclerosis and mycoplasma associated... Agent:

20120114628 - Cosmetic and therapeutic use of proteins of dj-1 type for treating skin dryness: The present invention relates to the use, especially the cosmetic and/or therapeutic use, of the protein DJ-1, of polypeptides derived from this protein or of analogues thereof, of a nucleic acid sequence coding for such a polypeptide or of a modulator of the activity, stability or expression of such a... Agent: L'oreal

20120114629 - Iga1 protease polypeptide agents and uses thereof: Polypeptide agents useful in the treatment of IgA1 deposition diseases and methods of using such polypeptide agents. Methods of screening for inhibitors of IgA1 proteases and agents that inhibit IgA1 proteases are also disclosed.... Agent: Tufts Medical Center, Inc.

20120114630 - Variants of plasminogen and plasmin: The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatylic destruction of the protease activity of plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed.... Agent: Thrombogenics Nv

20120114631 - Stable enzymatic preparations and methods of use thereof: The present invention relates to stable concentrated enzymatic compositions suitable for storage under ambient conditions, while maintaining their intended enzymatic activity. The invention further relate to kits comprising concentrated enzymatic compositions, methods for preparing debriding solutions from said concentrated enzymatic compositions and methods of using the diluted debriding solutions.... Agent: Ramot At Tel-aviv University Ltd.

20120114632 - Stabilized active halogen solutions: Disclosed are compositions for stabilizing a source of active halogen in aqueous solution. The compositions comprise (i) at least one substituted N-hydrogen compound, such as 5,5-dimethylhydantoin, and (ii) at least one additional nitrogen compound selected from ammonia, ammonium salts, and nitrogen compounds containing no carbon-hydrogen bonds, the molar ratio of... Agent:

20120114633 - Inhibitors of bacterial type iii secretion system: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive... Agent:

20120114634 - Methods for inducing a sustained immune response against a b-cell idiotype using autologous anti-idiotypic vaccines: The present invention relates to methods of inducing and maintaining an immune response against a B-cell idiotype in a subject using an autologous anti-idiotypic vaccine. In one embodiment, the immune response is induced and maintained for treatment of a B-cell derived malignancy selected from among non-Hodgkin's lymphoma. Hodgkin's lymphoma, chronic... Agent: Biovest International, Inc.

20120114635 - Antibodies to cross-linked amyloid beta oligomers: The invention relates to antibodies that bind cross-linked amyloid β oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease.... Agent: The General Hospital Corporation D/b/a Massachusetts General Hospital

20120114643 - 4-pyridinone compounds and their use for cancer: e

20120114644 - Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent... Agent: Genentech, Inc.

20120114638 - Combination therapy: The present invention relates to a combination therapy of 2,2-dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N′-(2,2,3,3,3-pentafluoro-propyl)-malonamide, or a pharmaceutically-acceptable salt thereof, and bevacizumab for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example a brain tumor.... Agent:

20120114639 - Compositions and methods for inhibiting viral and/or bacterial infections: We describe herein compositions and methods related to inferring with microbial infection. Generally, the compositions include an infection antagonist that inhibits formation of a heparin sulfonated proteoglycan (HSPG)-containing infection complex. Generally, the methods include administering to a subject an amount of a composition as described herein effective to inhibit infection... Agent:

20120114636 - Low molecular weight cyclin e (lmw-e) as a biomarker for personalization of cancer therapies: Methods are disclosed for predicting a patient response to anti-Her2 therapy or anti-aromatase therapy. In certain embodiments, the methods involve the identification of low molecular weight cyclin E (LMW-E) in cancers, such as breast cancer cells, as a predictive and prognostic marker. In further embodiments, LMW-E expression by a cancerous... Agent: Research Development Foundation

20120114640 - Modulation of the tgf- ß and pi3k/akt pathways in the diagnosis and treatment of squamous cell carcinoma: Described herein is the finding that the PI3K/Akt and TGF-β pathways act cooperatively to promote squamous cell carcinoma (SCC), such as head and neck squamous cell carcinoma (HNSCC). In particular, it was found that conditional deletion of transforming growth factor-β receptor type I (TGFBR1) and phosphatase and tensin homolog (PTEN)... Agent:

20120114637 - Mtor pathway inhibitors for treating ocular disorders: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are ophthalmic formulations that deliver a variety of therapeutic agents, including but... Agent: Santen Pharmaceutical Co., Ltd.

20120114642 - Targeting vegf-b regulation of fatty acid transporters to modulate human diseases: The present invention provides materials and methods for modulating FATP expression and/or activity in vivo. The materials and methods have numerous diagnostic, prophylactic, and therapeutic applications for various diseases and conditions that are influenced by FATPs, or characterized by excessive or inadequate FATP expression or activity.... Agent: Ludwig Institute For Cancer Research

20120114641 - Therapeutic combination comprising a plk1 inhibitor and an antineoplastic agent: The present invention provides a combination comprising (a) a compound of formula (I) and (b) one or more antineoplastic agents selected from the group consisting of an antimetabolite agent, analkylating or alkylating-like agent, an intercalating agent, a topoisomerase I or II inhibitor, an antimitotic agent, a kinase inhibitor, a proteasome... Agent: Nerviano Medical Sciences S.r.l.

20120114647 - anti-serum album single variable domains: The invention relates to improved anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variable domains, compositions, nucleic acids, vectors and hosts.... Agent: Glaxo Group Limited

20120114646 - Lyophilized formulations for small modular immunopharmaceuticals: The present invention provides, among other things, stable formulations for small modular immunopharmaceutical (SMIP™) proteins. In some embodiments, the present invention provides a formulation containing a lyophilized mixture of a small modular immunopharmaceutical protein, wherein less than 7% of the lyophilized small modular immunopharmaceutical protein exists in aggregated form. Formulations... Agent: Wyeth LLC

20120114645 - Use of il-1 antagonists to treat pseudogout: Methods of treating, inhibiting, or ameliorating gout, including chronic active (refractory) gout, pseudogout, or drug-induced gout, in a human subject, are provided. The methods comprise administering to a subject in need thereof a therapeutic amount of an interleukin 1 (IL-1) antagonist, such as IL-1 trap rilonacept.... Agent: Regeneron Pharmaceuticals, Inc.

20120114648 - Compositions of pd-1 antagonists and methods of use: Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful... Agent: Amplimmune, Inc.

20120114649 - Compositions of pd-1 antagonists and methods of use: Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful... Agent: Amplimmune, Inc. Delaware

20120114651 - Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in... Agent:

20120114650 - Single chain antibodies against beta-amyloid peptide: Anti-AβP scFvs and single domain antibodies were generated, and when these antibodies were displayed on filamentous phage or as soluble protein molecules, stabilized by the maltose binding protein, they could prevent the fibrilization of Aβp 1-40 and disaggregate Aβp 1-40 fibrils generated in vitro. The anti-Aβp scFv antibodies also stained... Agent: Ramot At Tel-aviv University Ltd.

20120114652 - Anti-pai-1 antibodies and methods of use thereof: Provided are anti-PAI-1 antibodies or antibody fragments and methods of using them.... Agent: Abbott Laboratories

20120114653 - Antibody therapy for treatment of diseases associated with gluten intolerance: The present invention includes a pharmaceutical compositions and methods for treating diseases associated with gluten intolerance in a patient, comprising: administering to the patient an effective amount of an antibody having specific activity against gluten or gluten-derived peptides. Such diseases include, for example, celiac disease and dermatitis herpetiformis.... Agent: Avaxia Biologics, Inc.

20120114654 - Human antibodies to human tnf-like ligand 1a (tl1a): A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1A antibodies are useful in treating diseases or disorders associated with TL1A, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis... Agent: Regeneron Pharmaceuticals, Inc.

20120114655 - Xylan utilization regulon for efficient bioprocessing of hemicellulose and uses thereof: The subject invention provides at least one nucleic acid sequence encoding an aldouronate-utilization regulon isolated from Paenibacillus sp. strain JDR-2, a bacterium which efficiently utilizes xylan and metabolizes aldouronates (methylglucuronoxylosaccharides). The subject invention also provides a means for providing a coordinately regulated process in which xylan depolymerization and product assimilation... Agent: University Of Florida Research Foundation, Inc.

20120114656 - Human monoclonal antibodies protective against bubonic plague: In this application are described fully human monoclonal antibodies which specifically recognize F1 or V antigen of Y. pestis and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection,... Agent:

20120114657 - Human monoclonal antibody specific for lipopolysaccharides (lps) of serotype iats 01 of pseudomonas aeruginosa: The present invention relates to a human monoclonal antibody specific for the serotype IATS 01 of P. aeruginosa, and a hybridoma producing said monoclonal antibody. In addition, the present invention relates to pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding said antibody.... Agent: Kenta Biotech Ag

20120114658 - Treatment of cancer: Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.... Agent:

20120114659 - Antibodies for guanylyl cyclase receptors: Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.... Agent: Boehringer Ingelheim Pharmaceuticals Inc.

20120114660 - Antibodies against llg polypeptides of the triacylglycerol lipase family: Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also... Agent: Aventis Pharmaceuticals Inc.

20120114661 - Methods of identifying infectious disease and assays for identifying infectious disease: Methods of identifying infectious disease infection prior to presentation of symptoms, assays for identifying genomic markers of infectious disease, and methods for diagnosing the underlying etiology of infectious disease.... Agent:

20120114662 - Human monoclonal antibodies against bacillus anthracis protective antigen: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human... Agent: Medarex, Inc.

20120114663 - Methods to treat allergic conditions: Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3.... Agent: National Jewish Health

20120114664 - Antibodies against h5n1 strains of influenza a virus: Provided are human antibodies that can neutralize a H5N1 strain of influenza A virus. Also provided are antibodies that can neutralize a strain of influenza A virus in clade 2 of the H5 subtype, that can neutralize a H5N1 strain of influenza A virus and have a lambda light chain,... Agent: Institute For Research In Biomedicine

20120114669 - Compositions and method for the diagnosis, prevention and treatment of alzheimer's disease: Disclosed herein are methods of diagnosing, preventing and treating Alzheimer's disease based on the use of an inhibitor for the binding of amyloid-β (Aβ) to FcγRIIb, and a method of screening the inhibitor. The inhibitor is selected from the group consisting of an FcγRIIb protein or a variant thereof, an... Agent: Seoul National University Industry Foundation

20120114665 - Human antibodies to human rankl: Isolated human antibodies or antigen-binding fragments thereof, which specifically bind to human RANKL and block hRANKL binding to a RANK receptor, are provided. The antibodies are useful in preventing or treating disorders and/or diseases, which are associated with RANKL/RANK interactions, including bone disorders or cancer.... Agent: Regeneron Pharmaceuticals, Inc.

20120114668 - Method for modulating angiogenesis using fibromodulin: Described herein are compositions and uses thereof to inhibit or enhance the activity of fibromodulin (FMOD). Such compositions are useful in methods for treatment of age-related macular degeneration involving choroid neovascularization in a subject comprising administering a therapeutically effective amount of a fibromodulin activity inhibitor to the subject.... Agent: Children's Medical Center Corporation

20120114666 - Neurological autoimmune disorders: The invention relates to a method of diagnosing an autoimmune neurological disorder in a mammal comprising the step of detecting, in a bodily fluid sample from the mammal, autoantibodies to an epitope of at least one Kv1-complex protein; and related methods, assay kits, isolated or purified autoantibody or antibody fragments,... Agent: Isis Innovation Limited

20120114667 - Targeted binding agents directed to a5beta1 and uses thereof: The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.... Agent: Medimmune Limited

20120114672 - Antibodies specific to cadherin-17: The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to Cadherin-17 with high affinity. Nucleic acid molecules encoding Cadherin-17 antibodies, expression vectors, host cells and methods for expressing the Cadherin-17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the Cadherin-17 antibodies are also provided. Methods... Agent: Oxford Biotherapeutics Ltd.

20120114670 - Methods and compositions related to synergistic responses to oncogenic mutations: Disclosed are compositions and methods related to new targets for cancer treatment.... Agent: University Of Rochester

20120114671 - Therapeutic agents for the treatment of diseases associated with undesired cell proliferation: The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted... Agent: Fundacio Privada Institut D'investigati&#xd3 Oncol&#xd2 Gica Vall D'hebron (vhio)

20120114673 - Compositions and methods for the diagnosis and treatment of tumor: The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same.... Agent:

20120114680 - Dendritic cell compositions and methods: Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1° C.-34° C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. After the incubation period, the monocytes can then be induced... Agent: Argos Therapeutics, Inc.

20120114675 - Foxp3+ natural killer t-cells and the treatment of immune related diseases: In one aspect, the invention provides isolated populations of cells comprising Foxp3+ natural killer T-cells, methods of generating Foxp3+ natural killer T-cells and methods for suppressing the immune response in specific organs, including the liver and the lungs.... Agent:

20120114676 - Methods of treating cancer with phenformin: Methods of using phenformin to treat certain types of cancers are described.... Agent: The Trustees Of The University Of Pennsylvania

20120114677 - Modified nicotinic compounds and related methods: Provided herein are compounds and related composition and methods that may be used to raise an antibody response to nicotinic compounds, in some embodiments.... Agent: Selecta Biosciences, Inc.

20120114674 - Molecular antigen array: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The... Agent: Cytos Biotechnology Ag

20120114679 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells: The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors in humans, using compounds based on small peptides. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone... Agent: Nymox Pharmaceutical Corporation

20120114678 - Treatment for nephritis: This invention relates to methods for treatment of nephritis. This invention further provides a method of treating with nephritis comprising administering to the subject an amount of herbal pharmaceutical composition thereof effective to treat the subject. Move particularly, this invention provides an herbal pharmaceutical composition comprising Rhizoma Atractylodis macrocephalae, Eucommiae... Agent: Development Center For Biotechnology

20120114682 - Peptides for binding fibrinogen and fibrin: Compositions and methods for targeting substances to fibrinogen, fibrin monomers, or fibrin polymers are provided. These compositions and methods generally involve the use of fibrin knob peptides that bind fibrin(ogen), which can be used to detect fibrin(ogen) and modulate fibrin polymerization and fibrinolysis.... Agent:

20120114681 - Use of specific peptides in the preparation of a medicament for the treatment of monoclonal gammopathy of undetermined significance (mgus) or of smoldering multiple myeloma (smm): The present invention relates to the use of a peptide comprising or essentially consisting of a sequence motif as shown in SEQ ID NO: 1 for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). Moreover, the present... Agent: Ruprecht-karts-universitat Heidelberg

20120114683 - Nucleic acid encoding tgev and prrsv sequences for improved expression of prrsv sequences: e

20120114686 - Compositions and methods related to protein a (spa) variants: Disclosed are methods and compositions for treating or preventing a Staphylococcus bacterial infection using a non-toxigenic Protein A (SpA) variant.... Agent: University Of Chicago

20120114685 - Compositions comprising angiogenic factors and methods of use thereof: The present invention provides recombinant Listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a PEST-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.... Agent:

20120114684 - Compounds and methods for treatment and diagnosis of chlamydial infection: Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with... Agent: Corixa Corporation

20120114687 - Tuberculosis vaccines comprising antigens expressed during the latent infection phase: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more... Agent: Statens Serum Institut

20120114688 - Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising Leishmania antigens, in particular, SMT and NH antigens or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.... Agent: Infectious Disease Research Institute

20120114690 - External use composition for skin: The present disclosure provides an external use composition for skin comprising a tarajo holly leaf extract and a Japanese knotweed leaf extract, a brown algae extract and an egg shell membrane derived peptide (ESM-P) having a molecular mass of 3 kDa or higher. The composition according to the present invention... Agent:

20120114689 - Nicotinamide compositions for treatment of skin diseases and disorders: The present invention is directed to compositions of nicotinamide derivatives combined with wakame seaweed, wakame extracts, or glycosaminoglycans, and their use in treating skin diseases and disorders.... Agent: Cortria Corporation

20120114691 - Vaccine against african horse sickness virus: The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness... Agent:

20120114692 - Immunogenic compositions containing phospholipid: Immunogenic compositions containing phospholipid adjuvants, including microparticle and emulsion compositions. According to one aspect of the invention, an immunogenic microparticle composition is provided comprising: water; a polymer microparticle; an antigen adsorbed to the microparticle; and a phospholipid compound, e.g., a synthetic phospholipid compound comprising: (i) one or more phosphoryl groups... Agent: Novartis Ag

20120114693 - Nucleic acid mucosal immunization: Mucosal delivery of antigens using, for example, a replication-defective gene delivery vehicle, particularly replication-defective alphavirus vectors and particles, is described. Also described are compositions comprising a mucosal adjuvant and one or more antigens derived from HIV. Also provided is the use of these gene delivery vehicles in inducing mucosal, local,... Agent: Novartis Vaccines And Diagnostics, Inc.

20120114694 - Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.... Agent: The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services

20120114695 - Hsv-1 and hsv-2 vaccines and methods of use thereof: This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated... Agent:

20120114696 - Small-molecule botulinum toxin inhibitors: This disclosure relates to materials and methods for inhibiting Botulinum neurotoxin, and more particularly to materials and methods for inhibiting the zinc endopeptidase of Botulinum neurotoxin serotypes A, D and/or E (BoNTA, BoNTD and/or BoNTE).... Agent:

20120114697 - Treatment of holocrine gland dysfunction with clostridia neurotoxins: Methods of using clostridial toxins and other biological agents to control holocrine gland dysfunction in humans is provided. In preferred embodiments the methods provide beneficial effects in humans.... Agent:

20120114698 - Salmonella marker vaccine: The present invention relates to a Salmonella strain suitable as a marker vaccine having an inactivated gene.... Agent:

20120114699 - Allergoids derived from allergens: wherein R and R2 are independently selected from H, C1-C5 alkyl, phenyl, phenyl substituted in ortho, meta, or para with a hydroxy, C1-C4 alkoxy, halogen, amino, alkylamino, dialkylamino, mercapto, C1-C4 alkylmercapto group; X represents O, S, or NR3, where R3 is H, alkyl with 1-6 carbon atoms, phenyl, or CN;... Agent: Lofarma S.p.a.

20120114700 - Lat adapter molecule for enhanced t-cell signaling and method of use: LAT (Linker for Activation of T-cells) is a protein involved in signaling through the T-cell receptor (TCR). The invention provides a LAT protein including mutations at ubiquitylation sites that result in an increase in stability of LAT in stimulated and unstimulated cells, and enhanced signaling through the TCR. The invention... Agent: Government Of The United States Of America, As Rep By The Secretary, Department Of Health And

20120114701 - Bifidobacterium longum ncc2705 (cncm i-2618) and immune disorders: The present invention generally relates to the field of preventing and/or treating inflammatory and infectious disorders, in particular by boosting the endogenous antimicrobial defences. One embodiment of the present invention is the use of B. longum NCC2705 (deposit number CNCM I-2618) for use in the treatment or prevention of disorders... Agent: Nestec S.a.

20120114703 - Botulinum toxin administration to treat various conditions: Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.... Agent: Allergan, Inc.

20120114710 - Carbon nanotubes complexed with multiple bioactive agents and methods related thereto: The present invention includes fullerene carbon nanotube compositions complexed with multiple bioactive agents and methods related to such fullerene carbon nanotube compositions.... Agent:

20120114702 - Compositions and methods for treating asthma and other lung disorders: Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or symptoms thereof (e g, asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (CaPO) and CaPO-associated conditions (e g, bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, in-fluenza, SARS, tuberculosis, and whooping... Agent: Revalesio Corporation

20120114713 - Compositions of adult disc stem cells and methods for the treatment of degenerative disc disease: This invention provides an isolated disc stem cell population, compositions, and methods of obtaining and growing the same. Moreover, this invention provides an isolated discosphere, compositions, and methods of obtaining and growing the same. An artificial disc containing the cells of the present invention is provided together with methods of... Agent:

20120114704 - Compounds, compositions and methods of treating cancer and fibrotic diseases: The present invention provides antibodies or antigen-binding fragments thereof that specifically hind the ENDO180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the ENDO180 polypeptide... Agent:

20120114706 - Endorphin therapy compositions and methods of use thereof: Methods and compositions for treating cancer and other disorders by β-endorphin therapy are disclosed.... Agent:

20120114716 - Flowable carrier matrix: A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter... Agent: Warsaw Orthopedic, Inc.

20120114709 - Formulations for use in inhaler devices: A formulation for use in an inhaler device comprises carrier particles having a diameter of at least 50 μm and a mass median diameter of at least 175 μm; fine particles of an excipient material having a mass median aerodynamic diameter of not more than 20 μm; and active particles.... Agent: Vectura Limited

20120114708 - Integrin heterodimer and an alpha subunit thereof: A recombinant or isolated integrin heterodimer comprising a novel subunit α11 in association with a subunit β is described. The integrin or the subunit α11 can be used as marker or target of all types of cells. The integrin or subunit α11 thereof can be used as marker or target... Agent: Hansa Medical

20120114714 - Method for the treatment and prevention of erectile dysfunction: Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.... Agent:

20120114711 - Pharmaceutical composition having improved solubility: It is desired to provide a pharmaceutical composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof, or a solvate thereof, which exhibits an inhibitory effect on activated blood coagulation factor X (FXa), and is useful as an agent for preventing and/or treating thrombosis, wherein the... Agent: Daiichi Sankyo Company, Limited

20120114707 - Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein: This invention is an improved process to formulate polymeric microspheres/nanospheres and encapsulate therapeutic proteins or other useful substances, and a polymer sphere apparatus. The invention is also methods of purifying protein-containing-polymeric-microspheres from unused polymer, and an apparatus therefore.... Agent:

20120114717 - Tableting agent having a low water content, and method for the production thereof: The present invention relates to a Tabletting aid with a low water content and to a process for the preparation thereof. The Tabletting aid composition is a directly compressible composition, the use of which results in improved tablet properties.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120114712 - Umbilical cord biomaterial for medical use: The present invention provides a biomaterial comprising a mammalian umbilical cord membrane. The biomaterial can additionally comprise Wharton's jelly and/or one or more umbilical cord vessels. The biomaterial is preferably dry, and can be flat, tubular, or shaped to fit a particular body structure. The invention further provides laminates comprising... Agent: Anthrogenesis Corporation

20120114715 - Use of larch wood for treating inflammation: The application of wood material from a tree of the genus Larix for treatment and prophylaxis of inflammation in humans or animals is described. The present invention is based on the use of raw larch wood material as a medicament and an anti-inflammatory food/feed supplement for animals and humans, wherein... Agent: The University Of Veterinary Medicine Vienna

20120114705 - Water soluble film for oral administration with instant wettability: A composition containing therapeutic agents and/or breath freshening agents for use in the oral cavity is disclosed. The carrier comprises water-soluble polymers in combination with certain ingredients and provides a therapeutic and/or cosmetic effect. The film is coated and dried utilizing existing coating technology and exhibits instant wettability followed by... Agent:

20120114721 - Method for producing a vesicle composition: The present invention is a method for producing a vesicle composition having an aqueous phase as a continuous phase, the method including a step of dissolving an oil phase containing component (A) a branched fatty acid having a predetermined structure; component (B) a tertiary amine having a predetermined structure; and... Agent:

20120114720 - Solid, fragrance-transmitting composition having good cold-water solubility: The invention relates to a solid fragrance-transmitting composition, comprising a particulate, water-soluble carrier, a perfume, and at least partial shell made of a saccharide. The solid fragrance-transmitting composition is very soluble in cold water and is thus suitable for use in the rinse cycle of a washing machine.... Agent: Henkel Ag & Co. Kgaa

20120114718 - Solid-state method for producing functionalized calcium phosphate hybrid organic/inorganic chemical systems for dental remineralization applications: A method of repairing weakened teeth, including combining a first predetermined amount of an inorganic calcium source with a second predetermined amount of an organic material to define a mixture, placing the mixture in a milling vessel operationally connected to a planetary mill, introducing milling media into the milling vessel,... Agent:

20120114719 - Topical macqui berry formulation: The present invention provides a topical formulation and method of use where the formulation comprises macqui berry or a macqui berry extract containing anthocyanins having a very high oxygen radical absorbance capacity (ORAC). The formulation provides the macqui berry in a stabilized form which includes a glucuronide or glycuronide, a... Agent: Tracie Martyn International, LLC

20120114722 - Antimicrobial substrate: A method of preparing antimicrobial-containing polymeric products is provided, the method involving electrospinning a dispersion comprising a dispersible polymer, a fiberizing polymer, and one or more antimicrobial agents. The electrospun material is heated to remove solvent and the fiberizing polymer, giving a nonwoven polymeric material having antimicrobial agent incorporated therein.... Agent:

20120114723 - One step fire ant control: The present invention relates to a method for controlling fire ants with a single step application of a combination of a bait and a controlled release treatment composition, and to the novel bait/controlled release treatment composition combination used in the method of the present invention.... Agent:

20120114724 - Antimicrobial agent, method of preparing an antimicrobial agent and articles comprising the same: The present disclosure is directed to method of preparing an antimicrobial agent comprising heating a dialdehyde polysaccharide. The method comprises subjecting a dialdehyde polysaccharide, such as a dialdehyde starch or a dialdehyde cellulose, to heating and/or sonication for a period of time. Also provided herein is an antimicrobial composition comprising... Agent: University Of Florida Research Foundation, Inc.

20120114725 - Information medium having antiviral properties, and method for making same: The present invention relates to an information medium to be handled by a large number of users, such as a banknote, and having antiviral properties, and to a method for making same.... Agent: Arjowiggins Security

20120114727 - Insecticidal sheet-like structure for protecting humans and domestic animals: e

20120114726 - Insecticide-coated substrate for protecting humans and pets: A substrate treated with a composition comprising a pyrethroid, chlorfenapyr and a special acrylate binder is suitable for controlling harmful insects in buildings, for protecting humans and domestic animals from such harmful insects and for protecting humans and domestic animals from vector-transmitted diseases which are transmitted by the harmful insects.... Agent: Basf Se

20120114728 - Biodelivery systems: According to one embodiment of the invention, antimicrobial compound containing liposomes are added to water systems prone to biofouling and biofilm formation. The liposomes, being similar in composition to microbial membranes or cells, are readily incorporated into the existing biofilm. Once the antimicrobial compound containing liposomes become entrained with the... Agent:

20120114730 - Compositions and methods for treating precocious puberty: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and... Agent: Endo Pharmaceuticals Solutions Inc.

20120114732 - Elastin stabilization of connective tissue: A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm... Agent: Clemson University Research Foundation (curf)

20120114731 - Multilayer protein films, methods of making, and drug delivery devices and biomedical implants employing the films: A multilayer protein film has a mass of greater than 0.5 μg/cm2 and consists essentially of protein. A drug delivery device comprises the multilayer protein film onto which a pharmaceutically active agent can be loaded. A biomedical implant comprises an implant substrate and the multilayer protein film on at least... Agent: Addbio Ab

20120114729 - Silicone-peroxide compositions for long-term, controlled oxygen release: A composite for delivering extended-release of oxygen is disclosed. The composite can include a biocompatible polymeric support having a plurality of solid peroxide particles suspended therein. The polymer support can exhibit an oxygen tension value of at least 40 mmHg for a period of 14 days. The weight ratio of... Agent: University Of Miami

20120114733 - Implant material and production method thereof: The present invention provides an implant material comprising an organic-inorganic complex porous article and a production method thereof. The organic-inorganic complex porous article is a biodegradable and bioabsorbable bioactive porous article in which a bioactive bioceramics powder is uniformly dispersed in a biodegradable and bioabsorbable polymer, wherein it has continuous... Agent: Takiron Co., Ltd.

20120114734 - Nanostructure surface coated medical implants and methods of using the same: Compositions including a surface or film comprising nanofibers, nanotubes or microwells comprising a bioactive agent for elution to the surrounding tissue upon placement of the composition in a subject are disclosed The compositions are useful in medical implants and methods of treating a patient in need of an implant, including... Agent:

20120114735 - Compositions and methods for the treatment of throat discomfort: The physiological cooling agent N-ethyl-2,2-diisopropylbutanamide exhibits a surprising selectivity for throat cooling over mouth cooling, especially when consumed in the form of a confection. Methods of treating throat discomfort using N-ethyl-2,2-diisopropylbutanamide are described. Also described are various confections that incorporate N-ethyl-2,2-diisopropylbutanamide, including hard candy confections, soft candy confections, and center-filled... Agent:

20120114736 - Zeolite composite materials for waste odor control: A composite material for environmental odor control is useful in controlling odors from waste, for example, as an alternative daily cover for landfills and in composting applications. The composite material includes a fiber web and a zeolite containing metals to promote absorption of odorous gas.... Agent: University Of Maine System Board Of Trustees

20120114737 - Silicone acrylate hybrid composition and method of making same: A silicone acrylate hybrid composition includes the reaction product of a silicon-containing pressure sensitive adhesive composition, an ethylenically unsaturated monomer, and an initiator. The silicon-containing pressure sensitive adhesive composition includes acrylate or methacrylate functionality. A method of making the hybrid composition includes polymerizing the ethylenically unsaturated monomer and the silicon-containing... Agent:

20120114738 - Transdermal patch: The present invention provides a transdermal patch having excellent preservation stability and transdermal absorbency of DMAE or its pharmacologically acceptable salt. The patch has a support and a plaster layer integrally laminated on one surface of the support, and the plaster layer includes: 2-amino-1-(2′,5′-dimethoxyphenyl)ethanol or its pharmacologically acceptable salt; 40... Agent:

20120114744 - Compositions and methods to treat muscular & cardiovascular disorders: The present invention relates to a novel microRNA, mir-208-2, implicated in muscular and cardiovascular disorders. The present invention also relates to oligonucleotide therapeutic agents (antisense oligonucleotides and/or double stranded oligonucleotides such as dsRNA) and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2.... Agent: Novartis Ag

20120114746 - Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes: The present invention relates to a composition for enhancing an immune response, an epitope having immunogenicity, screening and preparing method thereof, a antibody to peptide antigen and screening and preparing method thereof. The composition of the present invention may be effectively used for preventing or treating diverse immune-deficiency diseases such... Agent: Industry Academic Cooperation Foundation, Hallym University

20120114745 - Method for treating or ameliorating mucocutaneous or ocular toxicities: A method for treating or ameliorating mucocutaneous, ocular toxicities, or side effects induced by blocking cellular growth and survival signal transduction pathways. The method comprises administering to a subject in need thereof an effective amount of a histone deacetylase inhibitor and a pharmaceutically acceptable carrier, salt or solvate thereof, wherein... Agent:

20120114742 - Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also... Agent: Mountain View Pharmaceuticals, Inc.

20120114739 - Pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors: The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.... Agent:

20120114740 - Sustained release formulation of a non-steroidal anti-inflammatory drug: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments... Agent: Pacira Pharmaceuticals, Inc

20120114741 - Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions: The invention is directed to topical formulations and methods of treating a migraines and/or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations... Agent: Afgin Pharma LLC

20120114743 - Transdermal ricinoleic acid compositions: Transdermal compositions containing castor oil are described. The compositions comprise ricinoleic acid and a transdermal vehicle with optional additional agents. One optional additional agent is an adrenergic drug which may cause the ricinoleic acid to penetrate the skin more deeply and have a longer lasting effect. The compositions can be... Agent:

20120114749 - Compositions and methods for delivery of embolics: Described herein are compositions comprising one or more embolics attached to an inert, dissolvable matrix as well as kits comprising these novel embolic formulations. Also described are methods of making and using these embolic formulations.... Agent: Boston Scientific Scimed, Inc.

20120114747 - Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same: The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is... Agent: Globoasia, LLC

20120114748 - Tanaproget compositions containing ethinyl estradiol: Compositions containing micronized tanaproget, or a pharmaceutically acceptable salt thereof, and ethinyl estradiol and methods of preparing the same are provided. Also provided are kits containing the compositions, methods of contraception and hormone replacement therapy including administering a composition containing micronized tanaproget and ethinyl estradiol.... Agent: Wyeth LLC

20120114750 - Pharmaceutical composition 271: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.... Agent: Astrazeneca Ab

20120114751 - Pharmaceutical composition for treating hcv infections: The present invention relates to a granular pharmaceutical composition comprising an HCV protease inhibitor and at least one poloxamer.... Agent:

20120114752 - Stable tablet containing 4,5-epoxymorphinan derivative: The present invention relates to a stable tablet comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the tablet according to the present invention comprises: (1) as the effective ingredient, a specific 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt;... Agent: Toray Industries, Inc.

20120114753 - Multi-layer tablet comprising effervescent layer: The present invention provides a multi-layer tablet comprising: an effervescent layer comprising hydrochlorothiazide or amlodipine or its salt as an active ingredient, a carbonate salt, and an organic acid; and a telmisartan-containing layer.... Agent: Dasan Medichem Co., Ltd.

20120114754 - Rapidly disintegrating solid oral dosage form: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The... Agent: Elan Pharma International Ltd.

20120114755 - Methods and materials for tissue repair: This document relates to methods and materials for treating tendon injury. Specifically, methods and materials for preventing adhesion formation and promoting tissue healing following tendon injury and surgical repair are provided.... Agent: Mayo Foundation For Medical Education And Research

20120114756 - Sustained-release drug carrier composition: The present invention provides compositions for extended release of one or more active ingredients, comprising a lipid-saturated matrix formed from a non-biodegradable polymer or a block-co-polymers comprising a non-biodegradable polymer and a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the... Agent: Polypid Ltd.

20120114757 - Particles comprising drospirenone encapsulated in a polymer: The present invention relates to particles comprising Drospirenone encapsulated in a polymer selected from the group consisting of glycolic acid polymer, lactic acid polymer, poly caprolactones, poly anhydrides and any copolymer of these, e.g., poly(lactic acid-co-glycolic acid) polymer and any combination of these. Furthermore, the present invention also relates to... Agent: Bayer Pharma Aktiengesellschaft

20120114758 - Beverage for pregnancy & lactation: The invention generally relates to nutrient enhanced beverages which include certain levels of the most current Daily Recommended Intakes of macronutrients and Micronutrients, and the rationale for increased allowances during pregnancy. The beverages of the invention generally comprise one or more macronutrients, vitamins and minerals recommended for consumption by pregnant... Agent:

20120114759 - Peptide/particle delivery systems: Polymeric nanoparticles, microparticles, and gels for delivering cargo, e.g., a therapeutic agent, such as a peptide, to a target, e.g., a cell, and their use for treating diseases, including angiogenesis-dependent diseases, such as age-related macular degeneration and cancer, are disclosed. Methods for formulating, stabilizing, and administering single peptides or combinations... Agent: The Johns Hopkins University

20120114760 - Compositions for treating wounds and processes for their preparation: Embodiments of the invention are directed to methods of treating a wound by administering a wound-healing composition and the wound-healing composition. The wound-healing composition has a purified platelet-removed platelet-rich plasma and a wound-healing component. The wound-healing component is a protein, a peptide, or combinations thereof. The methods of treatment utilize... Agent:

20120114761 - Skincare stimulant having a platelet dry powder: A skincare stimulant having an effective dose of platelets and pharmaceutically acceptable solvents and/or excipients, wherein the effective dose refers to the presence of at least 1000 platelets in every milligram of skincare stimulant.... Agent: Central Medical Technologies Inc.

20120114762 - Physico-chemical-managed killing of penicillin-resistant static and growing gram-positive and gram-negative vegetative bacteria: Systems and methods for the use of compounds from the Hofmeister series coupled with specific pH and temperature to provide rapid physico-chemical-managed killing of penicillin-resistant static and growing Gram-positive and Gram-negative vegetative bacteria. The systems and methods represent the more general physico-chemical enhancement of susceptibility for a wide range of... Agent:

20120114763 - Method for producing collagen/apatite composite membrane for guided bone regeneration: Disclosed is a method for producing a collagen/apatite composite membrane useful as a barrier to protect fibrous connective tissues from infiltrating into a site of defective tissue or bone in guided tissue regeneration (GTR) or guided bone regeneration (GBR) procedures. Such composite membrane can be obtained by the steps of... Agent: Seoul National University Industry Foundation

20120114764 - Multifunctional produce wash: A produce wash is provided that significantly reduces the amount of chlorine used in treating produce and inhibits the growth of micro-organisms on pre-harvest and post-harvest produce. A method of using the produce wash extends the shelf life of harvested produce.... Agent: Contact Marketing Solutions, LLC

20120114765 - Anti-neoplastic compounds, compositions and methods: Disclosed are novel compounds which are useful as therapeutics, especially in anti-neoplastic therapy and in other therapeutic regimes where cysteine protease inhibition is implicated.... Agent:

20120114766 - Substituted chroman derivatives, medicaments and use in therapy: Novel substituted chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.... Agent: Marshall Edwards, Inc.

20120114767 - System and method for diagnosis and treatment of neuropsychiatric disorders: An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCH1 gene, alone... Agent: The Research Foundation For Mental Hygiene

20120114768 - Angiogenesis regulating composition and method for regulating angiogenesis: An angiogenesis regulating composition used to treat/prevent an angiogenic disease in a subject, that contains in an effective amount at least one of nitrate, nitrite, and a compound convertible into nitrate or nitrite after the compound is absorbed into the subject, and an angiogenesis regulation method administering to a subject... Agent: Air Water Inc.

20120114769 - Insect and disease control: The invention provides a method for controlling pests or pathogenic organisms in an agricultural structure, the method comprising applying a pesticidal composition to surfaces susceptible to infestation or colonization by the pest or pathogenic organism, wherein the composition includes terpenoids, essential oils, plant extracts, or combinations thereof.... Agent:

20120114770 - High amylose wheat: Provided is a Wheat grain (Triticum aestivum) comprising an embryo, starch and one, two or three SBEIIa proteins, said embryo comprising two identical alleles of an SBEIIa-A gene, two identical alleles of an SBEIIa-B gene and two identical alleles of an SBEIIa-D gene, wherein the starch has an amylose content... Agent:

20120114771 - Oxidized protein hydrolase activity enhancer: The present invention provides an enhancer for enhancing the activity of oxidized protein hydrolase. The oxidized protein hydrolase activity enhancer according to the present invention contains an extract of at least one plant selected from the group consisting of Compositae Anthemis, Saururaceae Houttuynia, Rosaceae Crataegus, and Vitaceae Vitis.... Agent: Arkray Inc.

20120114773 - Estrogenic extracts of ligustrum lucidum ait. of the oleaceae family and uses thereof: Extracts of various species of the Moraceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Ligustrum lucidum Ait. of the Oleaceae Family possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF)... Agent: Bionovo, Inc.

20120114772 - Process for obtaining insoluble substances from genipap-extract precipitates, substances from genipap-extract precipitates and their uses: The present invention relates to the precipitation of genipap extract (Genipa americana) for obtaining a substance insoluble in polar and/or non-polar media for applications in cosmetic, pharmaceutical, textile, paint and varnish an food compositions. According to an embodiment of the invention, a process is claimed for the obtainment of substances... Agent: Natura Cosmeticos S.a.

20120114774 - Methods and compositions for treating and preventing laminitis, founder and overeating in an ungulate: The present invention relates to the production and use of feed compositions useful in the treatment and prevention of laminitis, founder and overeating, particularly in horses and ponies. The feed composition may reduce the effects of carbohydrate overload whilst providing a controlled release of metabolizable energy to avoid excessive fermentation... Agent: Kystockfeeds Pty Ltd

20120114775 - Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances: The invention relates to methods for treatment and prevention of a metabolic imbalance, including diabetes mellitus and other related diseases or disorders, using an extract from a fruit of genus Elaeis.... Agent: Brandeis University

20120114776 - Methods for preparing probiotic nanoparticles: Various embodiments of the present invention are directed toward a method for preparing probiotic nanoparticles from natural sources, comprising performing a biological preparation phase such as isolating any cells derived from either prokaryote or eukaryote cells, performing a chemical preparation phase such as performing an enzymatic procedure (or heating, or... Agent:

20120107231 - Metalloproteinase binding proteins: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.... Agent: Dyax Corp.

20120107229 - Novel nano-probes for molecular imaging and targeted therapy of diseases: The present inventions relate to compositions and methods for imaging and treating atherosclerotic diseases, pathogen infections, and tumors by administering actively targeting magnetic nanoparticles. In particular, the present inventions provide new types of targeting ligands attached to magnetic nanoparticles for magnetic resonance imaging. The use of these targeted magnetic nanoparticles... Agent:

20120107230 - Treatment of hyperproliferative diseases with vinca alkaloid n-oxide analogs: The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.... Agent: State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The

20120107232 - Kit for preparing a radiolabeled liposome and a method using the same: A kit for preparing a radiolabeled liposome is provided, the kit including a liposome suspension and a radionuclide, wherein the liposome suspension includes a conjugate with a structure of [chelator-hydrophilic polymer-lipid]. A method for preparing a radiolabeled liposome using the kit is also disclosed herein, thereby the radiolabeled liposome being... Agent: Institute Of Nuclear Energy Research Atomic Energy Council, Executive Yuan

20120107235 - Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof: The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.... Agent: Immunomedics, Inc.

20120107233 - Cytotoxicity mediation of cells evidencing surface expression of cd44: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The... Agent: Hoffmann-la Roche Inc.

20120107234 - Pan-her antibody composition: The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the... Agent:

20120107236 - Liver- receptor imaging injection, dispensing method and pharmaceutical composition thereof: The present invention is related to a pharmaceutical composition for a liver-receptor imaging injection, the pharmaceutical composition including a bi-functional compound which has a ASGPR specificity, wherein the bi-functional compound includes a backbone of alpha-amino acid (or the derivatives thereof) and a poly-galactosamine chain (or a poly-lactose chain) connected to... Agent: Institute Of Nuclear Energy Research Atomic Energy Council, Executive Yuan

20120107237 - Arg-gly-asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same: The present invention is directed to novel non-invasive diagnostic and therapeutic tools/compounds comprising a hybride cyclic peptide which utilizes a cyclic peptide chelating group wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear... Agent: Stc.unm

20120107238 - Compound containing a carbon or an oxygen isotope, preparation and use thereof, and composition comprising thereof: The present disclosure relates to a compound comprising at least one of a carbon or an oxygen isotope and a process for preparing the compound. The process comprises irradiating a compound comprising at least one of a carbon or an oxygen atom using photons or particles having an energy in... Agent: Beijing Top Grade Medical Equipment Co., Ltd.

20120107239 - Precursor of molecular probe for pancreatic islet imaging and use of the same: wherein -V-X represents a substituent on a benzene ring, V represents a bond, R1, of OR1, R1 represents a C1-C6 alkylene group, R2 represents H (hydrogen atom), a C1-C6 alkyl group, a C7-C10 aralkyl group, or a protecting group, X represents a OMs group, a OTs group, a OTf group,... Agent:

20120107240 - Probes and methods of melanoma imaging: Embodiments of the present disclosure provide for labeled probes such as a 3-18F-fluoropicolinamide probe, methods of making labeled probes, pharmaceutical compositions including labeled probes, methods of using labeled probes, methods of diagnosing, localizing, monitoring, and/or assessing melanin related diseases, cancers, tumors, precancerous cells, and related biological events (e.g., malignant melanoma),... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20120107242 - Nucleic acid-mediated shape control of nanoparticles for biomedical applications: Embodiments of a method for nucleic acid-mediated control of a nanoparticle shape are disclosed. In some embodiments, one or more nucleic acid oligomers are adsorbed to a metal nanoseed, and additional metal is deposited onto the nanoseed to produce a shaped nanoparticle. In certain embodiments, the nanoseed is gold and... Agent: The Board Of Trustees Of The University Of Illinois

20120107241 - Particles for inhalation having sustained release properties: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of... Agent: Massachusetts Institute Of Technology

20120107243 - Peptide-mediated non-covalent delivery of active agents across the blood-brain barrier: The peptides described herein can function as carrier peptides. These peptides can associate with (e.g., non-covalently bind) biologically active molecules or imaging agents to transport the biologically active molecules or imaging across the blood-brain barrier. In some cases, such transport may increase the effectiveness of the biological molecules or imaging... Agent: Mayo Foundation For Medical Education And Research

20120107246 - Methotrexate-modified nanoparticles and related methods: Methotrexate-modified nanoparticles that target tumors, compositions that include the nanoparticles, methods of imaging tissues using the nanoparticles, and methods for treating tissues using the nanoparticles.... Agent: Washington, University Of

20120107248 - Imaging gastrointestinal volumes and motility: This disclosure relates to contrast agents and compositions comprising the same that are capable of blocking the hydrogen/potassium adenosine triphosphatase enzyme system, and more particularly to the use of such compositions for imaging stomach and colon volume and motility.... Agent: Mayo Foundation For Medical Education And Research

20120107249 - Diagnostic imaging contrast agents with extended blood retention: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical... Agent: Lantheus Medical Imaging, Inc.

20120107244 - Monomeric variants of the tetrameric eqfp611: Monomeric eqFP611 variants exhibit red fluorescent properties and DNA encoding monomeric eqFP611 variants.... Agent: Universit&#xe4 T Ulm

20120107245 - Dental composition for detection of carious tissue, detection method: A dental composition and method for detecting carious tissue on the surface of a tooth, and the use of the dental composition to manufacture a remedy for detection of carious tissue. The dental composition can comprise an aqueous solution of 1) at least one acidic compound, 2) at least one... Agent: 3m Espe Ag

20120107247 - Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines: The present invention is directed to reagents useful for generating immune responses to Mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to M. tuberculosis.... Agent: University Of Medicine And Dentistry Of New Jersey

20120107250 - Abuse-proofed dosage form: An abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.... Agent: Gruenenthal Gmbh

20120107251 - Oregano oral care compositions and methods of use thereof: A multi-benefit oral composition is provided. The oral composition is efficacious as an antibacterial, antiplaque, anti-inflammatory, anti-oxidant, and anti-halitosis oral composition. The active ingredient has one or more active compounds from an extract of oregano. The oral composition can be in the form of a mouth rinse; a dentifrice, including... Agent: Colgate-palmolive Company

20120107254 - Long wear topical composition: This disclosure relates to a long wear topical composition for keratinous surface. The composition includes at least one coupling agent having at least two reactive functional groups and at least one performance ingredient.... Agent:

20120107252 - Method for forming cyclodextrin polymer and lipophilic compound emulsions, resulting emulsions, and compositions including said emulsions: The present invention relates to a method for preparing a cyclodextrin polymer and/or a hydrophilic polymer emulsion having cyclodextrins as well as lipophilic compounds, the emulsions having a remarkable stability. In particular, the method includes: (i) adding a lipophilic compound into an aqueous solution of a cyclodextrin unit polymer or... Agent: Centre National De La Recherche Scientifique- Cnrs

20120107256 - Personal care emulsions comprising waxy materials and organopolysiloxanes: The invention provides an aqueous emulsion for use in a personal care, health care or household care composition. This emulsion comprises at least 1% by weight of a waxy material having a melting point of at least 10.5° C. and at least 1% by weight of an organopolysiloxane which is... Agent:

20120107255 - Photostabilization of cholecalciferol with alkoxycrylene compounds: e

20120107253 - Sunscreen formulations using natural oceanic clay (aka marine glacial clay): Sunscreen formulations use the Natural Oceanic Clay when combined with sunscreen actives such as zinc oxide, can provide significant enhancement in absorbance of UVA, UVB, and UVC, with increased SPF and PFA readings.... Agent:

20120107257 - Pigmentary aqueous dispersion and cosmetic uses thereof: The invention relates to an aqueous dispersion comprising at least one pigment and polyvinylpyrrolidone with a weight average molecular weight of less than 40,000 g/mol, its preparation method and its cosmetic uses.... Agent: Sensient Cosmetic Technologies

20120107260 - Deodorant compositions: This invention relates to deodorant compositions containing polytrimethylene ether glycol homo- and copolymers and/or polytrimethylene glycol ester(s) in a variety of physical forms. In at least one embodiment, the polytrimethylene ether glycol homo- and copolymers and/or polytrimethylene glycol ester(s) can be made from monomers (e.g., 1,3-propanediol) obtained from renewable resources,... Agent: E. I. Du Pont De Nemours And Company

20120107259 - Method to improve skin and hair fragrance retention from personal care compositions: A personal care composition and a method of using personal care compositions which results in increased fragrance retention when such compositions are applied to a keratin surface including hair and skin. The personal care compositions contain a quaternary ammonium compound, one or more fragrances, and a personal care acceptable carrier.... Agent: Elementis Specialties, Inc.

20120107258 - Omega-cyclohexylalkan-1-oles and use thereof as antimicrobial actives to combat body odor: p

20120107261 - Cosmetic compositions having suspensions of silver salts: An anhydrous cosmetic or dermatological preparation includes an aqueous suspension of at least one silver halide having a water content of up to 90 wt. %, relative to the total mass of the suspension, applied to a carrier, in combination with one or more passivating agents selected from the group... Agent:

20120107262 - Composition and method for levelling hair colour: The present invention relates to a composition and a method of levelling hair colour, especially lighter coloured hair or including lightened streaks or bleached streaks or bleached as a whole and after certain period of time contrast—difference in colour—between the re-growth and formerly lightened parts is clearly visible. The first... Agent: Kpass Kao Professional Salon Services Gmbh

20120107263 - Long-wear, waterproof and washable mascara composition: The present invention is directed to long wear, washable and waterproof eye makeup composition containing: (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) water; (d) at least one non-volatile oil capable of solublizing the oil-soluble polar modified polymer; (d) at least one volatile solvent;... Agent: L'oreal S.a.

20120107264 - Nucleic acid delivery compounds: Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell.... Agent: Nitto Denko Corporation

20120107266 - Compositions and methods for attracting noctuid moths: The invention provides compositions for attracting noctuid moths, which include at least one pheromone and at least one synergist. The synergist is a naturally-occurring phytochemical compound. The synergist is preferably β-caryophyllene, iso-caryophyllene, α-humulene, or combinations thereof. The invention also provides traps containing the composition for attracting noctuid moths, and methods... Agent:

20120107265 - Method for producing monoterpene and monoterpinoid compounds and use thereof: In various embodiments, the present disclosure provides a method and enzyme for forming various compounds, such as monoterpenes and monoterpenoid compounds. In a specific example, the present disclosure provides a method for producing one or more of (−)-ipsdienol, (−)-ipsenol, ipsenone, and ipsdienone. The present disclosure also provides methods of using... Agent:

20120107270 - Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer: This invention relates to the treatment of cancer using anti-ErbB antibodies, such as cetuximab or trastuzumab, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C.... Agent:

20120107267 - Interleukin-21 variants having antagonistic binding to the il-21 receptor: The invention relates to isolated IL-21 variant peptides having antagonistic binding to the common gamma chain (yC) of the IL-21 receptor, to pharmaceutical compositions comprising said peptides and to the use of said peptides in therapy.... Agent: Novo Nordisk A/s

20120107268 - Lymph node-targeting nanoparticles: Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1α, IL-10, IL-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin... Agent:

20120107269 - Thiophene derivatives: o

20120107274 - 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment:

20120107276 - Anti-arenaviral compounds: Described herein are 4-methyl-piperazine-1-carbothioic acid amide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by hemorrhagic fever viruses, such as Arenaviruses.... Agent: Siga Technologies, Inc.

20120107271 - Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections: The present invention provides compounds of Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and pro-drugs of said compounds, wherein each of R, R1, X, Y, Z, R2,... Agent:

20120107275 - Fused heterocyclic derivatives and methods of use: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention... Agent: Amgen Inc.

20120107273 - New piperazine compound and use thereof as a hcv polymerase inhibitor: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful... Agent: Japan Tobacco Inc.

20120107272 - Synthetic methods and derivatives of triphosphate oligonucleotides: which are capable of inducing an anti-viral or an antibacterial response, in particular, the induction of type I IFN, IL-18 and/or IL-1β by binding to RIG-I. The invention relates to methods of making and using modified oligonucleotide comprising at least one triphosphate or analogs thereof. The invention further relates to... Agent: Alnylam Pharmaceuticals, Inc.

20120107277 - Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis: This invention is related to the use of the combination of teriflunomide and interferon beta thereof, for the preparation of a medicament for use in treating multiple sclerosis.... Agent: Sanofi-aventis U.s LLC

20120107278 - Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype: Disclosed herein is a method for administering an abbreviated hepatitis C virus (HCV) treatment regimen for an HCV-infected, rs12979860 single nucleotide polymorphism (SNP) (C/C) patient, which comprises: administering to said patient an effective amount of each of a direct-acting antiviral, pegylated interferon alfa-2a, and ribavirin; wherein the abbreviated HCV treatment... Agent: Pharmasset, Inc.

20120107285 - Mitochondrial enhancement of cells: Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, methods of modifying stem cells, or methods of administering modified stem cells... Agent: Searete LLC A Limited Liability Corporation Of The State Of Delaware

20120107286 - Pluripotent stem cells: Methods and compositions for the generation and use of footprint-free human induced pluripotent stem cells are provided.... Agent: The Salk Institute For Biological Studies

20120107284 - Stem cells for transplantation and methods for production thereof: A medicament for cell differentiation to alleviate cell and cell-related deficiencies in a mammal is described. The medicament comprises in two or more parts in vitro produced non-activated inducible gene construct(s) capable of expressing transcription factor(s), and optionally additional suppressor(s) or activator(s) of expression of said transcription factor(s), in a... Agent:

20120107280 - Biofungicidal composition for controlling phytopathogenic fungi: Biofungicide composition derived from a biologically pure culture of a Chilean bacterial isolate obtained from the skin of grapes, corresponding to Serratia plymuthica CCGG2742, to be used as an environmentally friendly biological control agent against fungal diseases of vegetables, in particular fruits susceptible to the infection of Botrytis cinerea, efficiently... Agent:

20120107279 - Prevention and treatment of rotavirus diarrhoea: This invention relates to Bifidobacterium breve CNCM I-3865, to a composition comprising Bifidobacterium breve CNCM I-3865 and to the use of Bifidobacterium breve CNCM I-3865 in the prevention or treatment of rotavirus diarrhoea. prevention and treatment of rotavirus diarrhoea... Agent: Nestec S.a.

20120107287 - Specialized medical nutrition for surgical and trauma patients containing probiotics: The present invention relates to the field of specialized nutritional compositions. In particular, the present invention provides nutritional compositions for providing complete nutrition to hospitalized patients comprising probiotic micro-organisms. Such probiotic micro-organisms may be non-replicating micro-organisms, such as bioactive heat-treated probiotic micro-organisms, for example.... Agent: Nestec S.a.

20120107291 - Bifidobacteria for treating diabetes and related conditions: This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired... Agent: Danisco A/s

20120107288 - Compositions and methods for inhibiting pathogenic growth: The invention includes methods and compositions for treating an animal to inhibit the incidence and growth of E. coli O157:H7 and other pathogenic bacteria. The treatment method comprises administering a therapeutically effective amount of Lactobacillus acidophilus or one or a combination of a number of other probiotic bacteria to an... Agent:

20120107289 - Lactic bacteria and their use in the prevention of diarrhea: The present invention concerns a lactic composition useful for the prevention or treatment of diarrhea such as antibiotic associated diarrhea or “tourista.” The composition according to the invention contains at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus acidophilus I-1492, Lactobacillus casei and a mixture... Agent: Bio-k Plus International, Inc.

20120107290 - Non-replicating micro-organisms and their immune boosting effect: The present invention generally relates to the field of probiotic bacteria. In particular, the present invention conceras non-replicating probiotics, such as the genus Lactobacillus, Bifidobacterium or combinations thereof, for example Lactobacillus paracasei, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium breve or combinations thereof, and applications of these bacteria. One embodiment... Agent: Nestec S.a.

20120107281 - Compositions and methods for modifying cell surface glycans: Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.... Agent:

20120107283 - Human skin equivalents expressing exogenous polypeptides: The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present... Agent: Stratatech Corporation

20120107282 - Neural stem cell composition capable of treating cancer and method of treatment: Disclosed is a method of treatment of an individual suffering from primary brain tumors (glioma and medulloblastoma) and brain metastases of extracranial cancers using human stem cells encoding therapeutic genes. The method includes giving the individual a clinically acceptable therapeutic reagent by intravascular injection of a pharmaceutical composition. The pharmaceutical... Agent: S. Biomedics Co., Ltd.

20120107294 - Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umblical cord blood: Provided is a composition for in vivo transplantation for the treatment of human cervical cancer, comprising mononuclear cells derived from umbilical cord blood and a pharmaceutically acceptable carrier. When the umbilical cord blood-derived mononuclear cells are transplanted in vivo, cervical cancer can be effectively treated. In particular, the mononuclear cells... Agent:

20120107292 - Method for the simultaneous induction of ctl and gamma-delta t cell: Disclosed are: a method for culture of disease antigen specific CTLs and γδT cells in one culture step conveniently and efficiently; and a pharmaceutical agent and a therapeutic/prophylactic method both of which use a cell produced by the method. Blood is collected and peripheral blood mononuclear cells are separated from... Agent: Medinet Co., Ltd.

20120107293 - Methods and compositions for the treatment of cancer: A method of treating cancer comprises: (a) providing allogenic or autologous white blood cells from a suitable donor; and then (b) administering the white blood cells to the subject in an amount effective to treat the cancer. Preferably the white blood cells comprise innate immune cells. Preferably the white blood... Agent:

20120107295 - Methods and compositions for detecting pancreatic disease: Methods and compositions for at least determining whether a human subject has a pancreatic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a pancreatic glycoprotein (GP2) analyte to determine whether the subject at least has the pancreatic disease. Also provided are kits,... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20120107296 - Feed supplement: The present invention relates to a feed supplement comprising a phytase and a lipolytic enzyme, wherein said lipolytic enzyme has lipase activity at a pH in the range of about pH1.5 to about pH3.5.... Agent: Danisco A/s

20120107297 - Method for therapeutic angiogenesis: The present invention relates to the E2EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of UCP activity is accomplished by... Agent: Korea Research Institute Of Bioscience And Biotechnology

20120107298 - Use of lcat for treating anemia and red blood cell dysfunction: Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous LCAT or LCAT activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and... Agent:

20120107299 - Phosphorylation-inhibiting agent or dephosphorylating agent for pten: Provided is a preventive, progression inhibitor or remedy for a disease one of the causes of which is the activation of the P13K/AKT signaling pathway or vice versa. A phosphorylation-inhibiting and/or dephosphorylating agent, which has an effect of inhibiting the phosphorylation at least at one of the phosphorylation sites of... Agent: University Of Miyazaki

20120107300 - Cannabinoid compositions and methods: Cannabinoid compositions and methods of administering said cannabinoid compositions are disclosed. The cannabinoid compositions disclosed herein include compounds which have been strategically selected to eliminate, or least mitigate, one of the negative side effects associated with consuming cannabinoids. A daytime formula includes compounds aimed at nullifying the negative side effects... Agent:

20120107301 - Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells: Antibodies to antigen presenting cells may be utilized to interfere with the interaction of the antigen presenting cell and immune cells, including T cells. Peptides may be linked to said antibodies thereby generating an immune response to such peptides. Preferably peptides linked to the antibodies are associated with autoimmunity.... Agent: Alexion Pharmaceuticals, Inc.

20120107306 - Antibodies for epidermal growth factor receptor 3 (her3): The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.... Agent: Novartis Ag

20120107305 - Combination therapy: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent:

20120107304 - Combination therapy in treatment of oncological and fibrotic diseases: The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of a cell signalling and/or angiogenesis inhibitor in conjunction with an Aurora kinase inhibitor.... Agent: Boehringer Ingelheim International Gmbh

20120107312 - Combinations for the treatment of diseases involving cell proliferation: wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of... Agent: Boehringer Ingelheim International Gmbh

20120107302 - Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in... Agent:

20120107307 - Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors: This invention concerns N-(ortho phenylamino dihydropyridyl)sulfonamides and N-(ortho phenylamino dihydropyridyl), N′-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases.... Agent: Ardea Biosciences Inc.

20120107308 - Gene expression levels of egfr, vegfr2, and ercc1 associated with clinical outcomes of chemotherapy: The invention provides compositions and methods for identifying a cancer patient suitable for anti-VEGF therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients.... Agent: University Of Southern California

20120107313 - Mammalian receptor proteins; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.... Agent: Schering Corporation

20120107310 - Methods of antagonizing signal transduction in spinal cord cells: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.... Agent: Zymogenetics, Inc.

20120107309 - Polymorphism in k-ras 3' untranslated region associated with clinical outcomes of cancer treatments independent of k-ras mutation status: The invention provides compositions and methods for determining the likelihood of response or survival of cancer patients treated with anti-EGFR therapy, topoisomerase inhibitor therapy or anti-EGFR therapy/topoisomerase inhibitor therapy combination therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the... Agent: University Of Southern California

20120107303 - Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.... Agent: Idera Pharmaceuticals, Inc.

20120107311 - Targeted identification of immunogenic peptides: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific... Agent: The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.

20120107314 - Cab molecules: The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy.... Agent:

20120107315 - Predicting progression to advanced age-related macular degeneration using a polygenic score: The present invention relates to methods for identifying individuals with intermediate age-related macular degeneration (AMD) who possess a greater risk of progression to advanced AMD, using a polygenic score calculated based on the results of genome-wide gene association studies, using thousands of single-nucleotide polymorphisms (SNPs).... Agent:

20120107316 - Protective anti-glucan antibodies with preference for beta-1,3-glucans: Anti-β-1,3-glucan antibodies have been found to be protective against systemic fungal infection with Candida albicans. The present invention provides monoclonal antibodies that bind to β-1,3-glucan, hybridoma cell lines producing the antibodies, compositions comprising the antibodies and methods of using such antibodies for treatment of microbial infections, particularly against Candida albicans... Agent: Novartis Vaccines And Diagnostics, Inc.

20120107317 - Use of cytoplasmic c-myc for regulating immune responses: The subject invention provides novel uses of cytoplasmic c-Myc for modulation of innate immune responses. The invention is based, at least in part, on the surprising discovery that cytoplasmic c-Myc, instead of nuclear c-Myc, modulates pro-inflammatory immune responses via its role as a positive feedback regulator. Specifically, the subject invention... Agent: The University Of Hong Kong

20120107321 - Antibodies and epitopes specific to misfolded prion protein: The present invention relates to antibodies and immunogenic peptides specific to misfolded prion protein (PrP, e g, PrPSc), and uses thereof. The immunogenic peptides comprise the amino acid sequence tyrosine-methionine-leucine (YML). The antibodies or peptides can be used for treating or preventing a disease or disorder associated with misfolded PrP,... Agent: The University Of British Columbia

20120107320 - Antibodies specifically directed to the soluble form of ctla-4: The invention provides materials and methods relating to antibodies specific for the soluble form of CTLA-4 (sCT-LA-4). Such antibodies have been shown to have a strong boosting effect on antigen-specific human immune responses.... Agent: The University Court Of The University Of Aberdeen

20120107322 - Immunogenic and therapeutic compositions for streptococcus pyogenes: Compositions for preventing and/or treating S. pyogenes infection which comprise one or more active agents. The active agents are SLO antigens, nucleic acid molecules encoding the SLO antigens, and/or antibodies which selectively bind to the SLO antigens.... Agent: Novartis Ag

20120107318 - Methods of administering pif agonist peptides and uses thereof: A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing... Agent:

20120107319 - Pharmaceutical compositions comprising antibodies binding to the intracellular domain of ebv (epstein-barr virus) latent membrane protein-1 (lmp1): The invention relates to pharmaceutical and vaccine compositions comprising an antibody binding specifically to the intracellular domain of EBV protein LMP1.... Agent: Universite Claude Bernand Lyon 1

20120107323 - Kinase protein binding inhibitors: The invention provides compounds capable of treating a subject suffering from or being susceptible to a cell proliferative disorder (especially, cancer), methods of identifying and using the compounds, pharmaceutical compositions and kits thereof.... Agent: University Of Florida

20120107324 - Targeted binding agents directed to a5ß1 and uses thereof: The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.... Agent:

20120107325 - Il-17 antagonistic antibodies: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g.... Agent:

20120107326 - Neutralizing antibodies to influenza viruses: The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, including neutralizing antibodies against two or more of H1, H2, H3, H5, H7... Agent:

20120107327 - Immunogenic compositions of staphylococcus aureus antigens: The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from Staphylococcus aureus. The present invention also relates to immunogenic compositions, comprising Staphylococcus aureus capsule polysaccharides conjugated to a carrier protein. In addition, the invention relates to methods of inducing an immune response in subjects against Staphylococcus aureus using... Agent: Wyeth LLC

20120107329 - Egfr and par2 regulation of intestinal permeability: The present invention provides methods for diagnosing and treating an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mRNA or protein. After diagnosis, the disease may... Agent: University Of Maryland, Baltimore

20120107328 - Gamma secretase modulators: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I).... Agent:

20120107330 - Antagonists, uses & methods for partially inhibiting tnfr1: The present invention relates to anti-Tumor Necrosis Factor 1 (TNFR1, p55, CD120a, P60, TNF receptor superfamily member 1A, TNFRSF1A) antagonists for partially inhibiting TNFR1 useful for the treatment and/or prevention of TNFR1-mediated diseases or conditions such as arthritis, psoriasis, Crohn's disease, COPD, lung inflammatory conditions and asthma. The invention further... Agent:

20120107331 - Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches: Disclosed is the crystal structure of a GEMM riboswitch from V. cholerae bound to c-di-GMP. The crystal structures show that the RNA binds the ligand within a three helix junction that involves base pairing and extensive base stacking. The symmetric c-di-GMP is recognized asymmetrically with respect to the both the... Agent: Yale University

20120107332 - Beta-glucuronide-linker drug conjugates: Ligand Drug conjugate compounds comprising a β-glucuronide-based linker and methods of using such compounds are provided.... Agent: Seattle Genetics, Inc.

20120107334 - Method for enhancing immune response with peptide: An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion... Agent: Juridical Fdn The Chemo-sero-therapeutic Res. Ins

20120107336 - Modified defensins and their use: This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. Compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. Methods are provided for modulating an antimicrobial activity... Agent: The Government Of The U.s.a. As Represented By The Secretary Of The Dept. Of Health & Human Services

20120107337 - Novel formulations of tumour-associated peptides binding to human leukocyte antigen (hla) class i or class ii molecules for vaccines: The present invention relates to novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules as vaccines for the use in immunotherapeutic methods. In particular, the present invention relates to formulations for the immunotherapy of cancer, in particular renal and brain cancer, in particular... Agent: Immatics Biotechnologies Gmbh

20120107335 - Synthetic oligopeptides designed from mite cysteine proteases and methods for the production of: The invention refers to the design, synthesis and evaluation of 6 synthetic oligopeptides, that have not been previously described, designed from the T and B epitopes of allergens of group I of intradomiciliary mites of the species Dermatophagoides pteronyssinus, Dermatophagoides farinae and Blomia tropicalis, which can be used in the... Agent: Fundacion Universidad Del Norte

20120107333 - Vangl1 peptides and vaccines including the same: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 35, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino... Agent: Oncotherapy Science, Inc.

20120107338 - Identification of a novel retrovirus in patients with benign prostatic hyperplasia: Methods for producing an immune response to a benign prostatic hyperplasia (BPH) virus are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for inhibiting an infection with BPH virus, or treating an infection with BPH virus. Also disclosed are... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20120107339 - Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use: Chimeric fHBPs that can elicit antibodies that are bactericidal for different fHBP variant strains of N. meningitidis, and methods of use, are provided.... Agent:

20120107340 - Compositions for immunising against staphylococcus aureus: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.... Agent: Novartis Ag

20120107341 - Methods for producing an immune response to tuberculosis: Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for preventing an infection with Mtb, or treating an infection with Mtb. Pharmaceutical compositions for the prevention and/or treatment of... Agent: Oregon Health & Science University And The Govt. Of The Usa, Dba The Dep. Of Veterans Affairs

20120107342 - Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method: Described is an ex vivo animal or challenge model used as a method to identify protective (e.g., recombinant) proteins and rapidly measure protective immunity in intestinal segments directed against parasites and vaccines directed against parasitic infections. Further described are vaccines directed against infection with parasites, such as Fasciola hepatica, which... Agent: Stichting Dienst Landbouwkundig Onderzoek

20120107343 - Production of recombinant proteins in ciliates and uses thereof: This invention is directed to methods for recombinant polypeptide production and, in particular, methods and products for the production and purification of recombinant proteins in ciliates.... Agent:

20120107344 - Composition for treatment of menopause: A novel herbal extract, MF101, is effective in the treatment of symptoms of menopause.... Agent: Bionovo, Inc.

20120107345 - Manufacture of vaccines that contain both hepatitis b virus surface antigens and surfactant: When preparing HBsAg for use in a combination vaccine, it us known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification.... Agent:

20120107346 - Combination vaccines with low does of hib conjugate: Provided herein are combination vaccines comprising antigens for protecting a subject against at least diphtheria, tetanus, pertussis and Hib, wherein: (a) the antigen for protecting against Hib is a conjugate of a Hib capsular saccharide; (b) the concentration of the Hib conjugate in the vaccine is <15 μg/ml; and (c)... Agent:

20120107347 - Combination immunotherapy compositions against cancer and methods: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.... Agent: Globeimmune, Inc.

20120107348 - Multivalent pcv2 immunogenic compositions and methods of producing such compositions: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence... Agent: Boehringer Ingelheim Vetmedica, Inc.

20120107349 - Multivalent nanoemulsion vaccines: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods of inducing an immune response against one or a plurality of pathogens (e.g., vaccinia virus, H5N1 influenza virus, Bacillus anthracis, C. botulinum, Y. pestis, Hepatits B, and/or HIV, etc.) in a... Agent: The Regents Of The University Of Michigan

20120107353 - Composition: The invention relates to a composition comprising at least one ISCOM complex and at least one internal antigen which is not a surface antigen and not in the form of a part of a whole micro-organism. The internal antigen may be a nucleoprotein or presented as a member of the... Agent: Isconova Ab

20120107351 - In ovo vaccination of campylobacter in avian species: The present invention provides a method of inducing an immune response against Campylobacter in an avian species, especially a domesticated avian species such as chicken, turkey, duck, goose and quail, by administering, in ovo, live cells of Campylobacter.... Agent: Pfizer Inc.

20120107352 - Lipopolysaccharide of ochrobactrum intermedium and their use as immunostimulant of mammalians: The present invention relates to the isolation, purification and characterization of the Lipopolysaccharide (LPS) from Ochrobactrum intermedium strain LMG3306, and their use as immunostimulant of mammalians, the process for the preparation of a pharmaceutical compound for the treatment and/or prevention of the sepsis and adjuvant for a vaccine in immunosupressed... Agent:

20120107350 - Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof: Five optimized genes of capsid L1 protein from human papillomavirus type 16, 58, 18, 6 and 11, which are modified by using insect's preferred codons and so on. Method for modifying those genes to express more highly in insect cells. Virus-like particle's vaccine compositions comprising HPV L1 proteins or their... Agent:

20120107354 - Viral vaccine and process for preparing the same: The present invention provides a vaccine against a viral infection. The exemplary vaccine comprises a viral antigen of a vaccine strain of a virus; wherein the viral antigen is derived from a virus preparation of the vaccine strain of the virus; wherein the virus preparation of the vaccine strain of... Agent:

20120107355 - Method of rapidly producing improved vaccines for animals: A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or... Agent: Harrisvaccines, Inc.

20120107356 - Composition useful as rotavirus vaccine and a method therefor: Compositions and methods related to live or live attenuated pre-conditioned and typical viruses such as rotaviruses are disclosed. The live attenuated rotaviruses exhibit better stability characteristics and are useful for the prevention of a rotavirus infection and/or rotavirus gastroenteritis in children.... Agent: Bharat Biotech International Limited

20120107357 - Novel divergent picornavirus: cosavirus: Presented herein is the discovery of a new human picornavirus, Cosavirus (previously termed Dekavirus), methods of detecting the Cosavirus and diagnosing Cosavirus infection, methods of treating or preventing Cosavirus infection, and methods for identifying anti-Cosavirus compounds.... Agent: Blood Systems, Inc.

20120107358 - Subgenomic replicons of the flavivirus dengue: The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.... Agent: The Government Of The Usa, As Represented By The Secretary, Department Of Health & Human Services

20120107359 - Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents: The present invention relates to the rapid induction of a protective immune response against infectious agents using a poxvirus. An immune response can be induced by administering the poxvirus 7 to 2 days prior to infection with the infections agents.... Agent:

20120107360 - Gamma-glutamyl transpeptidase attenuated francisella: The present invention relates to a mutated Francisella bacterium, wherein the ggt gene is silenced or deleted; pharmaceutical compositions comprising the same, in particular, vaccine compositions, and use of the bacterium and compositions for treatment and/or prophylaxis, and in particular, the treatment or prophylaxis of tularemia.... Agent: The Secetart Of State For Defence

20120107361 - Albumin-free botulinum toxin formulations: This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.... Agent: Revance Therapeutics ,inc.

20120107362 - Neurotoxins exhibiting shortened biological activity: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a neurotoxin polypeptide exhibiting a reduced duration of the biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain of the neurotoxin polypeptide as well as vectors and... Agent: Merz Pharma Gmbh & Co. Kgaa

20120107363 - Immunogen against campylobacter infection: The invention relates to the use of Campylobacter jejuni gene product jlpA and immunogenic fragments of jlpA as a component of a pharmaceutical formulation capable of eliciting an anti-Campylobacter jejuni immune response. The invention also relates to a method of inducing an anti-Campylobacter immune response by the administration of C.... Agent:

20120107364 - Antibody having anti-cancer activity: By utilizing an SST-REX method, a cDNA encoding a protein expressed on a cell surface or secreted from the cell was selected from a cDNA library derived from a cancer cell line. Monoclonal antibodies against the protein encoding the selected cDNA were prepared. The in vitro and in vivo anti-cancer... Agent: Actgen Inc.

20120107375 - Antimicrobial material: An antimicrobial material comprises propolis dispersed within a solid carrier. The antimicrobial material is preferably in the form of a film The carrier may be a polymeric material.... Agent: Brightwake Limited

20120107366 - Block copolymer systems and their use in medical devices: The present disclosure relates to block copolymers, methods for their production, and the use of these copolymers in medical devices. In embodiments, the block copolymers may be used in tissue reinforcement including, for example, in hernia repair. The copolymers possess at least one block that is hydrophilic and fast degrading,... Agent:

20120107374 - Coenzyme q10-containing composition: The coenzyme Q10-containing liquid composition is obtained by dispersing and emulsifying coenzyme Q10 in an aqueous liquid containing a water-soluble substance consisting of octenylsuccinate starch and dextrin, and glycerin. The liquid composition may be dried to prepare a coenzyme Q10-containing solid composition.... Agent: Nisshin Pharma Inc.

20120107373 - Composites of hydroxyapatite and calcium carbonate and related methods of preparation and use: Carbonated calcium phosphate compositions and methods of preparation, affording enhanced biophysical properties.... Agent:

20120107368 - Compressible tablet material having an oil-containing active substance, tablet as well as method and device for the production thereof: r

20120107365 - Films and particles: Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses.... Agent: The Brigham And Women's Hospital, Inc.

20120107378 - High strength carbo substances: A black colouring substance, comprising carbo vegetabilis as a black pigment. The colouring substance may be used as a colouring agent in the manufacture of e.g. food and pharmaceutical products.... Agent: Chr-hansen A/s

20120107376 - Method for improving bioavailability of latanoprost: The present invention relates to a method for improving ocular bioavailability of latanoprost by adding an organic amine to an aqueous eye drop composition containing latanoprost. The invention further relates to an aqueous eye drop composition in which a better ocular bioavailability of latanoprost is achieved by adding an organic... Agent: Santen Pharmaceutical Co. Ltd

20120107370 - Methods and compositions for treating hiv-associated diarrhea: Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In... Agent:

20120107377 - Particulate composition and pharmaceutical composition containing the same: The present invention provides a particulate composition containing: block copolymer units being arranged radially with hydrophobic polymer-chain segments radially inside and hydrophilic polymer-chain segments radially outside; and a charged lipid which carries a charge opposite to the charge of a drug to be encapsulated, the charged lipid being attracted to... Agent:

20120107369 - Polymers and hydrogels: Methods and compositions related polymers and hydrogels. In some cases to biodegradable hydrogels for use in medical applications are disclosed. The polymers and hydrogels may be produced from cross-linked dextran and poly(epoxides). The poly(epoxides) may be poloxamers.... Agent: Nanoderm, LLC

20120107372 - Recombinant gelatins: The invention concerns a recombinant CBE gelatin and recombinant gelatins having multimers of the CBEmonomersequence that are of particular use in several applications involving cell attachment such as in cell culture work and applications involving cell cultures of anchor dependent cells and also in a variety of medical applications.... Agent:

20120107367 - Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules: Compositions which deliver adsorbents, alone or in combination with active drug “degrading molecules,” in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, and methods of treatment using the compositions, are disclosed. The compositions are ideally designed... Agent:

20120107371 - Stimuli-responsive systems for controlled drug delivery: A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades.... Agent: Massachusetts Institute Of Technology

20120107380 - Methods of saponifying xanthophyll esters and isolating xanthophylls: This invention relates to a practical and effective process for converting esterified xanthophylls, including zeaxanthin, to non-esterified xanthophylls through saponification. In addition, the invention provides a process for obtaining esterified zeaxanthin in high yields and purities, isolating the xanthophylls from interfering substances such as waxes, oils, and fats. A product... Agent: Kalamazoo Holdings, Inc.

20120107379 - Water base slurry composition for cosmetic products and methods of use: This invention relates to water based slurry compositions of cosmetic and personal care products and methods of making and using water based slurry compositions for cosmetic and personal care products such as foundations, eye shadows, lotions, and creams.... Agent: U.s. Cosmetics Corporation

20120107381 - Powder formulations of potassium-binding active agents: The present invention is directed to powder formulations of a potassium-binding active agent, a suspending agent, and a glidant; optionally, other excipients can be added to the formulations. These formulations can be in a powder form and are useful to bind potassium in the gastrointestinal tract.... Agent: Relypsa, Inc.

20120107382 - Articles incorporating absorbent polymer and ceragenin compound: An absorbent article includes an absorbent polymer and a ceragenin compound. The ceragenin compound has a sterol group and a plurality of cationic groups that mimic naturally occurring antimicrobial peptides. The ceragenin compound is associated with the absorbent polymer such that upon absorption of a fluid, the ceragenin compound is... Agent: Brigham Young University

20120107384 - Apparatus for forming an implant: Implants for repairing tissue defects, such as cartilage tissue defects, and methods of their preparation and use are disclosed. A mold of a tissue defect is prepared by pressing upon the defect a substrate having shape memory, such as aluminum foil. The mold, which has contours substantially conforming to those... Agent: Isto Technologies, Inc.

20120107383 - Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same: Osteoconductive matrices and methods are provided that have one or more statins disposed in calcium phosphate particles. The matrices may be injected into a fracture site. The osteoconductive matrices provided allow for sustained release of the statin and facilitate bone formation and repair of the fracture site.... Agent: Warsaw Orthopedic, Inc.

20120107385 - Method of treating conditions associated with overactive bladder: The present invention is directed to a method of treating a condition associated with an overactive bladder, comprising administering to a female an intravaginal device, comprising: (a) an annular first matrix comprising a pocket and a pocket wall, wherein the pocket wall has a uniform thickness, and wherein the pocket... Agent: Teva Women's Health, Inc.

20120107386 - Composition and method for incorporating nutrients into condiments and use thereof in cooked foods: A composition comprising a nutrient encapsulated in a coating and a condiment is disclosed. A method of manufacturing the composition is also disclosed.... Agent: Vitaminspice LLC

20120107387 - Laminated sheet and process for producing the same: A laminated sheet is produced by forming an adhesion layer permeable to a liquid component and contactable with a skin on at least one side of a liquid-retention layer comprising a nonwoven structural member and having an ability to absorb the liquid component. The adhesion layer comprises a nonwoven structural... Agent: Kuraraykuraflex Co., Ltd.

20120107388 - Hemostatic composition, apparatus, and methods: The present invention provides hemostatic compositions comprising components of the flowers of pharmaceutical chamomile (Chamomilla recutita) and the leaves of dioecious nettle (Urtica dioica). Further inclusion of a biocompatible polymeric base, particularly an alignate, generates a composition with excellent and broad spectrum hemostatic capabilities, with concurrent antiseptic and anti-inflammatory properties.... Agent:

20120107389 - Amphoteric liposomal compositions for cellular delivery of small rna molecules for use in rna interference: The present invention provides method and pharmaceutical composition for efficient delivery of siRNA (small interfering ribonucleic acids) into cultured mammalian cells. In addition, the present invention provides methods and compositions for knocking down the expression of a specific target gene by treating cells with the formulations comprising cationic amphiphile, a... Agent:

20120107390 - Feline infectious peritonitis vaccine: FIP vaccines were provided that use an N protein with a specific structure, or a fragment thereof, as an antigen. Preferred antigens of this invention are N proteins derived from a specific type I virus strain (KU-2). Vaccines comprising such an N protein confer preventive effects against a wide range... Agent: Kitatsato Daiichi Sankyo Vaccine Co., Ltd.

20120107391 - Therapy of platinum-resistant cancer: The present invention concerns a method for treating platinum-resistant, ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma with the combination of a HER2 antibody that effectively inhibits HER dimerization as well as gemcitabine.... Agent: Genentech, Inc.

20120107392 - Use of huperzine for disorders: Methods and compositions containing huperzine are used to prevent and alleviate seizures. The invention is also directed to methods and compositions for using huperzine for the prevention and/or treatment of orthostatic hypotension.... Agent:

20120107394 - Immuno-compatible hydrogel system: An immuno-compatible hydrogel system is provided that is resistant to protein binding. The hydrogel system is prepared by contacting a hydrogel solution with a cross-linking agent to form a gel, exposing the gel to an aqueous solution comprising a first polyelectrolyte to form a polyelectrolyte-coated hydrogel, exposing the polyelectrolyte-coated hydrogel... Agent:

20120107393 - Pellets for delivery of biologically active substances: Pellets are made by combining a direct compression binder and a waxy spheronizing agent. The pellets may further contain additional pharmaceutical ingredients and/or a drug. The pellets may be compressed to form tablets or loaded into a capsule shell for oral administration, and the pellets may or may not have... Agent: University Of Tennessee Research Foundation

20120107395 - Probiotic soft gel compositions: Soft gel capsules are formed from an outer gelatin-containing shell and a filling. The filling includes a probiotic and a dessicant.... Agent: Viva Pharmaceutical Inc.

20120107396 - Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients: Described herein are novel methods and formulations for reducing suicidality in human subjects. Such formulations and methods are a combination of lithium and one or more other CNS therapeutic agents such as anti-depressant, mood-stabilizing, anxiolytic, anticonvulsant, antipsychotic, anti-addictive, and appetite suppressant drugs.... Agent:

20120107397 - Pharmaceutical compositions of valsartan: The present invention relates to the stable pharmaceutical composition comprising valsartan or a pharmaceutically acceptable salt thereof with mannitol as a filler and povidone as binder. The present invention also relate to the valsartan or pharmaceutically acceptable salt thereof in combination with hydrochlorothiazide or amlodipine or both; and optionally one... Agent: Hetero Research Foundation

20120107398 - Pharmaceutical compositions: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and pioglitazone, processes for the preparation thereof, and their use to treat certain diseases.... Agent: Boehringer Ingelheim International Gmbh

20120107399 - Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient: The present invention relates to a drying process of BIBW 2992 or the salts thereof, preferably the dimaleate salt, as well as of solid pharmaceutical formulations comprising BIBW2992 or a salt thereof, and to pharmaceutical compositions comprising BIBW 2992 or a salt thereof as the active product ingredient, characterized by... Agent: Boehringer Ingelheim International Gmbh

20120107400 - Sustained release composition of theraputic agent: A pH dependent drug delivery system comprising a pH sensitive graft copolymer, a therapeutically active agent and other pharmaceutically acceptable ingredients. More specifically, a composition which is capable of suppressing the drug release in the acidic pH prevalent in the stomach and releasing the drug over an extended period of... Agent:

20120107403 - Bladder reconstruction: The invention is directed to methods and devices for the reconstruction, repair, augmentation or replacement of laminarily organized luminal organs or tissue structures in a patient in need of such treatment. The device comprises a biocompatible synthetic or natural polymeric matrix shaped to conform to at least a part of... Agent: Children's Medical Center Corporation

20120107401 - Osteoconductive matrices comprising statins and methods of using the same: Osteoconductive matrices and methods are provided that have one or more statins disposed therein. The matrices may be injected into a fracture site. The osteoconductive matrices provided allow for sustain release of the statin and facilitate bone formation and repair of the fracture site.... Agent: Warsaw Orthopedic, Inc.

20120107402 - Process for analyzing and establishing dosage size in an ingestible film: The present invention is directed to a method of analyzing and establishing a proper dosage size in ingestible films for providing a more precise dosage delivery of an active ingredient.... Agent: Monosol Rx, LLC

20120107404 - Crystalline pharmaceutical and methods of preparation and use thereof: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.... Agent: Sarcode Bioscience Inc.

20120107406 - Dry powder formulations: A dry powder suitable for inhalation n a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles... Agent: Jagotec Ag

20120107405 - Method for the dry dispersion of nanoparticles and the production of hierarchical structures and coatings: The invention relates to a method for the dispersion of synthetic or natural nanoparticles and nanocomposite materials and to the use thereof in different sectors including those of ceramics, coatings, polymers, construction, paints, catalysis, pharmaceuticals and powdered materials in general.... Agent: Consejo Superior De Investigaciones Cient&#xbf &#xbf Ficas

20120107407 - Bone graft and biocomposite for prosthetic dentistry: A bone graft or biocomposite for treating osseous defects and neogenesis of bone which is a composite of a biodegradable polymer and granules of beta-tricalciumphosphate, further comprising as active ingredient and embedded in the biodegradable polymer a physiologically effective amount of underglycosylated recombinant human BSP as a muti-dental clathrate with... Agent:

20120107408 - Pharmaceutical microparticles: Microparticles consisting of (a) a matrix with a mixture of (a1) at least one hydrophobic, biologically degradable polymer and (a2) optionally at least one water-soluble polymer, (b) a pharmaceutical active ingredient distributed in the matrix, and (c) in addition at least one water-insoluble, surface-active substance from the group of lecithins... Agent:

20120107409 - Preparation and use of fish skin fermentation product: The present invention relates to a method for fermenting fish skin by using Aspergillus. Also provided is a use of the fermentation product obtained from the method in inhibiting the activity of tyrosinase, inhibiting the activity of angiotensin-converting enzyme and/or improving the survival of fibroblasts.... Agent: Food Industry Research And Development Institute

20120107410 - Product for the preparation of dermatological, cosmetic or cosmeceutical compositions intended for skin treatment: The present invention relates to a product obtained from gastropod spawn, to be used to prepare dermatological, cosmetic or cosmeceutical compositions designed for skin care; said product has the capacity to activate and mobilise skin stem cells, as well as prevent the loss thereof that takes place as a consequence... Agent: Industrial Farmaceutica Cantabria, S.a.

20120107411 - Treatment of stress: The use of fertilised eggs, e.g. hen's eggs, or extracts thereof in the treatment of stress, such as perceived stress as well as in the use of such eggs to normalise Cortisol response in both chronically stressed and non stressed individuals. The invention further relates to the use of the... Agent: Med-eq, As

20120107413 - Pre-natal mesenchymal stem cells: We describe an pre-natal mesenchymal stem cell obtainable from a pre-natal tissue such as a foetal tissue, a descendent of such a mesenchymal stem cell, a cell culture or a cell line comprising either. The pre-natal mesenchymal stem cell, cell culture or cell line may comprise a cell line F1Ib,... Agent: Agency For Science, Technology And Research

20120107412 - Use of cellular extracts for skin rejuvenation: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In preferred embodiments, the methods and agents comprise active extracts produced from fish eggs. The... Agent: Regenics As

20120107414 - Pharmaceutical formulations and methods for treating respiratory tract infections: The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca+2 to Na+ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods... Agent: Pulmatrix, Inc.

20120107415 - Combined disinfection and decontamination agent having increased effectiveness: The invention relates to a novel combined disinfection and decontamination agent comprising at least one vitamin, at least one metal ion, at least one active-surface compound, and at least one further antimicrobial active substance. The agent according to the invention surprisingly shows nearly complete nucleic acid disintegration in addition to... Agent:

20120107416 - Fungicidal compositions including hydrazone derivatives and copper: The present invention relates to the use of hydrazone compounds and copper for controlling the growth of fungi.... Agent: Dow Agrosciences LLC

20120107417 - Effective antitumor treatments: ET-743 is used in the preparation of a medicament for an effective treatment of a tumour by combination therapy employing ET-743 with another drug.... Agent: Pharma Mar, S.a.

20120107418 - Method and composition for in-situ generation of chlorous acid: This invention relates to methods and compositions for producing an antimicrobial solution with a high weight percent (wt %) conversion of chlorite anion to chlorous acid and/or derivatives of chlorous acid with substantially reduced chlorite residual. Furthermore, the invention presents methods for use of the antimicrobial solution thereby substantially improving... Agent:

20120107419 - Oral rinse formulation and method of use: A formulation and method of use for neutralizing the acidity in the mouth of a patient. The method comprises taking into the mouth an aqueous solution comprising a water soluble inorganic salt consisting of sodium and/or potassium chloride, a sodium phosphate buffer consisting of sodium monophosphate and/or sodium diphosphate and... Agent:

20120107422 - Compositions and method for preventing and treating fire blight: The disclosure relates to compositions for treating and/or preventing fire blight in plants or parts thereof, to their methods of production, to concentrates for producing said compositions and to uses and methods based on said compositions.... Agent: Chevita Tierarzneimittel Gmbh

20120107421 - Estrogen receptor alleles that are predictive of increased susceptibility to bone fracture: In one aspect, the present invention provides methods of determining susceptibility to bone fracture in a mammalian subject, wherein the methods comprise analyzing nucleic acid molecules obtained from the mammalian subject to determine which of the P, p X, and x alleles of the estrogen receptor α gene are present,... Agent:

20120107420 - Methods of prognosis in chronic kidney disease: The present invention relates to methods of prognosing the survival of a diseased subject, particularly a subject with chronic kidney disease (CKD), as well as selecting an end-stage renal disease subject for a kidney transplant. The methods involve detecting an elevated amount of macrophage inhibitory cytokine-1 (MIC-1) in a test... Agent: St Vincent's Hospital Sydney Limited

20120107423 - Methods of using inhaled nitric oxide gas for treatment of acute respiratory distress syndrome: The present invention provides a treatment of acute respiratory distress syndrome (ARDS) using short term dosing of nitric oxide.... Agent: Ino Therapeutics LLC

20120107424 - Anti dengue activity of cissampelos pareira extracts: The present invention relates to the anti dengue activity of the cissampelos pareira extracts. Pharmaceutical compositions comprising extracts of cissampelos pareira and processes for the preparation of extracts of cissampelos pareira are also provided.... Agent: Ranbaxy Laboratories Limited

20120107425 - Use of rhodiola crenulata extract via the topical route: The present invention enables making a cosmetic care such as: fighting against, or slowing down or preventing the loosening of the cutaneous tissue, increasing the plasticity of the cutaneous tissue, exerting an anti-wrinkle effect or slowing down or preventing the appearance of wrinkles, fighting against, slowing down or preventing the... Agent:

20120107427 - Composition for promoting adipocyte differentiation containing an extract of rehmannia glutinosa, licorice, coicis semen, hordei fructus, chaenomelis fructus, acanthopanacis cortex or puerariae radix: Disclosed is a composition containing an active ingredient comprising one or more extracts selected from the group consisting of Rehmannia glutinosa, licorice, Coix lacryma-jobi seed, wheat germ, Chaenomeles sinensis fruit, Acanthopanacis cortex and Radix puerariae. The composition promotes adipocyte differentiation and fat globule production, and is effective in reducing skin... Agent: Amorepacific Corporation

20120107426 - Ghrelin production promoter: The objectives are to find a substance or a composition capable of promoting the production of ghrelin with physiological activities such as growth hormone secretion effect, and to provide a pharmaceutical comprising it as the active ingredient. The pharmaceutical is a ghrelin production promoter comprising Rikkunshi-to as the active ingredient.... Agent: Nat. Uni. Corp. Hokkaido University

20120107428 - Repellents for pestiferous social wasps: Provided herein are essential oils and synthetic compounds, and combinations thereof, as repellent compositions for repelling insects, such as vespid social wasps (Vespidae), including yellowjackets, paper wasps, and hornets. Controlled release devices comprising these repellent compositions are also provided.... Agent: Sterling International Inc.

20120107429 - Composition for the prevention and treatment of influenza virus infection and composition for suppressing neuraminidase activity comprising turmeric extract: Disclosed is a composition comprising a turmeric extract for preventing and treating influenza virus infection and for inhibiting neuraminidase activity. A turmeric extract, its fraction, and a curcuminoid-based compound separated therefrom may inhibit neuraminidase activity and have antiviral and cell degeneration inhibitory effects on influenza virus, and may be useful... Agent:

20120107430 - Pre-procedure meal regimen: A colon prep method and kit for facilitating a method for evacuating a colon prior to a medical procedure, wherein the method minimizes potential patient discomfort. Three selected meals and a plurality of selected snacks are ingested on a day prior to the medical procedure. The meals include solid food... Agent:

20120107431 - Cosmetic composition containing a rubus coreanus extract for diminishing skin wrinkles: The present invention relates to a cosmetic composition containing a Rubus coreanus extract as an active ingredient, and more particularly to a cosmetic composition containing an extract from Rubus coreanus processed by traditional oriental medicinal processing technology, in which the Rubus coreanus extract has an excellent effect of reducing skin... Agent:

20120107432 - Composition of extract of emblica officinalis and method of preparing the same: The present disclosure relates to a composition of an extract of fruits of Emblica officinalis selected from the group consisting of liquid juice of fruits of Emblica officinalis, a powder of an alcoholic extract of fruits of Emblica officinalis, a powder of a hydro alcoholic extract of fruits of Emblica... Agent: